A clinicopathological and molecular genetic analysis of low-grade glioma in adults by Singh, Anushree
i 
 
 
 
 
 
A CLINICOPATHOLOGICAL AND MOLECULAR GENETIC 
ANALYSIS OF LOW-GRADE GLIOMA IN ADULTS 
 
 
Presented by 
 
ANUSHREE SINGH MSc 
 
A thesis submitted in partial fulfilment of the 
requirements of the University of Wolverhampton 
for the degree of Doctor of Philosophy 
 
 
Brain Tumour Research Centre 
Research Institute in Healthcare Sciences 
Faculty of Science and Engineering 
University of Wolverhampton 
 
November 2014 
 
 
ii 
 
DECLARATION 
 
This work or any part thereof has not previously been presented in any form to the 
University or to any other body whether for the purposes of assessment, publication or 
for any other purpose (unless otherwise indicated). Save for any express 
acknowledgments, references and/or bibliographies cited in the work, I confirm that the 
intellectual content of the work is the result of my own efforts and of no other person.  
The right of Anushree Singh to be identified as author of this work is asserted in 
accordance with ss.77 and 78 of the Copyright, Designs and Patents Act 1988. At this 
date copyright is owned by the author. 
 
Signature: Anushree 
 
Date: 30
th
 November 2014 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
iii 
 
ABSTRACT 
 
The aim of the study was to identify molecular markers that can determine progression 
of low grade glioma. This was done using various approaches such as IDH1 and IDH2 
mutation analysis, MGMT methylation analysis, copy number analysis using array 
comparative genomic hybridisation and identification of differentially expressed 
miRNAs using miRNA microarray analysis.  
IDH1 mutation was present at a frequency of 71% in low grade glioma and was 
identified as an independent marker for improved OS in a multivariate analysis, which 
confirms the previous findings in low grade glioma studies. IDH1 mutation was 
associated with MGMT promoter methylation when partially methylated tumours were 
grouped with methylated tumours.  
Grade II and grade III tumour comparison analysis revealed 14 novel significant 
miRNAs with differential expression. A miRNA signature was shown for histological 
subtypes, oligoastrocytoma and anaplastic oligoastrocytoma, following the miRNA 
expression analysis in grade II and grade III tumors based on histology. 
Oligoastrocytoma presented a more similar profile to oligodendroglioma, but anaplastic 
oligoastrocytoma was more similar to anaplastic astrocytoma. Five novel miRNAs were 
identified in grade III tumours, when comparing IDH1 mutant and IDH1 wild type 
tumours.  
Analysis of paired samples of primary/recurrent tumours revealed that additional 
genomic changes may promote tumour progression. For each of the pair, the two 
samples were genomically different and in each case, the reccurent tumours had more 
copy number aberrations than the corresponding primary tumours. 
iv 
 
Cell cultures derived from the tumour biopsies were not representative of the low grade 
glioma in vivo, which was evident from the differences identified in the miRNA 
expression and copy number changes in the paired samples. IDH1 mutation present in 
tumour biopsies was not maintained in their respective cell cultures.  
These findings give an insight into the molecular mechanisms involved in the 
tumourigenesis of low grade glioma and also tumour progression. 
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CHAPTER 1 
INTRODUCTION 
 
Glioma are the most common primary brain tumours, comprising 70% of all central 
nervous system (CNS) neoplasms and are classified according to the World Health 
Organisation (WHO) classification into grades I to IV based on their histopathological 
and clinical criteria (Louis et al., 2007). Grade I glioma, are usually curable with 
complete surgical resection and rarely progress to malignant phenotypes. Conversely, 
grade II and grade III glioma are invasive, often progress to higher-grade lesions and 
have a poor outcome. Grade IV tumours, glioblastoma multiforme (GBM), are the most 
malignant type of glioma and have a poor prognosis (Stupp et al., 2005; Wen et al., 
2008).  
 
1.1 INCIDENCE OF GLIOMA 
The age-adjusted incidence of all glioma ranged from 0.03 to 5.33 per 100,000 persons, 
while that for grade II astrocytoma was 0.70 to 5.33, for oligoastrocytoma was 0.03 to 
0.27, for oligodendroglioma was 0.10 to 0.40, for anaplastic astrocytoma was 0.13 to 
0.44, for anaplastic oligodendroglioma was 0.06 to 0.11 and for GBM was 0.59 to 3.69 
per 100,000 persons as shown in Table 1.1 (reviewed by Ostrom et al., 2014). Patients 
with grade II astrocytoma tumours were younger (typically 20-34 years) (Marko et al., 
2013), than those with oligodendroglioma and oligoastrocytoma tumours who were 
mainly in the 35-44 age group and patients with anaplastic astrocytoma and GBM had 
peak incidence in the 75-84 age group (Ostrom et al., 2014).  
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Table 1.1 Incidence rates per 100,000 persons by histology and country (all ages) 
(Modified from Ostrom et al., 2014) 
 
Histologic Type Region (organization) Years Overall 
Rate 95% CI 
 
Anaplastic astrocytoma 
Austria (ABTR) 2005 0.44 0.33–0.58 
Korea 2005 0.13  
US (CBTRUS) 2006–2010 0.37 0.36–0.38 
Glioblastoma Australia 2000–2008 3.40  
England 1999–2003 2.05  
Korea 2005 0.59  
US (CBTRUS) 2006–2010 3.19 3.16–3.21 
Greece 2005–2007 3.69  
Oligodendroglioma Austria (ABTR) 2005 0.20 0.13–0.30 
England 1999–2003 0.21  
Korea 2005 0.10  
US (CBTRUS) 2006–2010 0.27 0.26–0.28 
Anaplastic oligodendroglioma England 1999–2003 0.09  
Korea 2005 0.06  
US (CBTRUS) 2006–2010 0.11 0.10–0.11 
Oligoastrocytoma Austria (ABTR) 2005 0.27 0.19–0.39 
England 1999–2003 0.10  
Korea 2005 0.03  
US (CBTRUS) 2006–2010 0.20 0.20–0.21 
Astrocytic tumors Austria (ABTR) 2005 5.33 4.93–5.75 
England 1999–2003 3.48  
Europe (RARECARE) 1995–2002 4.80  
Oligodendroglial tumors Austria (ABTR) 2005 0.70 0.55–0.86 
Europe (RARECARE) 1995–2002 0.40  
 
ABTR, Austrian Brain Tumour Registry; CBTRUS, Central Brain Tumour Registry of 
the United States; RARECARE, Surveillance of rare Cancer in Europe (EU).  
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1.2 GLIOMA HISTOLOGY 
1.2.1 Astrocytoma 
Diffuse astrocytoma (A) (WHO grade II) is a slow-growing, well differentiated tumour 
with a tendency to infiltrate surrounding brain tissues (Ohgaki et al., 2005; Louis et al., 
2007). It consists of fibrillary and gemistocytic astroyctes on a loose matrix (Forst et al., 
2014) and has a low proliferative activity (Schiff et al., 2007). Typically, overall 
survival (OS) of patients with astrocytoma is 5-10 years (Smith et al., 2008; Bauman et 
al., 2009). It often shows recurrence after surgical resection and progresses to malignant 
phenotypes such as anaplastic astrocytoma (AA) (WHO grade III) and subsequently, to 
GBM (WHO grade IV).  
 
1.2.2 Oligoastrocytoma 
Oligoastrocytoma (OA) (WHO grade II) is comprised of a mixture of cells of two 
different neoplastic cell types morphologically similar to tumour cells in 
oligodendroglioma and low-grade astrocytoma (Okamoto et al., 2004). 
Oligoastrocytoma is intermediate between low-grade astrocytoma and 
oligodendroglioma with regards to gene abnormalities and patient survival. Anaplastic 
oligoastrocytoma (AOA) (WHO grade III) is a malignant oligoastrocytoma (Okamoto et 
al., 2004; Louis et al., 2007). 
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1.2.3 Oligodendroglioma 
Oligodendroglioma (O) (WHO grade II) is a slow-growing, well-differentiated, 
diffusely infiltrating tumour in adults, predominantly consisting of cells similar to 
oligodendroglia (Louis et al., 2007). It consists of uniform nuclei and perinuclear 
clearing, having a “fried-egg” appearance (Forst et al., 2014). It is characteristically 
located in the cerebral hemispheres (Louis et al., 2007; Rees et al., 2010). Patients with 
oligodendroglioma have OS of 10-15 years (Smith et al., 2008; Bauman et al., 2009). 
Anaplastic oligodendroglioma (AO) (WHO grade III) is a malignant oligodendroglioma 
with less favourable prognosis. 
 
1.2.4 Glioblastoma multiforme (GBM) 
GBM (WHO Grade IV) exhibits features of malignancy including vascular proliferation 
and necrosis. It develops from two different pathways and is classified as primary or 
secondary GBM (Ohgaki et al., 2007). Primary GBM develops de novo rapidly after a 
short clinical history in elderly patients and is distinguished by a distinct set of genetic 
aberrations when compared with the less frequent secondary GBM, which develops by 
progression from pre-existing low-grade glioma (LGG) (Figure 1.1). The median 
survival of GBM patients has been reported as 14.6 months and a 2-year survival rate of 
26.5% (Stupp et al., 2005; Stupp et al., 2009).  
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Figure 1.1 Primary and secondary GBM  
 
Pathways for the development of primary and secondary GBM showing genetic 
alterations in different histologic types of glioma (Modified from Masui et al., 2012). 
 
 
 
 
 
 
 
 
 
 
6 
 
1.3 CLINICAL SIGNS AND SYMPTOMS OF LGG 
Clinical signs and symptoms vary depending on the mass invasion of the tumour into 
the surrounding tissues (Forst et al., 2014). Siezure is the most common presenting 
symptom in about 80% of the patients, others include cognitive or behavioural changes, 
focal neurological deficits and clinical symptoms of increased intracranial pressure such 
as headache and papilledema. Some of the patients may be asymptomatic with no 
evidence of abnormalities on neurological examination.  
LGG are diagnosed by a combination of imaging, histopathological and molecular 
diagnostic analysis (Forst et al., 2014). On magnetic resonance imaging (MRI), LGG 
show low signal intensity on T1-weighted sequences and hyperintensity on T2-weighted 
and Fluid-Attenuated Inversion Recovery (FLAIR) sequences. Contrast enhancement is 
low and is more likely observed in oligodendroglioma tumours. Tumour grading cannot 
be determined by imaging alone and therefore, histopathological analysis of the tissue is 
the standard diagnostic and grading tool for these tumours. 
 
1.4 PROGNOSTIC FACTORS FOR LGG 
Clinical prognostic factors for LGG patients have been identified, including age, size of 
the lesion, histology subtype, tumour crossing the midline, performance status, mental 
status and localization of the tumour in an eloquent area (Pignatti et al., 2002; Shaw et 
al., 2002; Brown et al., 2004; Chang et al., 2008; Daniels et al., 2011).  
In two European Organization for Research and Treatment of Cancer (EORTC) trials, 
EORTC-22844 used as a construction set (281 patients) and EORTC-22845 used for 
validation (253 patients) (Pignatti et al., 2002), prognostic factors including age (< 40 or 
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> 40 years), largest diameter of the tumour (< 6 vs ≥ 6 cm), tumour crossing midline, 
WHO perfomance status (0 vs > 0) and histology subtype (oligoastrocytoma/mixed vs 
astrocytoma) were analysed. Multivariate analysis revealed that age ≥ 40 years (p = 
0.0077), largest diameter of the tumour ≥ 6cm (p = 0.0003), tumour crossing midline (p 
= 0.0005) and histology subtype, astrocytoma (p = 0.005) were significant unfavourable 
prognostic factors for survival in LGG. The results were confirmed in the validation set; 
age ≥ 40 years (p = 0.0005), largest diameter of the tumour ≥ 6cm (p = 0.0350), tumour 
crossing midline (p = 0.0051) and histology subtype, astrocytoma (p = 0.0006) (Daniels 
et al., 2011). Univariate analysis of the EORTC prognostic factors showed that 
astrocytoma histology (p = 0.004) and tumour ≥ 6cm (p = 0.0001) were significant 
predictors for poor OS and for progression free survival (PFS) (astrocytoma histology, p 
= 0.003 and tumour ≥ 6cm, p < 0.0001). Similarly, the NCCTG-RTOG-ECOG trial 
showed a significant association of longer OS with younger age, < 40 years (p = 
0.0245), smaller tumour size < 5cm (p = 0.008), oligodendroglioma/mixed histology (p 
= 0.0001) and high baseline Mini-Mental Status Examination (MMSE) status score of ≥ 
28 (p = 0.0030) (Shaw et al., 2002). Histological subtype and age combined were 
important predictors of OS. The 5-year survival rates for younger patients (< 40 years) 
with oligodendroglioma was 82% compared with 32% for older patients (≥ 40 years) 
with astrocytoma. Data collected from an intergroup trial was analysed to determine the 
prognostic significance of baseline MMSE score in 187 patients with LGG (Brown et 
al. 2004). The patients with an abnormal baseline MMSE score (< 26) had a worse 5-
year survival rate of 31% compared with 76% for those with normal baseline MMSE 
score (> 26) (p < 0.001). An abnormal baseline MMSE score was a predictor of worse 
OS for both high-dose and low-dose treatment patients. Another study collected data for 
281 patients with hemispheric LGG for assessment of predictors of OS (Chang et al., 
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2008). Multivariate analysis revealed that eloquent location of the tumour (p = 0.0018), 
age > 50 years (p = 0.0412) and tumour diameter > 4cm (p = 0.0014) were associated 
with a shorter OS.  
 
1.5 MANAGEMENT AND TREATMENT OF LGG 
The optimal management of LGG is a challenge as many patients remain asymptomatic 
for a prolonged period of time and may deteriorate after treatment due to side effects 
(Olson et al., 2000; Reijneveld et al., 2001; Surma-aho et al., 2001; Douw et al., 2009). 
Currently, treatment options include watch-and-wait policy, surgery, radiotherapy (RT) 
and chemotherapy (van den Bent et al., 2012).  
In case of watch-and-wait policy, neuroradiological follow-up is required for patients in 
need of histological diagnosis and treatment (van den Bent et al., 2012). Radioactive 
labeled PET (positron emission tomography) scanning may distinguish between LGG 
and histological high grade and MRI is used for non-enhancing tumours (Kunz et al., 
2011). The only evidence for early versus delayed treatment is the randomized EORTC 
22845 trial initiated in 1986 and long-term results have reported that early radiotherapy 
improved PFS with no change in OS (van den Bent et al., 2005). Patients from 24 
centres across Europe were selected and randomly assigned early radiotherapy or 
delayed radiotherapy until the time of progression (control group) with 157 patients in 
both groups. The median PFS in the early radiotherapy group was 5.3 years and 3.4 
years in the control group (p < 0.0001). OS was similar in the two groups; median 
survival in early radiotherapy group was 7.4 years and 7.2 years in the control group (p 
= 0.872). The study showed that outcome was not affected adversely with delayed 
radiotherapy. Radiotherapy treatment in LGG patients may lead to poor quality of life 
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and cognitive deficits (Taphoorn et al., 1994; Olson et al., 2000; Correa et al., 2008; 
Douw et al., 2009). 
1.5.1 Surgery 
Surgery on a patient with a suspected LGG provided four worthwhile benefits: (1) 
histological analysis of the lesion, (2) improvement in the neurological condition, (3) 
reducing the risk of tumour growth and (4) prevention of malignant transformation (van 
den Bent et al., 2012). Previous studies have shown that surgery may improve 
neurological condition and control the seizures (Duffau et al., 2002; Gunnarsson et al., 
2002; Chang, et al., 2008). Surgeons use preoperative functional MRI and tractography, 
as well as intraoperative neurophysiological monitoring to allow safe maximum 
resection of tumours involving eloquent areas (Forst et al., 2014). Intraoperative MRI 
and MRS (magnetic resonance spectroscopy) may be used to determine the extent of 
tumour resection during surgery and identify residual tumour (Pamir et al., 2009; Pamir 
et al., 2013). Patients with tumours that cannot be safely resected may undergo 
stereotactic biopsy using preoperative or intraoperative MRI imaging for 
histopathological diagnosis. For biopsy resection, surgeons target the potential high 
grade part of the lesion using contrast enhancement with reported accuracy rates of 51-
83% (Pouratian et al., 2007).  
1.5.2 Radiotherapy 
The importance of radiotherapy (RT) in LGG was demonstrated in the EORTC 22845 
trial, where an increase in time to progression with early RT in comparison to 
observation (with RT at the time of progression) was demonstrated (van den Bent et al., 
2005). The NCCTG-RTOG-ECOG trial observed a response to RT in one-third of the 
patients and small retrospective surveys suggested improvement in neurological 
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condition or improved seizure control after radiation (Shaw et al., 2002; Soffietti et al., 
2005). The randomized trial was conducted from 1986-1994 for adult supratentorial 
low-grade glioma with 203 eligible patients randomized for radiotherapy; 101 to low-
dose RT (50.4 Gy/28 fractions) and 102 to high-dose RT (64.8 Gy/36 fractions). 
Histology subtype was astrocytoma for 32% and oligodendroglioma for 68% of 
patients. Survival at 2 and 5 years (94% and 72% ) was better with low-dose RT than 
that with high-dose RT (85% and 64%) (log rank p = 0.48), however, this was not 
significant. Similar results were obtained from the EORTC 22844 trial, where the 
importance of RT and dose-response relationship was evaluated (Karim et al., 1996). A 
total of 379 patients with cerebral LGG were randomized to receive radiotherapy 
postoperatively (or post biopsy) with 45 Gy in 5 weeks or 59.4 Gy in 6.6 weeks. After a 
median follow-up of 74 months, there was no significant difference in OS (58% in low-
dose and 59% in high-dose group) or PFS (47% in low-dose and 50% in high-dose 
group) and there was no evidence of dose-response relationship for RT in LGG.  
1.5.3 Chemotherapy 
Recent studies regarding the role of chemotherapy in LGG have described using 
temozolomide (TMZ) and older studies have described using PCV (procarbazine, 
CCNU, vincristine).  
The RTOG 9802 trial compared LGG patients treated with radiation alone versus 
radiation followed by 6 weeks of PCV chemotherapy (Shaw et al., 2012). A total of 251 
patients were enrolled from 1998-2002 and a statistical significance was observed in 
PFS but not OS in the RT+PCV group. OS and PFS were similar in the first two years 
of treatment and longer follow-up demonstrated that 2-year survivors in RT+PCV group 
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had a significant probability of OS for additional 3 years and 5 years compared to non-
chemotherapy patients. 
In a phase II trial involving 46 patients with LGG, the response of patients to TMZ was 
examined and measured as an end point in this study. A total of 61% achieved response 
(24% achieved complete response and 37% achieved partial response) (Quinn et al., 
2003). The median PFS was 22 months with a 6-month PFS of 98% and a 12-month 
PFS of 76%. Another phase II trial with TMZ based chemotherapy in high-risk LGG 
was the RTOG 0424 trial, where 3-year survival of high-risk LGG patients treated with 
TMZ alone was compared with those enrolled in EORTC 22844 and 22845 (Fisher et 
al., 2013). In this study, patients received radiation and daily TMZ for 6 weeks followed 
by TMZ for an additional 12 months postradiation. Patients in the RTOG 0424 trial had 
a 3-year OS of 73.1%, which was longer than those in comparison from the EORTC 
trials. This study has a limitation due to the comparison with patients from EORTC 
trials conducted 20 years earlier (Forst et al., 2014).  
An observational study with 149 LGG patients was performed to determine the 
influence of 1p/19q co-deletion on the response and outcome of LGG treated with TMZ 
(Kaloshi et al., 2007). A total of 53% patients achieved an objective response to TMZ 
(15% with partial response and 38% with minor response), 37% were stable and 10% 
had progression. The median PFS was 28 months (95% CI: 23.4 to 32.6). Loss of 
heterozygosity (LOH) of 1p/19q was present in 42% of the patients and was 
significantly associated with longer objective response to TMZ (p = 0.017) and longer 
PFS (p = 0.000041) and OS (p = 0.04).  
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1.6 GENETIC ALTERATIONS IN LGG 
1.6.1 Copy number aberrations in LGG 
Karyotyping has been performed for only 22 untreated patients with grade II 
oligodendroglioma. Majority of these tumours had near-diploid karyotypes with a few 
numerical and/or structural chromosomal rearrangements (Mitelman et al., 2011). G-
banding using grade II oligoastrocytoma revealed only four tumours with loss of Y 
chromosome as the only aberration (Jenkins et al., 1989).   
The most common aberration in grade II diffuse astrocytomas is trisomy/polysomy of 
chromosome 7 (Reifenberger et al., 2004). Gain of chromosome 7 or 7q was detected in 
more than 50% of the cases using comparative genomic hybridization (Schrock et al., 
1996) or interphase fluorescent in situ hybridization (FISH) (Wessels et al., 2002). 
Aberrations at a smaller frequency include losses of 22q, 13q, 10p, 6 and the sex 
chromosomes (Kleihues et al., 2000). Comparative genomic hybridisation (CGH) 
experiments revealed the most predominant gains on the whole chromosome 7 or 7q 
and 8q in grade II astrocytoma and losses mainly on chromosome arm 1p, 10p and 19q 
(Schröck et al., 1996; Ichimura et al., 1998; Nishizaki et al., 1998; Shapiro, 2002; 
Hirose et al., 2003; Arslantas et al., 2007; Holland et al., 2010). The molecular changes 
in glioma are classified as early changes (chromosome 1p/19q loss and TP53 mutation) 
which are detected in LGG and are thought to be early events in tumour progression 
(Kujas et al., 2005). The late alterations are associated with anaplastic glioma; LOH 9p, 
p16 homozygous deletions, LOH 10q, LOH 19q without 1p loss and EGFR 
amplification. In a study of 131 LGGs, the most common aberrations were chromosome 
1p loss, p53 mutation (combined 89%) and chromosome 9p loss (44%) (Kujas et al., 
2005). Hirose et al., reported gain on chromosome 7q, 5p and losses on 19q and 1q as 
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the most common aberrations in grade II astrocytomas (Hirose et al., 2003). Gain of 
platelet-derived growth factor receptor α (PDGFRA) was investigated in a study of 
LGG consisting of 166 low-grade diffuse astrocytomas, 61 oligoastrocytomas and 115 
oligodendroglioma and it was correlated with IDH1 mutation (Motomura et al., 2013). 
PDGFRA gain was significantly more frequent in diffuse astrocytomas (16.3%) than in 
oligoastrocytomas (6.6%) and oligodendroglioma (2.6%) (p < 0.0001). Majority of 
diffuse astrocytomas (93%) had PDGFRA gain and/or IDH1/IDH2 mutations.  
The most common aberration in oligodendroglioma is a combined loss on 1p and 19q, 
present in about 50% of these tumours (Reifenberger et al., 1994; Louis et al., 2007; 
Rees et al., 2010). Loss of 1p/19q is mutually exclusive of LOH on 17p and TP53 
mutation (Maintz et al., 1997; von Deimling et al., 2000; Mueller et al., 2002; Ueki et 
al., 2002). Co-deletions of 1p/19q are present in 30-50% of oligoastrocytomas 
(Reifenberger et al., 1994; Kraus et al., 1995; Maintz et al., 1997; Okamoto et al., 2004) 
and TP53 mutations are present in 30% of them (Reifenberger et al., 1994; Maintz et 
al., 1997; Mueller et al., 2002; Okamoto et al., 2004). Oligoastrocytomas with 1p/19q 
codeletions have similar histological features as that of oligodendroglioma, while those 
with TP53 mutations are more similar to astrocytomas histologically (Maintz et al., 
1997). Other aberrations include deletions at chromosome 4, 6, 11p, 14, 22q, that are 
less frequent (Reifenberger et al., 2003; Jeuken et al., 2004) and losses of chromosome 
9 and 10, that are more frequent (Louis et al., 2007).  
 
1.6.2 TP53 abnormalities in LGG 
TP53 is located at 17p13.1 and p53 protein is involved in regulation of the cell cycle, 
the response of cells to DNA damage, cell differentiation and apoptosis (Marko et al., 
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2013). Activation of TP53 occurs as a result of DNA damage and further induces 
transcription of the p21 gene (Ohgaki et al., 2009). Wild type TP53 induces MDM2, 
which binds to both mutant and wild type TP53, thus inhibiting activation of 
transcription by wild type TP53. MDM4 also regulates TP53 activity and p14
ARF
 
negatively regulates TP53. Therefore, TP53 activity may be influenced by MDM2, 
MDM4 and p14
ARF
. 
TP53 mutations are present in about 60% of diffuse astroyctomas (Ichimura et al., 2000; 
Kleihues et al., 2000) and they are often accompanied by LOH on 17p, resulting in 
complete absence of wild type TP53 (Reifenberger et al., 2004). In a study of 360 LGG, 
TP53 mutations were present in 53% diffuse astrocytoma, 39% oligoastrocytoma and 
8% oligodendroglioma (Kim et al., 2010). The most common mutation was G:C to A:T 
at CpG sites in 42% followed by G:C to A:T at non-CpG sites in 16% and A:T to G:C 
in 14% of the cases.  
 
1.6.3 Altered epression of platelet derived growth factor receptor in low grade 
glioma 
Diffuse astrocytomas frequently exhibit increased levels of the PDGFRA and the 
corresponding ligand PDGFα, stimulating growth of the tumour cells (Hermanson et al., 
1992; Guha et al., 1995). Overexpression of PDGFRA was primarily found in tumours 
with LOH on 17p (Hermanson et al., 1996). The PDGF pathway was investigated by 
studying the kinase activity of PDGF receptor β (PDGFRB) in 130 cases of LGG 
(Debien et al., 2011). The authors showed that LGG patients with co-presence of high 
PDGFRB activity, low level of DNA methylation and low level of apoptotic activity 
had poor prognosis. This indicates that the PDGF pathway plays a crucial role in 
apoptotic evasion in LGG. 
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1.7 ENDOGENOUS ROLE OF IDH1 AND IDH2 
The IDH1 (isocitrate dehydrogenase 1) gene is located at 2q33.3 and the enzyme has 
been mostly detected in cytosol and peroxisomes (Narahara et al., 1985; Geisbrecht et 
al., 1999). It catalyses the oxidative carboxylation of isocitrate to α-ketoglutarate (α-
KG) leading to the production of nicotinamide adenine dinucleotide phosphate 
(NADPH) in the Kreb’s cycle (Geisbrecht et al., 1999; Devlin, 2006; Reitman et al., 
2010) (Figure 1.2). Heterozygous mutations in IDH1 hinder wild type IDH1 by 
formation of catalytically inactive heterodimers (Zhao et al., 2009). The isoform IDH2 
gene is located at 15q26.1 and expressed in the mitochondria (Grzeschik, 1976). IDH2 
may be the main catalyst for the oxidation of isocitrate to α-ketoglutarate in the Kreb’s 
cycle (Hartong et al., 2008). NADP
+
 functions as the electron acceptor for IDH1 and 
IDH2 proteins and both require a divalent metal ion, Mn
2+
 for enzymatic activity 
(Colman, 1972; Villafranca et al., 1972; Northrop et al., 1974; Carlier et al., 1978; 
Kelly et al., 1981a; Kelly et al., 1981b; Bailey et al., 1987).  
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Figure 1.2 Function of IDH1 and IDH2 
   
Part of Krebs cycle showing the role of IDH1 and IDH2 in the reversible conversion of 
isocitrate to α-ketoglutarate and NADP+ to NADPH (Modified from Reitman et al., 
2010).  
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1.8 FREQUENCY AND TYPE OF IDH MUTATIONS IN GLIOMA 
Mutations in IDH1 gene were first identified in 2008 as a result of large scale 
sequencing analysis of 22 GBM tumours (Parsons et al., 2008). All mutations were 
restricted to the conserved residue R132 located in the substrate-binding site of IDH1. 
Multiple studies confirmed these findings and also revealed that IDH1 mutations are 
most frequent (>80%) in LGG; diffuse astrocytoma, oligodendroglioma and 
oligoastrocytoma (Balss et al., 2008; Nobusawa et al., 2009; Watanabe et al., 2009; Yan 
et al., 2009). IDH2 mutations are mutually exclusive with IDH1 mutations (Hartmann et 
al., 2009; Sonoda et al., 2009; Yan et al., 2009). They are rare in occurence in grade II, 
grade III tumours and secondary GBM, affecting residue R172 only (Balss et al., 2008; 
Nobusawa et al., 2009; Yan et al., 2009). In addition, IDH2 mutations were reportedly 
more common in oligodendroglial tumours as compared to astrocytomas (Hartmann et 
al., 2009). Mutations of IDH1 and IDH2 are somatic, missense, heterozygous and affect 
only codon 132 in IDH1 and codon 172 in IDH2 (Kloosterhof et al., 2011). The most 
common mutation of IDH1 was R132H (92.7%) followed by R132C (4.1%), R132S 
(1.5%), R132G (1.4%) and R132L (0.2%) amongst all 716 tumours comprising 
astrocytoma, anaplastic astrocytoma, oligodendroglioma, anaplastic oligodendroglioma, 
oligoastrocytoma and anaplastic oligoastrocytoma (Hartmann et al., 2009). In case of 
IDH2, R172K (60%) was the most common followed by R172M (19%) and R172W 
(16%) in 31 tumours comprising the glioma mentioned above. The discrepancy in 
studies related to the low frequencies of IDH1-R132S, R132G and R132L may be due 
to variations in number of samples and different histological types analysed. IDH1 
mutations were present in majority of low-grade astrocytoma, oligodendroglioma and 
oligoastrocytoma suggesting that these mutations are early events in tumour formation.  
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In addition, IDH1 and IDH2 mutations have also been reported in acute myeloid 
leukemia (AML), acute lymphoblastic leukemia (ALL), myeloid proliferative 
neoplasms, chondromas and chondrosarkomas, prostate cancer, colon cancer and 
paraganglioma (Figueroa et al., 2010; Amary et al., 2011; Megova et al., 2014).   
 
1.9 FUNCTIONAL CONSEQUENCES OF IDH1 MUTATION 
1.9.1 HIF-1 pathway 
IDH1 mutation results in loss of function of IDH1 gene with reduced production of α-
KG from isocitrate leading to accumulation of hypoxia-inducible factor 1-alpha (HIF-
1α), suggesting that activation of HIF-1α pathway may be involved in oncogenesis 
(Zhao et al., 2009). HIF-1 is a transcription factor that detects low cellular oxygen 
levels and regulates expression of genes involved in glucose metabolism, angiogenesis 
and other signalling pathways that are important for tumour growth. HIF-1α protein 
levels in U87-MG cells were found to be high in response to IDH1 knockdown by 
shRNA and reduced HIF-1α protein levels were observed in HeLa and U87-MG cells 
due to overexpression of wild type IDH1. Overexpression of IDH1-R132H mutant 
resulted in increased HIF-1α protein levels in U87-MG and HEK293T cells. These 
findings suggest that IDH1 regulates HIF-1α levels via α-KG. Furthermore, reduction in 
IDH1 activity led to reduction in α-KG levels and stabilization of HIF-1α. The study 
also determined upregulation of HIF-1α target genes, Glut1 (glucose transporter 1), 
VEGF (vascular endothelial growth factor) and PGK1 (phosphoglycerate kinase 1) by 
inhibition of IDH1 enzyme activity. Quantitative RT-PCR was used to determine the 
expression levels of the target genes and the results revealed that knockdown of IDH1 
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induced the expression of HIF-1α target genes. Furthermore, IDH1-R132H mutant 
strongly induced the expression of the target genes and not IDH1 wild type.  
 
1.9.2 2-Hydroxyglutarate 
Mutation of IDH1 results in gain of function with conversion of α-KG to 2-
hydroxyglutarate (2-HG) (Dang et al., 2009), an oncometabolite that induces DNA 
hypermethylation, causing genome-wide epigenetic changes (Xu et al., 2011). α-KG is 
an important cofactor for enzymes such as TET (Ten-Eleven-Translocation) family and 
JHDMs (Jumonji-C-domain-containing histone demethylases) (Chowdhury et al., 2011; 
Xu et al., 2011). CpG islands are genomic regions with higher frequency of CG 
dinucleotides (CpG sites) including transcription start site and transcription factor 
binding sites and are involved in regulation of gene transcription. TET1 and TET2 
convert methylcytosine to hydroxymethylcytosine, a limiting step in the demethylation 
of CpG islands in the genome (Pastor et al., 2013) and JHDMs are involved in 
demethylation of lysine on histone, H3 (van Lith et al., 2014). IDH1 mutant tumours 
have high levels of glutamate uptake with conversion to α-KG in the cytosol, providing 
high levels of substrate for 2-HG production (Dang et al., 2009). Malignant tumours 
with IDH1 mutations were found to have 100-fold higher levels of 2-HG compared to 
tumours with IDH1 wild type. The increase in 2-HG levels in R132H IDH1 mutated 
tumours was statistically significant (p < 0.0001). Increased 2-HG levels result in 
increased ROS (reactive oxygen species) levels, with an increased risk of cancer 
(Kolker et al., 2002; Latini et al., 2003). 2-HG may also be toxic to cells by inhibiting 
glutamate and/or α-KG utilizing enzymes, which include α-KG dependent prolyl 
hydroxylases that regulate HIF-1α levels (Dang et al., 2009). 
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1.9.3 G-CIMP 
Glioma CpG island methylator phenotype (G-CIMP) was found to be associated with 
IDH1 mutations with majority (78%) of G-CIMP positive tumours presenting IDH1 
mutation (Noushmehr et al., 2010). G-CIMP that identified promoter hypermethylation 
of a specific set of genes was described in a TCGA study with GBM tumours. DNA 
methylation levels of 7 hypermethylated loci (ANKRD43, HFE, MAL, LGALS3, FAS-1, 
FAS-2, and RHO-F) and one hypomethylated locus (DOCK5) were determined in the 
cohort to validate the G-CIMP. A tumour was considered G-CIMP positive if at least 6 
of the genes were methylated including DOCK5 hypomethylation. Grade II tumours 
had approximately 10-fold higher frequency of G-CIMP positive tumours compared to 
GBM tumours and grade III tumours had an intermediate proportion. Based on the 
histology types, oligodendroglioma with G-CIMP positivity (93%) were approximately 
twice as compared to astrocytomas (45%). G-CIMP positive status was significantly 
associated with improved survival in LGG (p < 0.01) and was found to be maintained at 
recurrence. Turcan et al., (2012) demonstrated that IDH1-R132H mutation in primary 
human astrocytes induced histone modifications and extensive DNA hypermethylation, 
leading to remodelling of the methylome and establishing G-CIMP. Expression of IDH1 
mutant in human astrocytes led to production of 2-HG. Methylomes of astrocytes with 
wild type or mutant IDH1 was analysed over 50 successive passages. Increased 
hypermethylation of large number of genes was observed along with hypomethylation 
of few genes with expression of mutant IDH1. Methylome data included 
hypermethylated genes that had de nevo methylation as well as genes with originally 
low levels of methylation that acquired high levels of methylation.  
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1.9.4 PI3K-Akt signalling pathway 
IDH1 mutant has been shown to inhibit PI3K/Akt signalling pathway in a study of 354 
glioma patients comprising 72 grade II tumours (33 astrocytomas, 26 
oligodendroglioma, and 13 oligoastrocytomas), 32 grade III tumours (12 astrocytomas, 
8 oligodendroglioma, and 12 oligoastrocytomas) and 250 grade IV tumours (249 GBM 
and 1 gliosarcoma) (Birner et al., 2014). Activation of PI3K/Akt signalling pathway is 
associated with aggressive behaviour in glioma (Koul, 2008) and the activation is 
mainly caused by loss of the PI3K inhibitor PTEN (phosphatase and tensin homolog) or 
a gain-of-function mutation of PI3KCA (Cheng et al., 2009). PDPN (podoplanin) and 
RBP1 (retinol binding protein 1) are two of the top downregulated genes of PI3K 
pathway in glioma associated with a high frequency of IDH1 mutations (Noushmehr et 
al., 2010). IDH1 mutant was inversely associated with the presence of pAkt (p < 0.001, 
chi square test) and PDPN expression (p < 0.001, chi square test) (Birner et al., 2014). 
The expression of mutant IDH1 inhibited PI3K signalling in LN-319 glioma cells 
transfected with mutant IDH1, however, it was unable to downregulate PDPN 
expression in glioma cells.  
 
1.10 PROGNOSTIC VALUE OF GENETIC ALTERATIONS 
1.10.1 1p/19q 
Complete loss of chromosomes 1p and 19q is most commonly present in 
oligodendroglioma. In a study of grade II and grade III tumours, analysis of 1p/19q co-
deletion was carried out in 83 tumours, of which 43 were analysed by FISH, 18 by LOH 
and 22 by both methods (Sabha et al., 2014). Co-deletion of 1p/19q was identified in 
25% (10/40) astrocytoma, 50% (4/8) oligoastrocytoma, 89% (8/9) oligodendroglioma, 
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20% (3/15) anaplastic astrocytoma, 50% (2/4) anaplastic oligoastrocytoma and 100% 
(7/7) anaplastic oligodendroglioma tumours. Co-deletion of 1p/19q was also 
significantly associated with longer OS in the entire cohort (p = 0.01). Alentorn et al., 
(2014) investigated the clinical significance of 1p/19q co-deletion in LGG. Co-deletion 
of 1p/19q was present in 8.7% (2/23) astrocytoma, 10% (5/50) oligoastrocytoma and 
47.2% (25/53) oligodendroglioma tumours. The authors showed that co-deletion of 
1p/19q was associated with better prognosis in terms of PFS (p = 0.024) and OS (p = 
0.0002) and with oligodendroglial phenotype (p < 0.0001). A study involving LGG, 
anaplastic tumours and GBM reported complete loss of 1p/19q in 35% LGG (11% A, 
12% OA and 82% O), in 51% anaplastic tumours (14% AA, 13% AOA and 77% AO) 
and 3% of GBM tumours (Boots-Sprenger et al., 2013). Patients with LGG and 
anaplastic tumours having complete 1p/19q co-deletion were significantly associated 
with longer OS, while no significance with OS was found in GBM patients having co-
deletion of 1p/19q. 
 
1.10.2 MGMT 
The MGMT (O
6
-methylguanine-DNA-methyltransferase) gene is located at 10q26 and 
produces a DNA repair protein that removes alkyl groups from O
6
 position of guanine 
(Gerson, 2004). Hypermethylation of 5’CpG island leads to inactivation of MGMT, 
which is frequently observed in secondary GBM (>70%) and less often in primary 
GBM (~40%) (Weller et al., 2010). MGMT promoter methylation is heterogeneous in 
malignant glioma; it is not known which CpG sites need to be methylated to inactivate 
the gene. The most commonly used method to detect the methylation is methylation 
specific PCR (MS PCR) followed by direct sequencing. MGMT is an important 
molecular marker that predicts the response of malignant glioma to alkylating agents 
23 
 
such as nitrosoureas (Esteller et al., 2000), TMZ (Hegi et al., 2005) or a combination of 
both (Herrlinger et al., 2006). MGMT promoter methylation causes decreased 
expression and increased sensitivity to TMZ (Horbinski, 2013). In patients with GBM, 
MGMT promoter methylation predicted longer survival irrespective of the initial 
treatment (Wick et al., 2009; van den Bent et al., 2010). With regard to LGG treated 
with TMZ, patients with MGMT promoter methylation reportedly had better outcome in 
a phase II study (Kesari et al., 2009).  
 
1.11 CLINICAL CORRELATION OF IDH1 MUTATION 
A meta-analysis was performed involving 12 studies with a range of cohort sizes from 
49 to 407 patients, of  which one study included grade II tumours, four studies included 
grade III tumours, four studies included grade IV tumours, one study included grade II-
IV tumours and two studies included tumours of all grades (Zou et al., 2013). The 
authors showed that IDH mutations were independent prognostic markers for longer OS 
(p < 0.001) and PFS (p < 0.001). In a study involving 41 oligodendroglioma, 47 
anaplastic oligodendroglioma and 46 GBM, the prognostic significance of IDH1 
mutation was analysed (Myung et al., 2012). The median survival was 68.4, 54.2 and 
19.7 months for oligodendroglioma, anaplastic oligodendroglioma and primary GBM 
tumours respectively. OS was higher in both oligodendroglioma and anaplastic 
oligodendroglioma with IDH1 mutation compared to those without IDH1 mutation (p = 
0.03 and p = 0.013). No significant difference was seen in OS in patients with GBM. A 
positive correlation between IDH1 mutation and long-term survival was observed in 
grade II and III astrocytoma and oligodendroglioma and OS was similar for primary 
GBM with wild-type IDH1 and those with IDH1 mutation (Mellai et al., 2011). 
Mutations of IDH genes were associated with improved outcome in patients with GBM 
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and median OS of 31 months was reported, which was significantly higher than the 15 
month survival for patients with no mutation (p = 0.002) (Yan et al., 2009). The median 
OS for patients with anaplastic astrocytomas carrying IDH1 or IDH2 mutation was 65 
months as compared to 20 months for patients without mutations (p < 0.001; log-rank 
test). Longer survival was associated with IDH1 mutation in all tumours including 
astrocytoma, anaplastic astrocytoma, oligodendroglioma, anaplastic oligodendroglioma, 
oligoastrocytoma, anaplastic oligoastrocytoma and GBM (p < 0.001; log-rank test) 
(Ichimura et al., 2009). In LGG, IDH mutations were associated with a better 5-year 
survival rate (93% vs 51%, p = 0.000001) and lack of IDH mutations was an 
independent, unfavourable prognostic marker (p = 0.006) (Metellus et al., 2010). There 
was no significant difference in survival rates for IDH1 mutant primary and secondary 
GBM (Yan et al., 2009). Primary GBM with IDH1 mutation had a mean survival period 
of 30 months, which was significantly longer than 11.3 months for wild-type IDH1 
patients (p < 0.0001). Secondary GBM patients with IDH1 mutation had a mean 
survival time of 23.8 months (p = 0.4971). 
 
1.12 MOLECULAR CHANGES ASSOCIATED WITH IDH1 MUTATION 
Glioma with IDH1 mutation exhibit a different set of genetic alterations than those 
without IDH1 mutation (Yan et al., 2009). IDH1 mutations are mainly associated with 
TP53 mutation and co-deletions of 1p/19q in diffuse astrocytoma, oligoastrocytoma and 
oligodendroglioma, all of which undergo malignant progression (Ichimura et al., 2009; 
Watanabe et al., 2009; Toedt et al., 2011). 1p and 19q losses, separately or combined 
were significantly more associated with oligodendroglioma than astrocytoma or 
oligoastrocytoma (p < 0.0001) (Barbashina et al., 2005), while TP53 mutations were 
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frequent in astrocytoma and rare in oligodendroglioma (Mueller et al., 2002). Mutations 
of IDH1 are inversely associated with EGFR amplification (p = 0.005) (Nobusawa et 
al., 2009). 
 
1.12.1 EMP3 
EMP3 (epithelial membrane protein 3), located at 19q13.3 is a myelin-related gene that 
belongs to PMP22 (peripheral myelin protein) family of small membrane glycoproteins 
(Taylor et al., 1995; Ben-Porath et al., 1996; Taylor et al., 1996). It may be involved in 
cell proliferation, cell-cell interactions and apoptosis based on the functions of PMP22. 
EMP3 is mainly expressed in blood leukocytes, ovary, intestine and various embryonic 
tissues (Ben-Porath et al., 1996; Taylor et al., 1996). Hypermethylation in the promoter 
region of EMP3 was determined using MS PCR and higher frequency of EMP3 
hypermethylation was found in oligoastrocytoma (70%) and oligodendroglioma (63%) 
than astrocytoma (18%) (P < 0.0001) (Mellai et al., 2013). The frequency of 
methylation was 75% in grade II oligoastrocytoma, 62.5% in grade III 
oligoastrocytoma, 78.6% in grade II oligodendroglioma, 41.9% in grade III 
oligodendroglioma, 22.2% in grade I pilocytic astrocytoma, 33.3% in grade II 
astrocytoma and 37.5% in grade III astrocytoma. Methylation was significantly higher 
in secondary GBM (100%) than primary GBM (8.1%) (p < 0.0001). According to 
grades, hypermethylation was significantly more frequent in grade II tumours (71.4%) 
than grade III tumours (44.7%) (p = 0.0001). EMP3 hypermethylation was significantly 
associated with IDH mutations in astrocytoma (p = 0.0088), oligodendroglioma (p = 
0.0006), oligoastrocytoma (p = 0.0095) and GBM (p = 0.0012). The correlation of 
EMP3 hypermethylation with survival was evaluated in 64 oligodendroglial tumours 
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(38 grade II and 26 grade III) and Kaplan-Meier analysis revealed significantly longer 
OS in grade II (p = 0.001) and grade III tumours (p = 0.034).  
 
1.13 MICRORNA (miRNA) 
The recent discovery of microRNAs (miRNAs) and their pivotal role in regulation of 
genes leading to cancer development and progression has been widely examined in a 
number of studies. miRNA was first discovered in Caenorhabditis elegans in the early 
1990s, where a small RNA encoded by lin-4 was found to deregulate the expression of 
the protein-coding gene lin-14 (Lee et al., 1993; Wightman et al., 1993). The small 
RNA of lin-4 was subsequently revealed to be a miRNA.  
miRNAs are non-coding 20-22 nucleotide RNA molecules that regulate gene expression 
(Ambros et al., 2004; Lee et al., 2009). Over 1500 human miRNAs are currently known 
which contributes to regulation of about 30% of total mRNA (Kozomara et al., 2011). 
miRNAs regulate gene expression via sequence complementarity between the sequence 
of the miRNA and that of the mRNA leading to altered transcription and/or translation. 
Such alterations affect biological processes including differentiation, proliferation and 
apoptosis, which are hallmarks of cancer. miRNAs may downregulate the expression of 
tumour-promoting genes and act as a tumour suppressor or may inhibit the expression 
of tumour suppressing genes and act as oncogenic factors (Malzkorn et al., 2010). 
Mature miRNAs are generated using a multistep process, where pri-miRNA is 
transcribed and exported out of the nucleus with terminal processing forming a 21-23 
nucleotide mature miRNA (Karsy et al., 2012). The miRNA is taken up by the RNA-
induced silencing complex (RISC). Complete complementarity of the miRNA to mRNA 
leads to degradation of the mRNA via the RISC complex, while partial complementarity 
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may result in repression of translation or degradation of mRNA (Figure 1.3). Based on 
these molecular interactions, each miRNA is known to target multiple genes, 
subsequently altering a signalling pathway (Li et al., 2013).  
Figure 1.3 Formation of mature miRNAs  
 
 
Mature miRNAs are formed from pre-miRNA via a multistep process using RISC 
(Adapted from Garzon et al., 2009). 
 
 
1.13.1 miRNA in glioma  
Important pathways in GBM have been shown to be targeted by miRNAs including 
tyrosine kinase signalling, cell cycle progression, gliomagenesis via stem-cell regulation 
and malignant progression (Masui et al., 2012). The role of specific miRNAs including 
miR-17-92, mir-21, miR-23a, miR-30e*, miR-34a and miR-128 in glioma development 
have been described below in a few studies.  
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The miR-17-92 cluster consists of two regulatory loops (Li et al., 2013). In loop 1, miR-
17-92 suppressed proliferation and cell cycle progression by repressing E2F1 and c-
myc. In loop 2, CDKN1A was targeted, activating CCND1/CDK4 complex and cell 
proliferation (Esquela-Kerscher et al., 2006; Sylvestre et al., 2007; Woods et al., 2007; 
Monzo et al., 2008; Pickering et al., 2009; Osada et al., 2011; Knoll et al., 2013). 
During gliomagenesis, miR-17-92 cluster was overexpressed, promoting the 
proliferative effects of loop 2 and c-myc upregulation inhibited anti-proliferative 
function of miR-17-92 in loop 1. Therefore, miR-17-92 enhanced the progression of 
glioma with the regulation of the two loops (Ernst et al., 2010).  
 
miR-21 which is upregulated in glioma may contribute to TGF-β, p53 and EGFR-PI3K-
Akt signalling pathways (Zavadil et al., 2007; Gabriely et al., 2008; 
Papagiannakopoulos et al., 2008). miR-221/222 cluster targets p27, p57, PTEN, TIMP3, 
p53-upregulated modulator of apoptosis (PUMA) and connexion 43 (CX43), which are 
associated with biological processes such as cell cycle progression and cell 
survival/apoptosis (Fornari et al., 2008; Garofalo et al., 2009; Zhang et al., 2010; Hao et 
al., 2012). 
 
Studies have characterised miRNAs as regulatory molecules in the cellular signalling 
networks (Li et al., 2013). For example, mir-23a expression in GBM was found to be 
activated by cyclic adenosine monophosphate response element-binding protein 
(CREB), targeting and suppressing PTEN expression, leading to activation of the PI3K-
Akt signalling pathway (Tan et al., 2012).  
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In glioma, miRNAs were reported to disrupt the negative feedback loops, resulting in 
activation of oncogenic signalling molecules (Li et al., 2013). For example, miR-30e* 
was found to be upregulated in glioma, targeting IκBα mRNA and suppressing its 
expression, therefore, negating the inhibitory effect of IκBα on NF-κB. mir-486 also 
induced overactivation of NF-κB signalling by suppressing the expression of A20, 
CYLD and Cezanne proteins (Song et al., 2013).  
 
miR-34a expression was investigated by analysing the expression of its target genes, 
which includes mainly oncogenes such as c-Met, Notch-1, Notch-2, CDK6 and 
PDGFRA (Li et al., 2009). Transfection of miR-34a in U87 cells and glioma stem cells 
reduced protein levels of Notch-1, Notch-2 and CDK6. In GBM tissue, miR-34a 
expression was found to be lower than in normal brain and miR-34a was also found to 
inhibit malignancy by regulating c-Met and Notch expression. The authors suggest that 
miR-34a might be a potential therapeutic agent for glioma. 
 
1.13.2 Role of miRNA in malignant progression 
A study investigated the role of 157 miRNAs in malignant progression in a cohort of 4 
primary grade II tumours (3A, 1OA) that progressed to GBM (Malzkorn et al., 2010). 
Twelve miRNAs (miR-9, miR-15a, miR-16, miR-17, miR-19a, miR-20, miR-21, miR-
25, miR-28, miR-130b, miR-140 and miR-210) showed upregulation associated with 
progression and 2 miRNAs (miR-184 and miR-328) showed dowregulation associated 
with progression in a majority of tumours examined. miR-10b was found to be 
associated with glioma malignancy as the expression levels of miR-10b in GBM are 
much higher than in other tumour grades (Sasayama et al., 2009). Other miRNAs 
implicated in malignancy of glioma include miR-296, miR-15b, miR-146b, miR-125b, 
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miR-153, miR-196a, miR-195, miR-455-3p, miR-10a, let-7 and miR-182 (Zhang et al., 
2012). 
 
1.14 CELL CULTURE MODEL 
To study the functional and metabolic characteristics of the glioma, a cell culture model 
that represents the glioma in vivo is required. Short-term cell cultures derived from the 
original glioma or its archival source have been used to investigate their IDH mutation 
status, cell phenotype and growth rates. It has been reported by several studies that in 
vitro IDH1 mutation in standard cell culture conditions cannot be maintained 
(Piaskowski et al., 2011). The reason for the elimination of the mutation is not clearly 
understood. Direct sequencing analysis of the frozen tumour cells and their 
corresponding cell cultures was performed and IDH1 mutation was present in only the 
frozen tumour samples and not in cells derived from the tumours with IDH1 mutations 
even after first passage. Furthermore, none of the 15 commercially available cell lines 
presented IDH1 mutation.  
Luchman et al., (2012) have established a brain tumour stem cell line (BT142) with an 
endogenous IDH1 R132H mutation from an IDH1 mutant anaplastic oligoastrocytoma 
tumour biopsy. The neurosphere method was used to establish the cell line and an 
orthotopic xenograft model was also developed. Endogenous 2-HG production was seen 
in both cell culture medium and the xenograft serum.   
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1.15 AIMS AND OBJECTIVES  
Currently, there are no molecular markers that can determine the time and rate of 
malignant progression in LGG. This study focuses on understanding the genetic and 
epigenetic mechanisms involved in LGG that will allow identification of molecular 
markers for progression of LGG to more malignant tumours. The aims of this study 
include: 
 To determine the IDH1 and IDH2 mutation status, MGMT methylation status in 
a panel of tumour samples and correlation with clinical parameters such as 
grade, age and histology. Mutations in IDH1 and IDH2 have been strongly 
associated with low grade glioma and are prognostic factors for a better 
outcome. MGMT methylation has been linked with the presence of IDH1 
mutation and is a predictive marker for response to alkylating agents such as 
TMZ. 
 To identify and compare miRNA expression profiles of primary tumours based 
on grade, histology and IDH mutation status. Grade III tumours were included to 
determine if the grade III tumours were de novo or if they were grade II tumours 
misdiagnosed at the time of diagnosis.  
 To identify differentially expressed miRNAs associated with different grades of 
LGG as well as deregulated pathways and associated genes that may play a role 
in LGG progression. Paired samples of primary and recurrent tumours were 
analysed to determine significant miRNAs that may promote genes involved in 
tumour progression. Copy number analysis was performed for these paired 
samples to determine any additional changes that may influence tumour 
progression. 
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 To ascertain if short-term cell culture is a good representative model to study 
LGG in vitro. To achieve this, the growth characteristics of short-term cell 
cultures, the mutation and methylation status of IDH1/IDH2 and MGMT 
respectively was determined. The genomic and expression profiles of biopsy 
tissues and their derived short-term cell cultures were identified by copy number 
and miRNA expression analysis. 
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CHAPTER 2  
MATERIALS AND METHODS 
 
2.1 TUMOUR SAMPLES 
This study was conducted under ethical approval granted by the Life Sciences Ethics 
Committee, University of Wolverhampton, LSEC/22/0909. Consented tumour biopsy 
samples were taken from the Brain Tumour North West and Walton Research Tissue 
Banks, UK (Ethics Committee approval reference number 09/H0304/8). Additional 
historical samples collected from the National Hospital of Neurology and Neurosurgery, 
London, UK previous to 1996 before implementation of HTA (Human Tissue 
Authority) were also used in this study. All samples were anonymised at source.  
All samples were classified according to WHO classification (2007) (Louis et al., 2007) 
and they comprised of 36 A (WHO grade II), 7 OA (WHO grade II), 12 O (WHO grade 
II), 11 AA (WHO grade III), 16 AOA (WHO grade III), 10 AO (WHO grade III) and 3 
GBM (WHO grade IV).  
Analysis for primary/recurrent and biopsy/cell culture pairs was carried out using 12 
and 17 paired samples respectively, although, not all pairs were available for each 
experiment.   
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2.2 TISSUE CULTURE 
All cell culture protocols were performed in a sterile class II laminar flow cabinet 
(Telstar, UK) after sterilisation with 70% ethanol and 1% Trigene solution. Growth 
medium used for all cultures contained HEPES buffered Ham’s F10 nutrient mix (Life 
Technologies Ltd, UK) with 10% foetal calf serum (FCS) (Life Technologies Ltd, UK). 
2.2.1 Primary cultures: 
Immediately after surgical resection, the tumour biopsy was placed in growth medium 
without 10% FCS, which contained 100U/ml penicillin (Sigma-Aldrich Company Ltd, 
UK), 100 µg/ml streptomycin (Sigma-Aldrich Company Ltd, UK) and 50 µg/ml 
kanamycin (Sigma-Aldrich Company Ltd, UK). The biopsy was stored at 4ºC for 
collection until transfer to the laboratory.  
Approximately 10 mg of tissue was diced into fine pieces using crossed scalpels and 
transferred to a 25 ml universal tube containing the growth medium with the same 
concentration of antibiotics used in the collection media. The fragments were allowed to 
settle down and the supernatant was discarded after centrifugation at 11700 rpm for 5 
minutes, this process was repeated twice. The tissue fragments were re-suspended in 
growth medium with 1ml collagenase (2000 U/ml) (Sigma-Aldrich Company Ltd, UK) 
and incubated at 37ºC for 4 hours. The sample was pipetted several times to promote 
disaggregation, centrifuged at 333 rpm for 5 minutes and the supernatant discarded. The 
cell solution was re-suspended in fresh growth medium containing antibiotics and 
transferred to a 25 cm
2
 cell culture flask with overnight incubation at 37ºC. The medium 
was changed after 24 hours and cells were maintained at 37ºC. 
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2.2.2 Maintaining cells in culture: 
The medium was changed twice weekly or when the medium turned yellow. The old 
medium was aspirated and replaced with fresh growth medium. 
2.2.3 Passaging cells: 
At confluence, cells were passaged as mentioned below and the passage number of the 
cell culture was increased by 1 each time. Each flask was split in a ratio of 1:3. The old 
media was aspirated and cells were rinsed with 3 ml Hanks’ buffered salt solution 
(HBSS) (Sigma-Aldrich Company Ltd, UK). The cells were treated with 3ml trypsin 
(Life Technologies Ltd, UK) and incubated at 37ºC for 10-15 minutes to detach cells 
from the surface of the flask. The cell solution was transferred to a universal tube after 
addition of 7 ml media to inactivate trypsin and centrifuged at 1300 rpm for 5 minutes. 
The supernatant was carefully aspirated without disturbing the pellet, re-suspended in 
10 ml of growth medium and transferred to a cell culture flask. The flask was incubated 
at 37ºC and the growth of the cells was monitored periodically. Antibiotics were used in 
the medium until cells reached passage 1 (p1).  
Passaging of cells into flasks: 
1 x 25cm
2
 flask to 3 x 25cm
2
 flasks
 
or 1 x 75cm
2
 flask
 
 
1 x 75cm
2
 flask to 3 x 75cm
2
 flasks or 1 x 175cm
2
 flask 
1 x 175cm
2
 flask to 3 x 175cm
2
 flasks 
2.2.4 Reviving cells from storage in liquid nitrogen: 
Cell suspension along with 10 ml growth medium was transferred to a universal, 
centrifuged at 1300 rpm for 5 minutes and the supernatant was removed. The pellet was 
re-suspended in 10 ml media and transferred to a flask. The flask was incubated at 37ºC 
and media was changed after 24 hours.  
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2.2.5 Preparation of cells for storage in liquid nitrogen: 
The cells were trypsinised and re-suspended in fresh 10 ml media, as described above. 
Cells were counted using the Coulter Counter (Beckman Coulter Inc., USA) with 0.4 ml 
of cell solution and 19.6 ml of isoton solution (Beckman Coulter Inc., USA). The 
remaining cell solution was centrifuged at 1300 rpm for 5 minutes to form a pellet. The 
supernatant was removed and cells were re-suspended in a solution with 90% FCS and 
10% dimethyl sulfoxide (DMSO) (Sigma-Aldrich Company Ltd, UK) to a final 
concentration of 1x10
6
 cells/ml. A volume of 1ml cell solution was transferred to each 
cryovial and stored in liquid nitrogen. 
 
2.3 CALCULATION OF DOUBLING TIME 
A growth curve was generated for the cell cultures used in the study to determine the 
growth characteristics of each cell culture with calculation of doubling times. For each 
culture, 5000 cells per well were seeded in triplicates into 96-well plates. After 24 hours 
incubation, the cells were fixed with 10% trichloroacetic acid (TCA) followed by 
staining with sulforhodamine (SRB) solution (0.4% SRB dye and 1% Acetic acid) 
before reading the absorbance each day. The experiment was performed in triplicate for 
each cell culture for a maximum period of 11 days using a GloMax®-Multi+ Microplate 
Multimode Reader with Instinct® (Promega, UK) at 560nm. The growth curve is shown 
with three phases; lag phase, log phase and stationary phase. The lag phase represents 
the time it takes for the cells to attach, the log phase represents the time when the cells 
grow exponentially and the stationary phase is when the cell culture becomes confluent 
and the growth rate is slow. The population doubling time was calculated in Excel using 
two marked points on the log phase to determine the doubling time.  
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2.4 ASSESSMENT OF TUMOUR CELL GROWTH ON FEEDER LAYERS 
An assay with 3T3 cells as a feeder layer was performed to investigate the 
tumourigenicity of short-term cell cultures derived from tumour biopsy. Approximately 
1x10
6
 3T3 cells (NIH 3T3 mouse fibroblast cells; European Collection of Cell Cultures 
(ECACC)) were grown until confluent in a 25 cm
2
 flask and treated with 2 µg/mL 
mitomycin C (Sigma-Aldrich Company Ltd., UK) at 37°C for 2 hours to arrest the cell 
cycle. After incubation, the cells were washed three times with serum free media and 
maintained at 37°C in growth medium. Next day, the medium was changed and the cells 
were incubated at 37°C for 24 hours. LGG cells with a seeding density of 2.5-10 x 10
4
 
cells were seeded onto the 3T3 feeder layer and incubated at 37°C. The cells were 
grown for a period of time until colonies were observed.  
 
2.5 IMMUNOSTAINING 
Approximately 1x10
5
 cells were grown in each well of 8-well chamber slide (Thermo 
Scientific, UK) in 0.5 ml growth medium until 50-60% confluent. Media was removed 
and cells were washed with 1X Tris buffered saline (TBS) three times before fixing 
with pre-chilled 1:1 methanol:acetone. Cells were then rehydrated with TBS and 
washed three times. Cells were incubated for 30 minutes at room temperature with 100 
µl primary mouse monoclonal antibody against glial fibrillary acidic protein (GFAP at 
dilution 1:50) (Dako, UK), IDH1-R132H (1:200; Dianova, Germany), nestin (1:200; 
Millipore, UK), Ki-67 (1:50; Dako, UK), p53 (1:25; Dako, UK), CD34 (1:100; Leica 
Biosystems, UK), epithelial membrane antigen (EMA) (1:50; Leica Biosystems, UK) 
and MGMT (Abcam, UK). A negative control without any primary antibody was 
included. After incubation, the antibody solution was discarded and cells were rinsed 
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twice with TBS. 100 µl of biotinylated secondary antibody (Vectastain Universal Elite 
ABC Kit, Vector Laboratories, UK) was added to each chamber and incubated for 30 
minutes at room temperature. Cells were rinsed twice with TBS and 100 µl of tertiary 
antibody, streptABComplex/HRP solution, (Vectastain Elite ABC Reagent, Vector 
Laboratories, UK) was added to each chamber and incubated for 30 minutes at room 
temperature. The cells were washed twice with TBS and 100 µl diaminobenzidene 
(DAB) solution (Dako, Agilent Technologies, UK) and incubated for 5 minutes before 
washing with distilled water. Cells were counterstained with haematoxylin for 5 
seconds followed by rinsing with warm tap water several times and dehydration of cells 
through a  graded alcohol series. The chamber was removed after the last rinse and the 
slide was rinsed in xylene before mounting with a large coverslip using styrolite. 
Scoring was done following a certain criteria for each of the molecular markers. Scoring 
for MGMT expression was done using quick Allred score method based on the 
proportion of positively stained nuclei and intensity of staining (NHSBSP January 
2005). Tonsil was used as a positive control as recommended by the manufacturer of the 
antibody against MGMT. Scores for proportion were assigned as follows: 0, no 
staining; 1, <1% nuclei staining; 2, 1-10% nuclei staining; 3, 11-33% nuclei staining; 4, 
34-66% nuclei staining and 5, 67-100% nuclei staining. Scores for intensity were as 
follows: 0, no staining; 1, weak staining; 2, moderate staining and 3, strong staining. 
 
2.6 ISOLATION OF DNA  
DNA was extracted from frozen tissue, cultured cells and formalin-fixed paraffin 
embedded (FFPE) sections using QIAamp DNA Mini and Blood kit (Qiagen Ltd, UK) 
according to Agilent array comparative genomic hybridisation (aCGH) protocol (v4.0). 
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2.6.1 Frozen tissues: 
Approximately 25 mg of tissue was diced into smaller pieces, placed in a 1.5 ml 
centrifuge tube containing 180 µl buffer ATL. The solution was homogenised using a 
syringe with a gauge size of 0.6 mm x 30 mm (BD Microlance, USA). The tissue was 
incubated with 20 µl proteinase K (20mg/ml) at 56ºC for 30 minutes or until the tissue 
was completely lysed. The sample was centrifuged briefly before adding 200 µl buffer 
AL followed by vortexing and incubation at 70ºC for 10 minutes. The solution was 
transferred to the QIAamp Mini spin column after addition of 200 µl 100% ethanol and 
centrifuged at 8000 rpm for 1 minute. After centrifugation, the column was washed with 
buffer AW1 and 80% ethanol. The QIAamp Mini spin column was placed in a new 1.5 
ml centrifuge tube and 20 µl nuclease-free water was added to the column. The sample 
was centrifuged at 8000 rpm for 1 minute to elute the DNA and was stored at -20ºC 
until further use.  
2.6.2 Cultured cells: 
A cell pellet with 2-5 x 10
6
 cells was washed with 200 µl phosphate buffered saline 
(PBS) (Sigma-Aldrich Company Ltd, USA) and incubated with 20 µl of proteinase K at 
56ºC for 10 minutes to promote the lysis of cells. It was briefly centrifuged, 200 µl of 
100% ethanol was added and the tube vortexed. Thereafter, the same steps were 
followed as for the frozen tissues and DNA was stored at -20ºC.  
2.6.3 FFPE tissues: 
Paraffin cores measuring 2.0 mm were extracted using the Harris Uni-Core (Ted Pella, 
Inc., USA) from H&E sections that had been confirmed as tumour by a 
neuropathologist (Professor Tim Dawson, Royal Preston Hospital, UK). The core was 
washed with 480 µl PBS and 20 µl of 10% Tween 20 was added. The sample was 
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incubated at 90ºC for 10 minutes followed by immediate centrifugation at 13,000 rpm 
for 15 minutes and placed on ice for 2 minutes. The wax disc was removed using 
forceps and the supernatant was removed. To the pellet, 1 ml 100% ethanol was added, 
vortexed and centrifuged at 13,000 rpm for 5 minutes. Ethanol was removed without 
disturbing the pellet and residual ethanol was left to evaporate with the lid open at room 
temperature. The pellet was mixed with 400 µl of 1M sodium thiocyanate (NaSCN) 
solution (Sigma-Aldrich Company Ltd, UK) and incubated overnight at 37ºC. The 
sample was centrifuged for 20 minutes at 13000 rpm and the supernatant was removed 
followed by washing with 400 µl PBS. The sample was treated with 360 µl buffer ATL 
and 40 µl proteinase K and incubated overnight at 56ºC. The sample was centrifuged 
before addition of 40 µl proteinase K and incubation at 56ºC for 6-8 hours. Another 40 
µl proteinase K was added to the sample and incubated at 56ºC overnight. Finally, 400 
µl buffer AL was added to the mix and incubated at 56ºC for 10 minutes. The sample 
was centrifuged at 8000 rpm for 30 seconds and 440 µl of 100% ethanol was added. The 
sample mix was added to the DNeasy Mini spin column, centrifuged for 1 minute at 
8000 rpm and the column was placed in a fresh 2 ml collection tube. Buffer AW1 and 
80% ethanol was used to wash the column and the same steps were performed to elute 
the DNA as for the frozen tissues.  
The quality of the DNA extracted from the paraffin tissue was determined by 
electrophoresis through a 2% agarose gel at 100 V for 1 hour and compared with a 1 Kb 
ladder (Thermo Scientific, UK). Good quality FFPE DNA was visualised as a smear 
using a UV transilluminator (Syngene, UK) and photographed using GeneSnap 
(Syngene, UK). 
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2.7 ISOLATION OF miRNA  
Total RNA containing microRNA was extracted using the mirVana miRNA isolation kit 
(Life Technologies Ltd, UK) according to the manufacturer’s instructions. For cultured 
cells, 3-6 x 10
6
 cells were lysed using 300-600 µl Lysis/Binding solution depending on 
the size of the pellet. The solution was vortexed briefly to lyse the cells completely. For 
frozen tissue, 10 volumes of Lysis/Binding buffer were added to approximately 25 mg 
of tissue on ice. The solution was homogenized using a syringe with a needle gauge size 
of 0.6 mm x 30 mm (BD Microlance, USA) and 1/10 volume of miRNA homogenate 
additive was added to the mixture followed by 10 minutes incubation on ice. A volume 
of Acid-Phenol:Chloroform (Sigma-Aldrich Company Ltd, UK) equal to the lysate 
volume was added and vortexed. The sample was centrifuged at 13000 rpm speed at 
4ºC to separate the aqueous and organic phases. The aqueous (upper) phase was 
transferred into a fresh 1.5 ml centrifuge tube and 1.25 volumes of 100% ethanol was 
added and passed through the column followed by centrifugation at 13000 rpm for 15 
seconds. The column was washed with 700 µl miRNA Wash Solution 1 and twice with 
500 µl Wash Solution 2/3. Total RNA was eluted in 20 µl nuclease-free water by 
centrifuging at 13000 rpm speed for 20-30 seconds and stored at -80ºC.  
 
2.8 ASSESSMENT OF DNA AND RNA  
The quantity and quality of DNA and RNA was assessed using a NanoDrop 2000 
spectrophotometer (Thermo Scientific, UK). Samples with an A260/280 ratio of 1.8-2.0 
and A260/230 of more than 2.0 were considered good quality DNA. Good quality RNA 
with an A260/280 ratio of 2.0 and A260/230 of 2.0-2.2 was used for miRNA expression 
analysis.  
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For miRNA quality assessment, Agilent 2100 Bioanalyzer (Agilent Technologies Ltd, 
UK) was used and the sample was screened for the presence of two ribosomal peaks 
representing 18S and 28S along with a peak for smaller RNAs. The Bioanalyzer 
assigned an RIN number (RNA Integrity number) ranging from 1 to 10; 1 being the 
most degraded and 10 being the most intact. Samples with a high RIN number > 9 and 
with a peak representing the smaller RNAs were used for miRNA array analysis. 
 
2.9 PCR AMPLIFICATION FOR IDH1 AND IDH2 
IDH1 and IDH2 primer sets (Sigma-Aldrich Company Ltd, UK) used for PCR 
amplification were adopted from a study by Sonoda et al. (2009). A negative control 
containing all PCR components except template DNA was included in each experiment. 
Exons 4 of IDH1 and IDH2 genes containing codons 132 and 172 respectively were 
amplified using the primer sequences, IDH1 forward – ATAGGTCGTCATGCT, IDH1 
reverse – AGCATGACGACCTA and IDH2 forward – 
CAAGCTGAAGAAGATGTGGAA, IDH2 reverse – 
CAGAGACAAGAGGATGGCTA. 
PCR amplification was performed using 100ng DNA in a final volume of 20 µl 
containing 10 mM dNTP mix, 10 mM of forward and reverse primers and 2 U 
HotStarTaq DNA polymerase (Qiagen Ltd, UK) supplemented with 25 mM MgCl2. 
Following a 15 minute denaturation step at 95°C, 40 cycles of 30 seconds at 95°C, 30 
seconds at 56ºC and 40 seconds at 72ºC with a final 10 minute extension at 72ºC was 
used. Amplification products were visualised under UV light after separation through a 
2% agarose gel containing 1X TAE and 10 mg/ml ethidium bromide solution at 100 V 
for 1 hour using a 100 bp ladder (Thermo Scientific, UK).   
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2.10 PREPARATION OF PCR PRODUCTS FOR SEQUENCING 
The amplification products were purified using GenElute PCR Clean-Up Kit (Sigma-
Aldrich Company Ltd, UK) according to the manufacturer’s instructions. A GenElute 
Miniprep Binding column was prepared with 0.5 ml of column preparation solution and 
centrifuged at 13000 rpm for 1 minute. The eluate was discarded and 5 volumes of 
binding solution were added to 1 volume of PCR product. The solution was transferred 
into the binding column and centrifuged at 13000 rpm for 1 minute. The column was 
washed with 0.5 ml of wash solution and centrifuged at maximum speed (> 14000 rpm) 
for 3 minutes to remove leftover ethanol. The miniprep column was transferred to a 
fresh 2 ml collection tube and 15 µl elution solution was added to elute purified DNA.  
 
2.11 DIRECT SEQUENCING 
The Sanger sequencing method (Sanger et al., 1977) was used to determine the 
sequence of nucleotides within a sample. PCR purified products (1 ng/µl per 100bp) 
were analysed by Source BioScience LifeSciences (Cambridge, UK). The sequencing 
was performed using the BigDye® Terminator v3.1 cycle sequencing kit (Life 
Technologies Ltd, UK) with 3.2 pmol of each primer on an ABI 3730xl DNA analyser 
(Applied Biosystems Ltd, UK). Analysis was performed using the Sequence Scanner 
software v1.0 (Life Technologies Ltd, UK).  
 
2.12 BISULFITE MODIFICATION OF DNA 
DNA was bisulfite-modified using EZ DNA Methylation-Gold Kit (Zymo Research, 
UK) with 200–500 ng of DNA as starting material. The sample was mixed with CT 
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conversion reagent and incubated at 95°C for 12 minutes and 64°C for 2.5 hours. The 
DNA mix was added to a column placed in a collection tube with 600 µl M-binding 
buffer. The sample was mixed well with inversion a few times and centrifuged at 13000 
rpm for 30 seconds. Flow-through was discarded; 100 µl of wash buffer was added to 
the column and centrifuged at 13000 rpm for 30 seconds. Desulphonation buffer was 
added to the column, incubated at room temperature for 15-20 minutes and centrifuged 
at full speed (> 14000 rpm) for 30 seconds. The sample was washed twice with wash 
buffer followed by addition of elution buffer to elute the DNA. DNA was stored at -
20°C until further use.  
 
2.13 METHYLATION SPECIFIC PCR (MS PCR) 
Amplification of MGMT gene was carried out using two sets of primers for 
unmethylated and methylated modified DNA, previously described by Esteller et al., 
(1999). PCR amplification was performed in a final volume of 20 µl containing 10x 
buffer (Qiagen Ltd., UK), 200 µM dNTP mix (Sigma-Aldrich Company Ltd., UK), 10 
pmol of forward and reverse primers (Sigma-Aldrich Company Ltd., UK), 5U 
HotStarTaq DNA polymerase (Qiagen Ltd., UK) and 200 – 500 ng bisulfite-modified 
DNA. A positive control (IN699) and a negative control (with no DNA) were included 
in each experiment. Following an initial incubation at 95°C for 15 minutes, 35 cycles at 
94°C for 30 seconds, 59°C for 30 seconds and 72°C for 30 seconds were performed 
with a final extension at 72°C for 5 minutes.  
Amplification products were separated using a 3% agarose gel at 100 V for 1 hour and a 
50bp ladder (Thermo Scientific, UK). PCR products were visualised under UV light.  
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2.14 STATISTICAL ANALYSIS 
Statistical analysis was performed using GraphPad Prism v6 (USA) and SPSS statistics 
v20 (IBM, USA). Non-parametric tests such as log-rank (Mantel Cox) test, Fisher’s 
exact test and Mann Whitney test were used to determine significance between various 
molecular characteristics and correlation with PFS and OS as described in Chapter 3. 
Non-parametric tests were appropriate for this study as they are more robust and take 
fewer assumptions. Cox proportional hazard model for multivariate analysis was used to 
determine strong and independent factors for a better outcome. A p-value < 0.05 was 
considered as statistically significant. 
 
2.15 ARRAY COMPARATIVE GENOMIC HYBRIDIZATION (aCGH) 
Array CGH was carried out on a 244K array (Agilent Technologies Ltd, UK) using 
Agilent Oligonucleotide Array-Based CGH for Genomic DNA Analysis v4.0. 
2.15.1 Heat fragmentation 
The optimal size range of DNA for aCGH is 1000-3000bp (Agilent specialist 
recommendation) and high molecular weight samples as well as reference samples 
underwent heat fragmentation for 0, 5 and 10 minutes to achieve this size range. 
Following fragmentation, the size range of each sample was assessed using a 0.8% 
agarose gel and HighRanger 1 kb DNA ladder (Geneflow Ltd, UK) as shown in 
Appendix II. 
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2.15.2 Labelling 
A concentration of 1500 ng DNA in a final volume of 16.5 µl made up with nuclease-
free water was heat-fragmented at 95°C for an appropriate time determined as above 
and kept on ice for 3 minutes. A master mix (3.5 µl) with 10x labelling solution (2 µl) 
and ULS-Cy3 or ULS-Cy5 dyes (1.5 µl for both; Agilent Technologies Ltd, UK) was 
prepared; tumour samples were labelled with Cy3 and sex-matched with reference 
samples (male/female human genomic DNA; Promega, UK) labelled with Cy5. The 
sample mixture containing the DNA and labelling mix was incubated at 85°C for 30 
minutes, 4°C for 3 minutes and centrifuged briefly after incubation. Agilent KREApure 
columns were used for removal of non-reacted ULS-Cy by preparing the columns and 
rinsing them with nuclease-free water. ULS-labelled DNA was added to the column and 
centrifuged at maximum speed to collect the purified labelled DNA which was 
quantified to determine the degree of labelling calculated as below: 
Degree of labelling = 340 x pmol per µl dye     x 100% 
                                   ng per µl DNA x 1000 
 
The optimal range for Cy5 degree of labelling was 0.75-2.5% and for Cy3 was 1.75-
3.5% with a Cy3 minus Cy5 range of 1-2%.  
Labelled gDNA sample was mixed with the reference sample to a total volume of 37 µl. 
If required, DNASpeed Vac DNA 110 (Savant Instruments Inc., USA) was used to 
concentrate the samples to a volume of 37 µl in order to give a final volume of 390 µl 
following the addition of the hybridisation mix described below.  
2.15.3 Hybridisation 
Blocking agent (100x) (Agilent Technologies Ltd, UK) was prepared with nuclease-free 
distilled water, vortexed and incubated at room temperature for 60 minutes to 
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reconstitute before storage at -20°C. Hybridisation master mix was made with nuclease-
free water (37.8 µl), 1.0 mg/ml Cot-1 DNA (50 µl; Invitrogen, UK), 100x Agilent 
Blocking agent (5.2 µl) and 2x HI-RIPM hybridisation buffer (260 µl; Agilent 
Technologies Ltd, UK) and added to each labelled gDNA sample. Sample mix was 
incubated at 95ºC for 3 minutes and 37ºC for 30 minutes before Agilent-CGH Block 
(130 µl; Agilent Technologies Ltd, UK) was added and mixed well to stop the labelling 
reaction.          
A clean gasket slide was loaded onto the Agilent SureHyb chamber (according to 
manufacturer’s instructions) and hybridisation sample mix was slowly dispensed in a 
drag and dispense manner. A microarray slide was placed onto the gasket slide and the 
SureHyb chamber was then covered onto the slides with tightening of the clamps 
firmly. The assembled chamber was vertically rotated to assess the mobility of the 
bubbles and to uniformly spread the liquid on the slides. The assembly was tapped hard 
to move the stationary bubbles. The assembled chamber was incubated at 65ºC rotating 
at 20 rpm for 40 hours in a hybridisation oven (Agilent Technologies Ltd, UK).  
2.15.4 Microarray washes 
After the incubation, the microarray slide was washed with wash buffer 1 at room 
temperature for 5 minutes, wash buffer 2 at 37°C for 1 minute, acetonitrile at room 
temperature for 10 seconds and stabilisation and drying solution at room temperature 
for 30 seconds. The slides were placed in a slide holder and stored in dark until ready to 
be scanned to avoid oxidising of the Cy5 dye. 
2.15.5 Array scanning and Analysis 
The Agilent Microarray scanner (model G2565B) was used to scan each microarray 
slide with the AgilentHD_CGH protocol (CGH_107_Sep09) with the following default 
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QC settings: scan region of 61 x 21.6 mm, scan resolution of 5 µm, 16 bit TIFF image 
and laser scanning at 100% for both red and green signals.  
The TIFF image was used for data extraction using the Feature Extraction program 
(Agilent Technologies Ltd) generating a QC report and .txt file containing all the probes 
and aberrations. The .txt file was analysed using CytoGenomics (v2.7; Agilent 
Technologies Ltd, UK) and Partek Genomics Suite (version 6.6; Partek Inc., USA) 
softwares.  
The Feature Extraction program summarises the statistics for the metrics on each QC 
report and shows if the thresholds were exceeded. The metrics include grid, derivative 
of log ratio SD, for both red and green signals, background noise, signal to noise and 
signal intensity. Arrays with QC metrics within the excellent and good ratio thresholds 
were used for further analysis. 
  
2.16 miRNA ARRAY 
The quality of the RNA samples was assessed using Agilent 2100 bioanalyser (Agilent 
Technologies Ltd, UK) and QC (quality control) reports were generated for each sample 
showing the RNA integrity represented by RIN as discussed previously in this chapter. 
Both QC and microarray analysis were performed at Cambridge Genomics Services 
(Cambridge, UK). Microarray analysis was performed using 3D Gene Human miRNA 
oligo chips (Toray, Japan) containing 1719 human miRNAs selected from the miRBase 
database, release 19. Spike controls were included in the array for QC. High quality 
RNA sample containing miRNA was assessed using a bioanalyser and 250 ng of sample 
was used for the microarray.  
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2.16.1 Labelling 
The extracted RNA was labelled with Hy5 using the miRCURY LNA Array miR 
labeling kit (Exiqon, Vedbaek, Denmark). Total RNA with a concentration of 250 ng in 
5 µl volume was made up with nuclease-free water and placed in a 1.5 ml centrifuge 
tube. A labelling reaction mix containing the total RNA, 0.5 µl CIP buffer, 0.5 µl Calf 
intestine phosphatase and 1 µl miRNA spike control to a total volume of 4 µl made up 
with nuclease-free water was incubated at 37°C for 30 minutes, 95°C for 5 minutes and 
left on ice for 2 minutes. Three µl labelling buffer, 1.5 µl fluorescent label (Hy5), 2 µl 
DMSO and 2 µl labelling enzyme were then added to a total volume of 12.5 µl. The 
reaction was incubated at 16°C for 1 hour followed by 15 minutes at 65°C and was 
stored at 4°C until hybridisation.  
2.16.2 Preparation of hybridisation solution 
To the labelled miRNA, 0.6 µl hybridisation buffer A and 52.5 µl miRNA hybridisation 
buffer V2 was added and degasified (ULVAC, Inc.: MDA-015) for 18 minutes. The 
degasified solution was incubated at 65°C for 3 minutes before centrifuging at 16000 
rpm for 1 minute. The hybridisation solution was incubated at 32°C for 5 minutes 
before proceeding to the next step.  
2.16.3 Hybridisation 
The reaction chamber on the 3D-Gene miRNA chip was loaded with 50 µl of the 
hybridisation solution and sealed with a cover. The hybridisation chamber was mounted 
on the shaker and 30 µl nuclease free water was added into both sides of the chamber to 
maintain humidity. The chamber was placed horizontally with the cover plate on top 
and screwed to seal the chamber. The hybridisation was carried out at 32°C for 16 hours 
rotating at 250 rpm in a hybridisation oven.  
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2.16.4 Washing 
The 3 wash solutions were warmed up at 30°C before removing the hybridisation 
chamber from the oven. The slide was washed in first wash solution for 5 minutes, 
second wash solution for 10 minutes and third wash solution for 5 minutes with 
constant shaking. The miRNA chip was stored in the dark until ready to be scanned.  
2.16.5 Scanning and analysis 
The fluorescent signals were scanned by a 3D-Gene scanner (Toray) with default 
settings and the raw data files were analysed using Partek Genomics Suite (version 6.6; 
Partek Inc., USA) software.  
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CHAPTER 3 
ANALYSIS OF IDH MUTATION AND MGMT METHYLATION IN 
PRIMARY LOWER GRADE DIFFUSE GLIOMA 
 
3.1 INTRODUCTION 
IDH1 mutation is most frequent in LGG (~80%) and is an important prognostic marker 
for better outcome (Thon et al., 2012). The isoform IDH2 is less frequently mutated and 
occurs mutually exclusively to IDH1 mutation. The most frequent mutation of IDH1 
involves substitution of arginine residue at position 132 to histidine (R132H) and the 
IDH2 mutation involves the equivalent position 172 where arginine is substituted to 
lysine (R172K) as the most common mutation. MGMT promoter methylation is the only 
predictive marker for response to alkylating agents such as TMZ used in chemotherapy 
(Takahashi et al., 2013). In tumours with hypermethylation of MGMT, expression of 
MGMT is reduced and cytotoxicity of alkylating agents is enhanced. Both IDH1 
mutation and MGMT methylation are associated with better outcome in glioma.  
The aim of this chapter was to investigate relationships between IDH1 and IDH2 
mutation and/or MGMT methylation status and clinicopathological parameters including 
grade, age, histology and outcome in primary tumours. The hypothesis was that tumours 
with IDH1 mutation are MGMT methylated and tumours with IDH1 wild type are 
unmethylated. The comparative assessment of two methods for analysis of MGMT 
methylation, MS PCR and immunohistochemistry (IHC) is also described in this 
chapter. Moreover, association of IDH1 mutation, MGMT status, age and grade with 
PFS and OS was determined.  
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3.2 SAMPLE COHORT 
The sample cohort comprised 66 primary tumours, 38 of which were grade II tumours 
(25 A, 6 OA, 7 O) and 28 were grade III tumours (8 AA, 13 AOA, 7 AO). Patients were 
treated with a range of different therapies including radiotherapy and chemotherapy 
using PCV and TMZ. Treatment information was available for 15 cases as detailed in 
Appendix III. 
 
3.3 IDH MUTATION ANALYSIS  
The IDH mutation status of 66 tumour samples was determined by direct sequencing 
and the frequency and spectrum of the mutations is summarised in Table 3.1. IDH1 
mutation was detected in 60% A (15/25), 83% OA (5/6), 100% O (7/7), 25% AA (2/8), 
38% AOA (5/13) and 57% AO (4/7). All mutations were heterozygous and the 
overwhelming majority (97%, 37/38) were R132H (CGT to CAT) with R132S (CGT to 
AGT) present in only 1 AO tumour (BTNW67). IDH2 mutation analysis was completed 
for 41 cases due to constraints on availability of tumour DNA. An R172K (AGG to 
AAG) mutation was detected in BTNW15 (AO) which was IDH1 wild type. Numerous 
studies have demonstrated that IDH2 mutations are mutually exclusive with IDH1 
mutations (Hartmann et al., 2009; Sonoda et al., 2009; Yan et al., 2009). Of the 25 
tumours for which IDH2 mutation analysis was not completed, 22 had IDH1 mutation, 
and hence, it is extremely unlikely that concurrent IDH2 mutations were present. 
Examples of the chromatograms for the mutations identified in this study are given in 
Figure 3.1.  
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Table 3.1 IDH mutation status in primary grade II and grade III glioma 
 
Tumour Agea Sexb Grade Histologyc IDH1 statusd IDH2 statuse PFSf OSg 
BTNW17 69 F II A WT WT 4.5 4.5 (D) 
BTNW20 26 M II A R132H WT 83 94 (A) 
BTNW61 32 M II A R132H WT - 88.5 (A) 
BTNW124 29 M II A WT WT - 65.5 (D) 
BTNW160 35 M II A R132H NA 67 78 (A) 
BTNW203 42 F II A R132H WT 52.5 75 (A) 
BTNW210 53 F II A R132H NA - 74.5 (A) 
BTNW212 50 M II A R132H NA - 45.5 (D) 
BTNW365 42 F II A R132H WT 28.5 37.5 (D) 
BTNW367 56 M II A WT WT 1 62 (A) 
BTNW381 54 M II A WT WT - 25.5 (D) 
BTNW680 59 M II A WT WT - 13 (D) 
BTNW736 63 F II A WT WT - 8 (D)  
BTNW761 25 M II A R132H NA - 40.5 (A) 
BTNW818 60 F II A WT WT 24.5 29 (D)  
BTNW823 61 F II A R132H NA - 36.5 (A) 
BTNW830 21 M II A WT NA - 36 (A) 
BTNW868 39 F II A R132H NA 22.5 33.5 (A) 
BTNW870 17 M II A WT WT 1 33 (A) 
BTNW931 30 M II A R132H NA - 28.5 (A) 
BTNW1005 43 F II A R132H NA - 13.5 (A) 
BTNW1028 40 M II A R132H NA - 13.5 (A) 
Liv002 34 F II A R132H WT - 25 (A) 
Liv003 30 F II A R132H WT - 22 (A) 
Liv007 40 M II A WT WT - 8 (D) 
BTNW13 40 F II OA R132H NA 44.5 74 (D) 
BTNW503 51 M II OA R132H NA 42.5 53.5 (A)  
BTNW613 37 M II OA R132H NA 37 49.5 (A) 
BTNW726 45 M II OA R132H NA 17 43.5 (A) 
BTNW929 43 F II OA WT WT - 29 (A) 
Liv015 36 M II OA R132H WT - 13 (A) 
BTNW188 43 F II O R132H NA - 76 (A) 
BTNW326 56 F II O R132H NA 33.5 37.5 (D) 
BTNW531 29 M II O R132H NA - 52 (A) 
BTNW882 82 M II O R132H NA - 32 (A) 
Liv020 75 M II O R132H WT - 24.5 (A) 
Liv024 30 M II O R132H WT - 12 (A) 
Liv026 58 M II O R132H WT - 13.5 (A) 
BTNW19 42 F III AA R132H NA - 70 (D) 
BTNW38 48 M III AA WT WT - 4.5 (D) 
BTNW126 66 M III AA WT WT 5 6 (D) 
BTNW173 50 M III AA R132H WT - 5.5 (D) 
BTNW211 72 M III AA WT WT - 2 (D) 
BTNW421 59 M III AA WT WT - 7.5 (D) 
BTNW458 71 F III AA WT WT - 17 (D) 
BTNW925 78 M III AA WT NA - 1.5 (D) 
BTNW9 62 F III AOA WT WT - 17.5 (D) 
BTNW14 43 M III AOA R132H WT 64.5 95.5 (A) 
BTNW120 27 M III AOA R132H NA 95.5 138 (D) 
BTNW174 42 F III AOA WT WT 36 45.5 (D) 
BTNW183 66 F III AOA WT WT - 0.5 (D) 
BTNW325 46 M III AOA WT NA 230.5 263 (D) 
BTNW495 71 F III AOA WT WT - 8.5 (D) 
BTNW527 59 F III AOA WT WT - 2.5 (D) 
BTNW614 49 M III AOA R132H NA 14.5 21.5 (D) 
BTNW686 56 M III AOA WT WT - 16 (D) 
BTNW703 46 M III AOA R132H NA - 45.5 (A) 
BTNW825 62 F III AOA WT WT - 36 (A) 
BTNW864 39 M III AOA R132H NA - 34 (A) 
BTNW15 56 M III AO WT R172K 13.5 14.5 (D) 
BTNW67 62 F III AO R132S WT - 2 (D) 
BTNW179 35 F III AO R132H WT - 14.5 (D) 
BTNW460 29 M III AO R132H WT - 22 (D) 
BTNW738 66 M III AO WT WT - 12 (D) 
BTNW757 72 M III AO WT WT - 6 (D) 
BTNW804 44 M III AO R132H WT - 11 (D) 
 
a
 Age at diagnosis in years; 
b
 M, male; F, female; 
c
 A, astrocytoma; OA, oligoastrocytoma; O, 
oligodendroglioma; AA, anaplastic astrocytoma; AOA, anaplastic oligoastrocytoma; AO – anaplastic 
oligodendroglioma; 
d
 R132H, IDH1 mutant; WT, wild type; 
e
 R172K, IDH2 mutant; WT, wild type; 
f
 PFS 
in months; 
g  
OS in months; A, alive; D, dead; NA, not available. 
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Figure 3.1 Sequencing chromatogram depicting IDH1 and IDH2 mutations 
IDH1 mutation 
 
 
 
 
 
 
 
 
 
IDH2 mutation 
       
                                           
 
                                           
 
Representative examples for IDH1-R132H, IDH1-R132S and IDH2-R172K mutation as 
determined by direct sequencing. 
 
CGT-CAT   
                Wild-type  
       R132H Mutant  
CGT-AGT   
              Wild-type  
          R132S Mutant 
                Wild-type  
       R172K Mutant  
AGG-AAG   
55 
 
3.3.1 Relationship between IDH1 status and grade 
The frequency of IDH1 mutation was significantly higher in grade II tumours, 27/38 
(71%) compared with grade III tumours, 11/28 (39%) (p < 0.0001; Fisher’s exact test).  
 
3.3.2 Relationship between IDH1 status and histology 
IDH1 status was analysed in each of the histological groups comprising A, OA, O, AA, 
AOA and AO tumours and the results are summarised in Table 3.2. IDH1 mutations 
were most frequently present in grade II tumours with an oligodendroglial component 
(O 100%, 7/7; OA 83%, 5/6 too few cases in comparative groups to complete statistical 
analysis) compared to pure astrocytic tumours (A 60%, 15/25, p = 0.178; Fisher’s exact 
test). Similarly, in the grade III tumours, a higher proportion of AO (57%, 4/7, p = 
0.011; Fisher’s exact test) and AOA (38%, 5/8, p = 0.008; Fisher’s exact test) carried 
IDH1 mutations compared to AA (27%, 2/6, p = 0.054; Fisher’s exact test). 
 
3.3.3 Relationship between IDH1 status and age 
Patients with IDH1 mutations were younger than those with wild type IDH1 (p = 
0.0002; Mann Whitney test) and the data is represented in Figure 3.2. The median age 
for patients with tumours carrying IDH1 mutation was 42 years and that of patients with 
IDH1 wild type tumours was 59 years. When broken down by histology as illustrated in 
Figure 3.3 and Table 3.3, patients with IDH1 wild type tumours tended to be older than 
those with IDH1 mutant tumours in all histological groups although this only reached 
statistical significance for AOA (p = 0.0081). 
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Figure 3.2 Relationship between age and IDH1 status 
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Patients with IDH1 wildtype (n = 28) and IDH1 mutant (n = 38) tumours were used for 
the relationship analysis. The bar represents the median age for the patients with mutant 
and wildtype tumours. The median for patients with wildtype tumours was 59 years and 
that for patients with mutant tumours was 42 years. Patients with IDH1 mutations were 
significantly younger than those with wild type IDH1 (p = 0.0002).  
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Table 3.2 Relationship between IDH1 status and histology 
Histology IDH1 Mutant IDH1 Wild type p value 
Number of 
cases 
% Number of 
cases 
% 
A 15 60 10 40 0.178 
OA 5 83 1 17 N/A 
O 7 100 0 0 N/A 
AA 2 25 6 75 0.054 
AO 3 57 3 43 0.011 
AOA 5 38 8 62 0.008 
 
 
Table 3.3 Summary of tumour histology, grade and age in IDH1 mutant and wild type 
tumours 
Histology IDH1 mutant IDH1 wild type             p value 
Mean age  Median age      Mean age Median age 
A 38.8 39            46.8        55            0.178 
OA 41.8 40           43*         43*          N/A 
O 53.29 56           No data           No data          N/A 
AA 46 46            65.67         68.5            0.054 
AO 36 35            64.67        66            0.064 
AOA 40.8 43          58         60.5            0.008 
 
* single case only 
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Figure 3.3 Relationship between tumour histology, grade, age and IDH1 mutation 
status 
 
Tumour samples in red are IDH1 mutant tumours and samples in blue are IDH1 wild 
type. Significant difference in age was observed in only AOA group, IDH1 mutant vs 
IDH1 wild type.  
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3.3.4 Relationship between age, tumour grade and histology 
Patients with grade III tumours were significantly older than those with grade II 
tumours (p = 0.008). Patients with grade II tumours had an age range of 17-82 years 
with a median of 42 years and those with grade III tumours had an age range of 27-78 
years with a median of 56 years. Patients with AA were older than patients with either 
A (p = 0.0026) or OA (p = 0.007) with a trend towards AOA patients being older than A 
patients. 
 
3.3.5 Comparison of IHC and sequencing to identify IDH1 status 
IHC for mutated IDH1 protein had previously been performed in 27 samples with 
sufficient tissue available. Results for mutation analysis were consistent with both direct 
sequencing and IHC for all the 27 tumours analysed by the two methods. Of the 27 
cases, 15 were positive and 12 were negative for the IDH1 mutant protein and all the 
samples analysed had the IDH1 R132H mutation. Tumour samples were analysed by 
the neuropathologist (Professor Tim Dawson, Royal Preston Hospital, UK) after 
carrying out IHC using IDH1-R132H antibody (Dianova, UK). 
 
3.4 RELATIONSHIP BETWEEN CLINICAL PARAMETERS AND OUTCOME 
Kaplan Meier curves were generated to illustrate the correlations of molecular markers 
with OS and are shown in Figure 3.4. OS was defined as the time from diagnosis until 
death or last follow up of the patient. PFS was defined as the time between diagnosis 
and confirmation of recurrence by histological analysis. A patient with an AOA tumour 
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was the longest survivor in the cohort with OS of 263 months. Interestingly, the tumour 
was IDH1 wild type.  The upper limit for OS was taken as 150 months for the analysis.  
 
3.4.1 Relationship between tumour grade and outcome 
Patients with grade II tumours survived longer than those with grade III tumours (p < 
0.0001; log rank Mantel-Cox test) shown in Figure 3.4A. The median survival for 
patients with grade II tumours was 34.7 months and that for patients with grade III 
tumours was 14.5 months. 
 
3.4.2 Relationship between age and outcome 
Age was a significant factor for OS. Younger patients (< 50 yrs) lived longer than older 
patients (> 50 yrs) (p = 0.0002; log rank Mantel-Cox test) as shown in Figure 3.4B, and 
this relationship was observed in patients with both grade II (p = 0.0460; log rank 
Mantel-Cox test) and grade III (p = 0.0017; log rank Mantel-Cox test) tumours (Figure 
3.4C and D). The median survival for patients aged < 50 years was 74 months and that 
for patients aged > 50 years was only 16 months. In patients with grade II tumours, the 
median survival for younger patients (< 50 yrs) was 39 months against 30.5 months in 
older patients (> 50 yrs). In patients with grade III tumours, the median survival for 
younger patients (< 50 yrs) was 45.5 months compared to only 7.5 months in older 
patients (> 50 yrs).  
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3.4.3 Relationship between tumour histologies and outcome 
Histology did not seem to be related to outcome in patients with grade II tumours, (p = 
0.4856; log rank Mantel-Cox test), but in patients with grade III tumours, patients with 
AOA lived longer than those patients with AO or AA (p = 0.0091; log rank Mantel-Cox 
test). These results are presented in Figure 3.4E and F. Patients with A, OA and O 
tumours had a median survival of 33.5 months, 46.5 months and 32 months 
respectively. The median survival for patients with AA, AOA and AO tumours was 
5.75 months, 33.5 months and 12 months respectively.  
 
3.4.4 Relationship between IDH1 status and outcome 
Patients with IDH1 mutant tumours lived longer than patients with wild type IDH1 (p < 
0.0001; log rank Mantel-Cox test). Patients carrying IDH1 mutation had a median 
survival of 37 months, which was longer than the 13.75 months for patients with wild 
type tumours (Figure 3.4G). Patients carrying IDH1 mutation had a favourable outcome 
in grade II tumours (p = 0.0001; log rank Mantel-Cox test) but the mutation did not 
seem to influence the outcome in grade III tumours (p = 0.0923; log rank Mantel-Cox 
test) (Figure 3.4H and I). In grade II tumours, the median survival of patients with IDH1 
mutant tumours was 45.5 months and that for patients with IDH1 wild type tumours was 
29 months. In grade III tumours, the median survival of patients with IDH1 mutant 
tumours was 22 months and that for patients with IDH1 wild type tumours was only 9 
months (Figure 3.4J).  
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Figure 3.4 Kaplan Meier survival curves depicting correlation of OS with IDH1 mutation, age and grade 
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Figure 3.4 Kaplan Meier survival curves depicting correlation of OS with IDH1 mutation, age and grade (cont’d) 
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3.5 ANALYSIS OF MGMT PROMOTER METHYLATION BY MS PCR AND 
IHC 
MGMT promoter methylation was determined by MS PCR in 57 tumours comprising 32 
grade II tumours (21 A, 5 OA, 6 O) and 25 grade III tumours (8 AA, 12 AOA, 5 AO). 
Of these, 14% (8/57) were methylated, 19% (11/57) were partially methylated and 67% 
(38/57) were unmethylated as detailed in Table 3.4. An example of MS PCR data is 
shown in Figure 3.5. 
IHC was carried out in 51 primary tumours and MS PCR data was available for 47/51 
of these samples (Table 3.4). Areas of high cellularity without any haemorrhage were 
selected to score the proportion of stained nuclei indicative of MGMT protein 
expression and 100 cells were examined in three fields to get an average score. The 
quick (Allred) scoring system was used to determine the proportion and intensity of the 
staining. Examples of IHC results are shown in Figure 3.6. Two tumours (BTNW 761 
and BTNW537) had completely negative staining and a score of zero. A further 14 
tumours had a combined Allred score of 1-4 (low expression), whilst the majority of 
samples (35) had a higher combined Allred score of 5-8 (high expression). If the 
proportion of stained cells only was considered, 11 tumours had a low expression score 
between 1-2 and 38 cases had a high expression score between 3-5.   
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Table 3.4 MGMT methylation status by IHC and MS PCR in primary grade II and grade III 
glioma 
Tumour Agea Grade Histologyb MGMT 
methylation 
status (MS PCR)c 
IHC 
proportion 
IHC 
intensity 
IHC 
Combined 
score 
PFSd OSe 
BTNW17 69 II A U NA NA NA 4.5 4.5 (D) 
BTNW20 26 II A U 1 3 4 83 94 (A) 
BTNW61 32 II A U 5 3 8 - 88.5 (A) 
BTNW124 29 II A U NA NA NA - 65.5 (D) 
BTNW160 35 II A PM 3 1 4 67 78 (A) 
BTNW203 42 II A U 4 2 6 52.5 75 (A) 
BTNW210 53 II A U 1 2 3 - 74.5 (A) 
BTNW212 50 II A M 3 2 5 - 45.5 (D) 
BTNW365 42 II A NA 3 2 5 28.5 37.5 (D) 
BTNW367 56 II A PM 5 3 8 1 62 (A) 
BTNW381 54 II A U 2 2 4 - 25.5 (D) 
BTNW680 59 II A U 5 2 7 - 13 (D) 
BTNW736 63 II A U 1 2 3 - 8 (D)  
BTNW761 25 II A U 0 0 0 - 40.5 (A) 
BTNW818 60 II A U 5 3 8 24.5 26 (D)  
BTNW823 61 II A U 3 3 6 - 36.5 (A) 
BTNW830 21 II A U 4 2 6 - 36 (A) 
BTNW868 39 II A U 4 3 7 22.5 33.5 (A) 
BTNW870 17 II A U 4 2 6 1 33 (A) 
BTNW931 30 II A NA 4 2 6 - 28.5 (A) 
LIV002 34 II A U NA NA NA - 25 (A) 
LIV003 30 II A PM NA NA NA - 22 (A) 
LIV007 40 II A U NA NA NA - 8 (D) 
BTNW13 40 II OA U 4 2 6 44.5 74 (D) 
BTNW503 51 II OA U 3 1 4 42.5 53.5 (A)  
BTNW613 37 II OA PM 5 3 8 37 49.5 (A) 
BTNW726 45 II OA U 5 3 8 17 43.5 (A) 
BTNW929 43 II OA NA 3 2 5 - 29 (A) 
LIV015 36 II OA U NA NA NA - 18 (A) 
BTNW188 43 II O M 4 2 6 - 76 (A) 
BTNW326 56 II O M 4 3 7 33.5 37.5 (D) 
BTNW531 29 II O M 3 2 5 - 52 (A) 
BTNW882 82 II O U 4 2 6 - 32 (A) 
LIV020 75 II O PM NA NA NA - 24.5 (A) 
LIV024 30 II O PM NA NA NA - 12 (A) 
BTNW19 42 III AA U NA NA NA - 70 (D) 
BTNW38 48 III AA PM 3 2 5 - 4.5 (D) 
BTNW126 66 III AA U 4 2 6 5 6 (D) 
BTNW173 50 III AA U 1 1 2 - 5.5 (D) 
BTNW211 72 III AA U 4 2 6 - 2 (D) 
BTNW421 59 III AA U 5 3 8 - 7.5 (D) 
BTNW458 71 III AA M 3 2 5 - 17 (D) 
BTNW925 78 III AA U 1 1 2 - 1.5 (D) 
BTNW9 62 III AOA U 1 2 3 - 17.5 (D) 
BTNW14 43 III AOA M 1 2 3 64.5 95.5 (A) 
BTNW120 27 III AOA PM 1 2 3 95.5 138 (D) 
BTNW174 42 III AOA M 3 1 4 36 45.5 (D) 
BTNW183 66 III AOA PM 4 2 6 - 0.5 (D) 
BTNW325 46 III AOA NA 3 2 5 230.5 263 (D) 
BTNW495 71 III AOA U 3 2 5 - 8.5 (D) 
BTNW527 59 III AOA U 0 0 0 - 2.5 (D) 
BTNW614 49 III AOA U 5 3 8 14.5 21.5 (D) 
BTNW686 56 III AOA U NA NA NA - 16 (D) 
BTNW703 46 III AOA U 4 3 7 - 45.5 (A) 
BTNW825 62 III AOA U 1 1 2 - 36 (A) 
BTNW864 39 III AOA U 3 3 6 - 33.5 (A) 
BTNW15 56 III AO M 3 2 5 13.5 14.5 (D) 
BTNW460 29 III AO U 3 3 6 - 22 (D) 
BTNW738 66 III AO U 2 2 4 - 12 (D) 
BTNW757 72 III AO U 4 2 6 - 6 (D) 
BTNW804 44 III AO PM 4 2 6 - 11 (D) 
 
a
 Age at initial diagnosis in years; 
b 
A, astrocytoma; OA, oligoastrocytoma; O, 
oligodendroglioma; AA, anaplastic astrocytoma; AOA, anaplastic astrocytoma; AO, anaplastic 
oligodendroglioma; 
c
 M, methylated; PM, partially methylated; U, unmethylated; 
d 
PFS in 
months; 
e 
OS in months; A, alive; D, dead; NA, not available.  
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Figure 3.5 MGMT methylation analysis by MS PCR 
              100bp     527              614             848              686              15                 107              460 
            ladder   U       M       U       M       U       M      U       M       U       M       U        M      U       M 
            
 
Amplification products were separated by electrophoresis through 2% agarose. 1 sample 
was methylated (BTNW15), 3 samples were partially methylated (BTNW614, 
BTNW848 and BTNW107) and 3 samples were unmethylated (BTNW527, BTNW686 
and BTNW460). M, methylated; U, unmethylated. 
 
 
 
 
 
 
 
 
 
 
 
 
 
U – 93bp 
M – 81bp 
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Figure 3.6 IHC staining for MGMT in tissues 
         
                                                                
     
                                                                               
 
Representative example, slides were stained positively with streptavidin/HRP-biotin 
staining and counterstained with haematoxylin. A: Tonsil used as a positive control for 
MGMT, 40x magnification; B: BTNW61 (A) showing clonal populations with areas of 
negative staining next to areas of positively stained cells, 20x magnification; C: 
BTNW367 (A) with 100% MGMT positive staining, 40x magnification; D: BTNW326 
(O) with an egg-fried appearance representing an oligodendroglioma with positive 
staining for MGMT, 40x magnification and E: BTNW527 (AOA) showing negative 
staining for MGMT, 40x magnification. 
A 
B 
C 
D 
A 
C 
E 
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3.6 COMPARISON OF MS PCR AND IHC METHODOLOGIES TO IDENTIFY 
MGMT METHYLATION 
In tumour samples with low IHC scores, MS PCR analysis would be expected to 
demonstrate MGMT methylation and conversely, cases with high Allred scores would 
be expected to have unmethylated MGMT promoter. Seven tumours had the highest 
combined score of 8 by IHC, 6 of which were unmethylated and 1 was partially 
methylated. However, two tumours (BTNW 761 and BTNW537) showed negative 
staining for MGMT by IHC, but had unmethylated MGMT detected by MS PCR.  
Both proportion and combined score of IHC staining was used for correlation between 
the two methods. For this analysis, low MGMT expression (Allred score 0-2 or 0-4) and 
high MGMT expression (Allred score 3-5 or 5-8) were compared with MGMT 
methylation status determined by MS-PCR as detailed in Table 3.5. There was no 
significant correlation between level of MGMT protein expression and gene promoter 
methylation regardless of whether partially methylated tumours were combined with 
unmethylated or methylated samples. Figure 3.7 shows a comparison of the MGMT 
staining patterns (determined using the Allred scoring system) in 47 tumours in which 
the methylation status of the MGMT promoter had been established using MS PCR.   
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Table 3.5 Comparison of MGMT methylation status determined by MS PCR and 
IHC 
MGMT methylation status 
MS PCR 
MGMT IHC  
overall score 
0-4 
MGMT IHC  
overall score 
5-8 
p value 
Unmethylated, n=32 13 19  
Partially methylated, n=7 3 4  
Methylated, n=8 2 6  
Unmethylated vs Partially 
methylated/Methylated 
  0.753 
Unmethylated/Partially 
methylated vs Methylated 
  0.692 
 MGMT IHC 
proportion score 
0-2 
MGMT IHC 
proportion score 
3-5 
 
Unmethylated, n=32 11 21  
Partially methylated,  n= 7 1 6  
Methylated, n=8 1 7  
Unmethylated vs Partially 
methylated/Methylated 
  0.175 
Unmethylated/Partially 
methylated vs Methylated 
  0.146 
 
Statistical analysis was performed using GraphPad Prism and p-values were determined 
using the Wilcoxon signed-rank test for each of the analyses.  
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Figure 3.7 Comparison of MGMT IHC staining patterns and MGMT promoter 
methylation status 
 
 
 
                 
A: Proportion of nuclei stained; B: Combined Allred score with proportion and intensity 
scores. Meth, methylated; Part Meth, partially methylated; Unmeth, unmethylated.  
 
 
 
 
 
 
 
 
 
 
         Methylated 
          Partially methylated 
          Unmethylated 
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3.6.1 Relationship between MGMT status and tumour grade 
By MS PCR, in grade II tumours, 12% (4/32) were methylated, 19% (6/32) were 
partially methylated and 69% (22/32) were unmethylated. In grade III tumours, 16% 
(4/25) were methylated, 20% (5/25) were partially methylated and 64% (16/25) were 
unmethylated. There was no significant association of MGMT methylation with tumour 
grade combining either unmethylated with partially methylated cases (p = 1.0) or 
partially methylated with methylated tumours (p = 0.781). Similarly, there was no 
significant association of level of MGMT expression (low compared to high) with 
tumour grade using either proportion or combined Allred scoring systems (p = 0.336 
and p = 0.547, respectively). 
 
3.6.2 Relationship between MGMT status and age 
There was no association between MGMT promoter methylation and age combining 
either unmethylated with partially methylated cases (p = 0.715) or partially methylated 
with methylated tumours (p = 0.101). In younger patients (< 50 yrs), MGMT 
methylation and partial methylation was observed in 16% (5/31) and 29% (9/31) of 
tumours respectively. MGMT was unmethylated in 55% (17/31) of cases. In older 
patients (> 50 yrs), methylation was detected in 11% (3/26) of tumours, partial 
methylation in 11% (3/26) of tumours and 77% (20/26) of cases were unmethylated. 
Similarly, there was no association between level of MGMT protein expression (low 
compared to high) with patient age using either proportion or combined Allred scoring 
systems (p = 0.207 and p = 0.791, respectively). 
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3.6.3 Relationship between MGMT status and tumour histology 
Promoter methylation was detected by MS PCR in 5% (1/21) A, 50% (3/6) O, 12% 
(1/8) AA, 17% (2/12) AOA and 20% (1/5) AO, partial methylation was present in 14% 
(3/21) A, 20% (1/5) OA, 33% (2/6) O, 12% (1/8) AA, 8% (1/12) AOA and 20% (1/5) 
AO and unmethylation was present in 81% (17/21) A, 80% (4/5) OA, 17% (1/6) O, 
75% (6/8) AA, 58% (7/12) AOA and 60% (3/5) AO. Low MGMT protein expression 
was present in 33% (6/12) A, 0% (0/4) O, 0% (0/5) OA, 29% (2/7) AA, 42% (5/12) 
AOA and 20% (1/4) AO determined by both proportion and combined Allred scoring 
systems. Statistical analysis could not be performed due to small number of samples in 
each group. However, when the number of tumours with methylation and partial 
methylation are combined, there appears to be a higher frequency of MGMT promoter 
methylation in O (83% of samples) compared to A (19%) and OA (20%).  This trend is 
also present to a lesser extent in the grade III tumours with 40% AO tumours having 
partial or complete MGMT methylation compared to 25% AA and 25% AOA. 
 
3.7 RELATIONSHIP BETWEEN IDH1 MUTATION AND MGMT 
METHYLATION 
The association between IDH1 mutation and MGMT promoter methylation was 
determined in 57 tumours, for which both IDH1 mutation and MGMT promoter 
methylation status had been established. In IDH1 mutated tumours, the MGMT 
promoter was methylated in 16% (5/31) of cases with partial methylation being present 
a further in 23% (7/31) of cases and no methylation detected in 61% (19/31) of the 
tumours as presented in Table 3.6. In the group of IDH1 wild type tumours, MGMT 
methylation and partial methylation were both detected in 11.5% (3/26) of cases and 
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77% (20/26) tumours were unmethylated at the MGMT promoter. The single case in the 
present series with an IDH2 mutation also had MGMT promoter methylation. The 
association of MGMT methylation status and IDH1 mutation status was analysed in two 
groupings, firstly counting those tumours with methylated MGMT promoter and those 
with partially methylated MGMT promoter. In this case, IDH1 mutation correlated with 
MGMT status (p = 0.014, chi square test, p = 0.0214, Fisher’s exact test). However, if 
MGMT methylation status was analysed by grouping the partially methylated tumours 
with the unmethylated cases, there was no correlation with IDH1 mutation (p = 0.34, chi 
square test; p = 0.41, Fisher’s exact test). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
74 
 
Table 3.6 Relationship between IDH1 and MGMT status 
IDH1 status MGMT Methylation status 
 Methylated  
(% of tumours) 
Partially methylated 
(% of tumours) 
Unmethylated 
(% of tumours) 
Mutant, n = 31 16 22 61 
Wild type, n = 26 11.5 11.5 77 
 
IDH1 status Methylated and partially 
methylated 
(% of tumours) 
Unmethylated 
(% of tumours) 
Mutant, n = 31 39 61 
Wild type, n = 26 23 77 
 
IDH1 Status Methylated 
(% of tumours) 
Partially methylated and 
unmethylated 
(% of tumours) 
Mutant, n = 31 16 84 
Wild type, n = 26 11.5 88.5 
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3.8 RELATIONSHIP BETWEEN MGMT METHYLATION AND OUTCOME  
MGMT promoter methylation was correlated with OS, where methylated/partially 
methylated were combined against unmethylated and unmethylated/partially methylated 
were combined against methylated; the results are summarised in Table 3.7 and neither 
combination were statistically significant in all cases or when samples were segregated 
by grade. Kaplan meier curves for MGMT methylation status by MS PCR are shown in 
Figure 3.8. Correlation of MGMT protein expression with OS was also performed using 
proportion and combined Allred scores as described. No significant association with 
level of MGMT expression (low versus high) with OS was observed (Table 3.7). 
 
In a multivariate analysis using the Cox proportional hazard model with IDH1 mutation 
status, grade, age and MGMT status as variables, IDH1 mutation (p = 0.001) and grade 
(p = 0.002) were strong and independent predictors for a better outcome.  
 
PFS data included 21 patients and a significant association was found with age (p = 
0.0038) and grade plus IDH1 mutation (p = 0.0249) (Figure 3.9). PFS was not 
significant for IDH1 mutation, grade and MGMT methylation.  
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Table 3.7 Correlation of OS with MGMT methylation by IHC and MS PCR 
Overall Survival Groups IHC Score 
 
p value 
MGMT IHC - Proportion  
All (Grade II, Grade III) Low 0-2 0.26 
 High 3-5 
Grade II Low 0-2 0.43 
 High 3-5 
Grade III Low 0-2 0.12 
 High 3-5 
MGMT IHC - Combined 
All (Grade II, Grade III) Low 0-4 0.88 
 High 5-8 
Grade II Low 0-4 0.69 
 High 5-8 
Grade III Low 0-4 0.74 
 High 5-8 
MGMT – MS PCR 
All (Grade II, Grade III) Methylated/Partial  0.30 
 Unmethylated  
Grade II Methylated/Partial  0.36 
 Unmethylated  
Grade III Methylated/Partial  0.52 
 Unmethylated  
All (Grade II, Grade III) Methylated  0.79 
 Partial/Unmethylated  
Grade II Methylated  0.75 
 Partial/Unmethylated  
Grade III Methylated  0.35 
 Partial/Unmethylated  
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Figure 3.8 Kaplan Meier survival curves showing correlation of OS with MGMT methylation status 
 
                   
 
                   
A B C 
D E F 
M, methylated; PM, partially methylated; U, unmethylated 
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Figure 3.9 Correlation of PFS with age and tumour grade plus IDH1 mutation 
shown using Kaplan Meier curves 
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3.9 DISCUSSION 
In this study, the mutation status of IDH1 and IDH2 and MGMT methylation status in 
glioma was determined in different grades and histological groups of primary tumours. 
OS and PFS was correlated with clinical criteria and analysis for relationships between 
the clinical parameters was performed.  
 
3.9.1 Incidence of IDH1 mutation 
Although IDH1 mutations were found in both grade II and grade III tumours and in all 
histological subtypes, they were more frequent in grade II tumours than grade III 
tumours and the mutation was associated with histological findings with the highest 
frequency in O followed by OA and A. Similarly, in grade III tumours, IDH1 mutation 
was more frequent in AO than AOA and AA. These results are consistent with previous 
studies reporting > 80% IDH1 mutations in LGG tumours. Watanabe et al., (2009) 
showed that  IDH1 mutation was present in 88% (60/68) A, 94% (16/17) OA and 79% 
(31/39) O. Yan et al., (2009) reported that IDH1 mutation was most frequent in grade II 
tumours, present in 83% (25/30) A, 100% (3/3) OA and 80% (41/51) O. Gupta et al., 
(2013) showed IDH1 mutation at a frequency of 75% (18/24) in A, 60% (3/5) in OA 
and 100% (14/14) in O. All mutations were R132H, except for one which was R132S in 
the current study. This is in accordance with previous studies showing IDH1 R132H as 
the most common mutation (Hartmann et al., 2009; Nobusawa et al., 2009; Sanson et 
al., 2009; Myung et al., 2012).    
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3.9.2 Incidence of IDH2 mutation 
IDH2 mutation is known to be less frequent in glioma and in this study it was present in 
only one AO tumour with wild type IDH1. Wang et al., (2014) determined IDH2 
mutation status in 980 tumours (61A, 134OA, 243O, 33AA, 141AOA, 220AO and 
312GBM) and IDH2 mutation was present in 3.1% (30/980) of the cases, with O and 
AO being the most common tumours to exhibit the mutation. No tumour had both IDH1 
and IDH2 mutation. Lu et al., (2013) also showed that IDH2 mutation was present at a 
low frequency (4.9%, 2/41) in a study of O and AO tumours. Another study involving 
287 glioma patients, reported that IDH2 mutation was present in only one case, an 
oligodendroglioma with IDH1 wild type (Mellai et al., 2011). Similarly, in AML cases, 
the frequency of IDH2 mutation was low at about 7% shown in multiple studies 
(Paschka et al., 2010; Patel et al., 2011; Chotirat et al., 2012; Berenstein et al., 2014).  
 
3.9.3 Relationship of IDH1 mutation to MGMT methylation 
IDH1 mutation is a prognostic factor while MGMT is a predictive marker for response 
to TMZ. As described previously, IDH1 mutations result in global hypermethylation 
establishing G-CIMP, which is correlated with MGMT promoter methylation (Molenaar 
et al., 2014). IDH mutations promote gene promoter methylation by accumulation of the 
oncometabolite 2-HG, which is converted from α-KG. 2-HG contributes to impaired 
demethylation of genomic DNA, subsequently leading to remodelling of the methylome 
and transcriptome, including methylation of MGMT. It would be expected that tumours 
carrying IDH mutation are more likely to have MGMT promoter methylation. However, 
this was not the case in the present study where only a small proportion (15%, 5/33) of 
tumours with IDH1 mutation had complete MGMT methylation and the majority (57%, 
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19/31) of the tumours had no methylation of MGMT, while the remaining cases (21%, 
7/33) showed partial methylation. The proportion of methylated tumours was much less 
(36%, 12/33) than expected even after combining the partially methylated and 
methylated tumours. In a study of 210 LGG, the correlation between IDH mutation and 
MGMT methylation was established (Leu et al., 2013). The authors reported that 84% 
of the IDH mutated tumours also had methylation of MGMT and IDH mutation was 
positively associated with MGMT methylation (p < 0.001). Similarly, Mulholland et al., 
(2012) reported that tumours with IDH mutations had a high frequency (98%, 127/129) 
of MGMT methylation irrespective of tumour grade and histology, in a sample cohort 
including A, OA, O, AA, AOA, AO and GBM tumours.    
A possible explanation for having a low frequency of MGMT methylated tumours is a 
small cohort size in the present study and also methods of MGMT detection such as 
IHC and MS PCR are less sensitive compared to pyrosequencing.  
 
3.9.4 IDH and outcome 
The clinical correlation was performed using OS instead of PFS as the data for OS was 
available for all cases included in this study and PFS was known for only a few patients. 
Different parameters may be used to establish time to progression and/or recurrence 
such as date of radiological MRI scans and date of biopsy or further resection plus 
histological diagnosis. 
Mutations in IDH1 and IDH2 do not exert the same effects including activation of HIF-
1 pathway, inducing G-CIMP and inhibition of PI3K-Akt signalling pathway, all of 
which are consequences of IDH1 mutation. The effects of IDH2 mutation in glioma are 
still unknown and need to be examined. Although IDH1 and IDH2 are isoforms, the 
82 
 
mutations in each of the genes might cause different effects. In terms of survival, 
patients with tumours carrying either IDH1 or IDH2 mutation have a better survival 
rate, as mentioned previously in Chapter 1. The explanation for a better outcome may be 
related to the biological effects of IDH mutation. Bralten et al., (2011) showed that 
overexpression of IDH1-R132H mutation in a transfected glioma cell line in vitro led to 
a decrease in proliferation rate, decreased Akt phosphorylation, alteration in 
morphology and more contact-dependent cell migration. The decrease in proliferation is 
due to D-2HG produced by IDH1 mutation. The transition of R132 with any of the 
amino acids observed in glioma (His, Ser, Gly, Cys, Val and Leu) may have a reduced 
affinity to isocitrate and dominantly inhibit activity of IDH1 wildtype through the 
formation of catalytically inactive heterodimers. This may lead to the cells being more 
susceptible to oxidative stress by chemotherapy and radiotherapy (Zou et al., 2013).  
It has been reported in a previous study that patients with grade II tumours having IDH1 
mutation had a median OS of 12.6 years compared to 5.5 years for those with tumours 
having IDH1 wild type (Sanson et al., 2009). Other studies have shown that IDH 
mutations were an independent prognostic indicator for longer PFS and OS in patients 
with grade III tumours (Hartmann et al., 2010; Juratli et al., 2012; Shibahara et al., 
2012). In LGG, IDH mutations were associated with a better outcome (p = 0.000001) 
and IDH wild type was an independent unfavourable prognostic factor (p = 0.006) 
(Metellus et al., 2010). In a study by Song-Tao et al. (2012), IDH mutations with 
MGMT methylation and 1p/19q co-deletion were associated with longer PFS. Wang et 
al., (2014) confirmed that in each of the grades, grade II, grade III and grade IV, 
patients with IDH mutated tumours had significantly longer OS and PFS than those with 
IDH wild type tumours. The authors also reported that IDH mutation was an 
independent predictor of a better outcome (p < 0.0001). Gorovets et al., (2012) showed 
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that tumours with IDH mutation were present significantly in younger patients with 
longer OS compared to those with IDH wild type tumours (p < 0.0001). In the present 
study, IDH1 mutation was significantly associated with a longer OS in grade II tumours 
but not in grade III tumours (p = 0.0001, p = 0.0923 respectively; log rank Mantel-Cox 
test).  
 
3.9.5 MGMT and outcome 
MGMT, the DNA repair enzyme removes alkyl groups from the O
6
 position of guanine, 
which is the site of chemotherapy induced alkylations. Promoter hypermethylation of 
MGMT is associated with reduced DNA repair enzyme activity and increased sensitivity 
to alkylating agents including nitrosourea and TMZ. MGMT methylation status has been 
linked with improved outcome in patients treated with TMZ. A meta-analysis study 
involving 16 studies investigated the prognostic significance of MGMT promoter 
methylation and it was shown that MGMT methylation was associated with longer OS 
in elderly patients treated with TMZ (12 studies, 635 patients, p < 0.0001) (Yin et al., 
2014). However, in the absence of treatment with TMZ, no significant difference for OS 
was found in patients with or without MGMT methylation (4 studies, 368 patients, p < 
0.0001) (Piccirilli et al., 2006; Malmstrom et al., 2012; Reifenberger et al., 2012; Wick 
et al., 2012). Leu et al., (2013) examined 210 LGG and showed that MGMT 
methylation had a significant and positive impact on OS (p = 0.053). In a study of 267 
malignant glioma including anaplastic astrocytoma, anaplastic oligoastrocytoma, 
anaplastic oligodendroglioma and GBM tumours, patients with tumours having MGMT 
methylation had longer survival than those without the methylation (p < 0.001) 
(Takahashi et al., 2013). In the present study, there was no correlation between MGMT 
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methylation status and OS which may be due to the relatively small cohort and patients 
receiving different treatment regimen including radiotherapy and chemotherapy using 
TMZ and PCV. Of the 15 patients for whom treatment information was available, 5 
patients underwent chemotherapy with TMZ. Furthermore, MGMT methylation data 
was not completed for all the cases due to availability of tissue.  
Some of the tumours were partially methylated for MGMT, which represents one allele 
as methylated and the other as unmethylated for MGMT or alternatively, there could be 
mixed population of cells, some with MGMT methylation and some without. A good 
example of this is BTNW61 showing clonal populations (Figure 3.6). The biological 
sequela of partial methylation has not been investigated and therefore, in this study, 
partially methylated tumours were grouped with both methylated and unmethylated 
tumours to determine the correlation of MGMT methylation status with OS. However, 
no significant association was found between MGMT methylation status and OS in 
either of the groups. There is a lack of standard criteria to identify tumours with partial 
methylation. In a study by Kitange et al. (2009), MGMT methylation was correlated 
with response to TMZ using 13 GBM xenograft lines. MS PCR was used to identify the 
MGMT promoter methylation status and the sample was considered to be methylated 
when the gel showed a single band for methylated DNA or for both methylated and 
unmethylated DNA. Conversely, the sample was unmethylated only when a single band 
for unmethylated DNA was observed. A method to determine the percentage of 
methylation would be more accurate to determine the MGMT methylation status 
compared to MS PCR, where tumours could be partially methylated. 
The clinical outcome results in the present study are not in accordance with these 
previous studies. The discrepancy in the results could be due to different techniques 
used for MGMT methylation analysis, one of which was a quantitative primer extension 
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based assay to determine the percentage of methylated DNA in the tumours. Secondly, 
the cohort size in the two previous studies were relatively much larger compared to the 
sample size in this study. 
 
3.9.6 Age, grade, histology and outcome 
Clinical features such as tumour grade, age and histology were correlated with outcome 
in this study. Multivariate cox proportional hazard model showed that patient age > 50 
years was associated with a shorter OS (p = 0.041) in a study of 281 LGG patients 
(Chang et al., 2008). Astrocytoma histology was a significant predictor of a worse OS 
(p = 0.004) shown in a study involving a dataset of 203 LGG patients treated in a North 
American Intergroup trial (86-72-51) (Daniels et al., 2011). Kim et al., (2010) showed 
that the median survival of patients with oligodendroglioma (60.2 months) was 
significantly longer than those with astrocytoma tumour (52.5 months; p = 0.0019) in a 
study of 443 LGG. The results in this study are in accordance with the previous studies; 
younger patients (< 50 yrs), patients with tumours having an oligodendroglial 
component and patients with grade II tumours, all of these parameters showed a positive 
correlation with a better outcome.  
 
3.9.7 MS PCR and IHC correlation 
The Allred scoring system, recommended by neuropathologist Professor Tim Dawson, 
was used to determine the MGMT protein expression by IHC. It is based on the 
assessment of the proportion and intensity of staining for a protein. There was a lack of 
correlation for MGMT methylation between the two methods, MS PCR and IHC, in this 
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study. Samples with low MGMT expression were expected to be methylated and those 
with high MGMT expression to be unmethylated but only a small proportion of the 
tumours showed a correlation between MGMT expression and promoter methylation 
status. The number of nuclei stained for MGMT would depend on the number of cells 
expressing the protein. The intensity of staining may be attributable to the technique or 
the definite reactivity of the cell expressing the protein or the number of protein 
molecules in each cell which would determine the percentage of MGMT expression. A 
standardised method for scoring needs to be implemented to compare results across 
different studies. For IHC scoring, only the proportion of stained nuclei should be 
considered and not the intensity of staining as it may lead to discrepancy in results due 
to observer variability. Comparatively, MS PCR is a more reliable method to identify 
MGMT methylation status in a tumour where primers used for MS PCR can be designed 
in such a way that all the CpG sites are covered in order to obtain accurate results. A 
comparative study of 5 methods to analyse MGMT methylation was performed using 
100 GBM patients and the authors confirmed the prognostic value of MGMT promoter 
methylation determined by MS PCR (Quillien et al., 2012). Several studies have shown 
significant association of MGMT expression by IHC (Jaeckle et al., 1998; Nakasu et al., 
2004; Brell et al., 2005; Pollack et al., 2006; Capper et al., 2008) and MGMT promoter 
methylation status (Hegi et al., 2004; Paz et al., 2004; Hegi et al., 2005; Idbaih et al., 
2007) with patient outcome in glioma. However, no significant association was 
observed in this study. The small number of samples analysed by both the methods may 
explain the inconsistency in the results. 
 
In conclusion, this study shows that IDH1 mutation, grade II and patient age < 50 years 
are all favourable prognostic markers for longer OS. In relation to age, patients with 
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grade III tumours were older than those with grade II tumours. Histology was not 
associated with outcome in grade II tumours, while grade III tumour patients with AOA 
had longer OS than those with AO or AA. Also, patients with grade II tumours carrying 
IDH1 mutant had a longer OS, however, in grade III tumours, IDH1 mutation was not 
associated with outcome. In case of MS PCR, partially methylated tumours could be 
categorised separately as these tumours did not behave like either methylated or 
unmethylated tumours. IDH1 mutation only correlated with MGMT promoter status, 
when tumours with MGMT methylated promoter and those with partially methylated 
promoter were combined. However, MGMT promoter status was not significantly 
associated with outcome in the entire cohort. 
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CHAPTER 4  
 
miRNA EXPRESSION PROFILING OF PRIMARY TUMOURS 
 
 
4.1 INTRODUCTION 
MicroRNAs (miRNAs) are small non-coding RNAs involved in regulation of biological 
processes such as cell proliferation, apoptosis, differentiation and metabolism 
(Brennecke et al., 2003; Xu et al., 2003; Sempere et al., 2004; Cheng et al., 2005). As 
mentioned previously in Chapter 1, a number of studies have been conducted to 
understand the role of miRNAs in GBM but little is known about their role in the 
development and progression of LGG. miRNAs have been shown to play a critical role 
in development and progression of cancers (Li et al., 2013). Deregulation of miR-9 for 
example, has been shown to play an important role in esophageal squamous cell 
carcinoma (ESCC) metastasis by inducing epithelial-mesenchymal transition (EMT) in 
ESCC, a key event in tumor metastasis (Song et al., 2014). Loss of miR-34a has also 
been found to accelerate medulloblastoma formation in animal models (Thor et al., 
2014).  
 
IDH mutations are also an important characteristic feature of LGG and the primary 
function of IDH1 mutation is to establish the G-CIMP, which alters the methylome and 
hence, transcriptome, as described in previous Chapters. As tumours with IDH 
mutations are genomically and transcriptomally distinct from those without the 
mutations, it is possible that miRNA expression profiles of IDH mutant tumours and 
IDH wild type tumours are different. The aims of this chapter were to identify 
differentially expressed miRNAs associated with different grades of LGG as well as 
deregulated pathways affected by those miRNAs that may play a role in LGG 
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progression. The potential relationships between miRNA expression and tumour grade 
and histology were also investigated.     
 
4.2 Tumour samples 
The samples for miRNA analysis consisted of biopsy tissues from primary grade II and 
grade III tumours for which IDH1 and IDH2 mutation status has been determined. The 
cohort of 32 samples is detailed in Table 4.1 and comprised 20 grade II tumours (15 A, 
2 OA, 3 O) and 12 grade III tumours (2 AA, 4 AOA, 6 AO). 
 
4.3 Data analysis 
miRNA expression analysis was performed using Partek Genomics Suite (version 6.6; 
Partek Inc., USA). Raw data was normalised with log 2 median and one-way analysis of 
variance (ANOVA) test was used to identify miRNAs that had ≥ 2-fold change in 
expression. Various analyses were performed using a number of sample cohorts with 
different criteria, grade II (n = 20) vs grade III tumours (n = 12); IDH
 
mutant (n = 13) vs 
IDH wild type (n = 7) in grade II tumours; IDH
 
mutant (n = 5) vs IDH wild type (n = 7) 
in grade III tumours; A (n = 15) vs OA (n = 2) in grade II tumours; OA (n = 2) vs O (n 
= 3) in grade II tumours; A (n = 15) vs O (n = 3) in grade II tumours; AA (n = 2) vs 
AOA (n = 4) in grade III tumours; AOA (n = 4) vs AO (n = 6) in grade III tumours and 
AA (n = 2) vs AO (n = 6) in grade III tumours. Supervised hierarchical clustering and 
principal components analysis (PCA) was used to determine differential miRNA 
expression amongst different group of samples. Significant miRNAs (p value < 0.05) 
with differential expression were reported in the study.  
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Table 4.1 Primary tumours used for miRNA analysis 
Sample Age at 
diagnosis
a 
Sex
b 
Grade Histology
c 
IDH1 
mutation
d 
IDH2 
mutation
e 
BTNW20 26 M II A R132H WT 
BTNW61 32 M II A R132H WT 
BTNW203 42 F II A R132H WT 
BTNW365 42 F II A R132H WT 
BTNW680 59 M II A WT WT 
BTNW818 60 F II A WT WT 
BTNW830 21 M II A WT ND 
BTNW868 39 F II A R132H ND 
BTNW1005 43 F II A R132H ND 
BTNW1028 40 M II A R132H ND 
IN2190 45 M II A WT WT 
IN2800 32 M II A WT WT 
Liv007 40 M II A WT ND 
Liv015 36 M II A R132H  ND 
Liv020 75 M II A R132H ND 
BTNW13 40 F II OA R132H ND 
UWLV7 38 M II OA R132H WT 
IN99/81 NA F II O R132H WT 
IN2723  55 F II O WT WT 
UWLV3 43 M II O R132H WT 
BTNW126 66 M III AA WT WT 
BTNW458 71 F III AA WT WT 
BTNW9 62 F III AOA WT WT 
BTNW527 59 F III AOA WT WT 
BTNW614 49 M III AOA R132H ND 
BTNW686 56 M III AOA WT WT 
BTNW15 56 M III AO WT R172K 
BTNW179 35 F III AO R132H WT 
BTNW460 29 M III AO R132H WT 
BTNW738 66 M III AO WT WT 
BTNW757 72 M III AO WT WT 
BTNW804 44 M III AO R132H WT 
 
a 
age at diagnosis in years; 
b 
M, male; F, female; 
c
 A, astrocytoma; AA, anaplastic astrocytoma; 
OA, oligoastrocytoma; AOA, anaplastic oligoastrocytoma; O, oligodendroglioma; AO, 
anaplastic oligodendroglioma; 
d 
R132H, IDH1 mutant; WT, wild type, 
e 
R172K, IDH2 mutant; 
ND, not done; NA, not available.  
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4.4 miRNA target prediction 
Predicted targets for the differentially expressed miRNAs were determined using 
TargetScan 6 (Lewis et al., 2005) (www.targetscan.org), miRDB (Wang et al., 2008; 
Wang, 2008) (http://mirdb.org/miRDB/) and miRanda database (John et al., 2004) 
(www.microrna.org). TargetScan determines the presence of conserved 8mer (an exact 
match to positions 2-8 of the mature miRNA) and 7mer (an exact match to positions 2-7 
of the mature miRNA) sites that matches the seed region of each miRNA (Lewis et al., 
2005). miRanda database predicts targets based on complementarity between mature 
miRNA and mRNA (John et al., 2004). miRNA target mining was performed with 
miRDB using the default settings that include targets with scores > 60 and miRNAs 
with < 800 targets. The top 10 targets chosen arbitrarily for each of the miRNA were 
mentioned in this study.  
 
4.5 Pathway analysis 
Pathway analysis for the differentially expressed miRNAs was performed using 
DIANA-miRPath v2.0  (Vlachos et al., 2012) and KEGG pathway analysis v58.1 
(Kanehisa et al., 2012).  
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4.6 miRNA EXPRESSION ANALYSIS OF PRIMARY TUMOURS 
Unsupervised clustering analysis was used to cluster samples with similar miRNA 
expression profiles irrespective of any molecular characteristics. Initially, unsupervised 
hierarchical clustering analysis of all 32 primary tumours comprising 18 tumours with 
IDH mutation and 14 IDH wild types was performed using 1719 miRNAs and is 
represented as a dendrogram with similar expression profiles clustered together (Figure 
4.1). Two samples, BTNW13 (OA) and IN99/81 (O) (both IDH mutant) clustered 
independently to any other tumour. The remaining 30 samples formed two large clusters 
that separated predominantly according to grade. Cluster 1 comprised mainly grade II 
tumours (12/14, 86%) with the two grade III cases (BTNW614 and BTNW126). The 
majority of tumours in cluster 2 were grade III (10/16, 62.5%). There was a relatively 
even distribution between tumours with mutant and wild type IDH between the two 
main clusters. In cluster 1, 9/14 (64%) of tumours were IDH mutant and 5/14(36%) 
were IDH wild type. In cluster 2, 9/16 (56%) of tumours were IDH mutant and 7/16 
(44%) were IDH wild type. IDH mutant tumours were marginally overrepresented in 
the predominantly grade II cluster 1 which probably reflects the predominance of IDH 
mutations in grade II versus grade III tumours. In cluster 1, 10/14 (71%) of tumours 
have a pure astrocytoma histology and 4/14 (29%) of cases have an oligodendroglial 
component. In contrast, only 7/16 (44%) of tumours in cluster 2 were purely astrocytic 
compared to 9/16 (56%) of cases with whole or partial oligodendroglial histology. 
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4.7 COMPARISON OF miRNA EXPRESSION PROFILES OF GRADE II AND 
GRADE III TUMOURS 
Supervised hierarchical clustering was used to determine differentially expressed 
miRNAs when comparing two groups of samples based on certain characteristic such as 
grade, IDH1 mutation status and histology. Forty two miRNAs were significantly 
differentially expressed between primary grade II and grade III tumours as illustrated in 
the hierarchical clustering dendrogram in Figure 4.2. Two grade II tumours, IN99/81 
(O) and IN2800 (A) clustered together, independently of the remaining cases which 
separated into two large clusters. Cluster 1 comprised mainly grade II tumours (8/10, 
80%) whereas cluster 2 contained equal numbers of grade II and grade III cases. 
Tumours with astrocytic and oligodendroglial components are equally distributed 
between the two large clusters. 
 
Of the 42 differentially expressed miRNAs, 21 miRNAs were differentially expressed 
between grade II and grade III tumours in ≥ 70% of cases. The 21 miRNAs were used to 
identify targets and pathways. These miRNAs were all upregulated in 70% of grade II 
tumours and downregulated in 83% of grade III tumours as detailed in Table 4.2. 
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Figure 4.1 Unsupervised hierarchical clustering for 32 primary tumours 
 
miRNA expression of 1719 miRNAs in 32 primary tumours using Partek Genomics Suite. Red colour represents high levels of miRNA 
expression and green colour represents low levels of miRNA expression in the tumour. II – Grade II, III – Grade III, Mut – IDH1/IDH2 
mutant, WT – IDH1/IDH2 wild type, A – astrocytoma, OA – oligoastrocytoma, O – oligodendroglioma, AA – anaplastic astrocytoma, AOA – 
anaplastic oligoastrocytoma, AO – anaplastic oligodendroglioma. 
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Figure 4.2 Supervised hierarchical clustering for 32 primary tumours (grade II vs grade III) 
 
All 42 significant miRNAs with differential expression of ≥ 2 fold change identified using Partek Genomic Suite by ANOVA and with a 
significance of p < 0.05. Red colour represents high levels of miRNA expression and green colour represents low levels of miRNA 
expression in the tumour. II – Grade II, III – Grade III, A – astrocytoma, OA – oligoastrocytoma, O – oligodendroglioma, AA – anaplastic 
astrocytoma, AOA – anaplastic oligoastrocytoma, AO – anaplastic oligodendroglioma.  
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Table 4.2 Differentially expressed miRNAs between grade II and grade III tumours (≥ 2 fold change) with percentage of differential expression in 
each grade.  
 
miRNA p-value Fold 
change  
(II vs III) 
Upregulation  
(% of tumours) 
Downregulation 
(% of tumours) 
Target Pathway 
Grade II Grade III Grade II Grade III 
miR-466 0.03 4 70 17 30 83 PHOSPHO2-KLHL23, PLCXD1, 
KLHL23, GPR137C, DCLK1, 
DCUN1D4, TNRC6B, VAMP4, 
RIMKLB, LEMD3 
PI3K-Akt signalling pathway, TGF-beta signalling 
pathway, T cell receptor signalling pathway, 
Chronic myeloid leukemia, Non-small cell lung 
cancer 
miR-3658 0.02 4 70 17 30 83 AEBP2, DCUN1D5, LPP, MCTS1, 
GNB4, LRP6, TMED5, UBE2K, 
SMAD5, UHMK1 
TGF-beta signalling pathway, GABAergic synapse, 
Wnt signalling pathway, Prostate cancer, Chronic 
myeloid leukemia  
miR-3142 0.03 4 70 17 30 83 WDFY3, EVC, SEH1L, SPOPL, 
CASK, PCYT1B, ITGB1BP1, 
OGFR, THAP4, GABRA1 
Renal cell carcinoma, Nicotinate and 
nicotinamide metabolism, mTOR signalling 
pathway 
miR-449c 0.03 4 70 17 30 83 NUP50, STMN2, CDK19, ODZ1, 
CREB1, PAPOLA, MAPK1IP1L, 
ACTL6A, TMEM48, STK38L 
Hepatitis B, Phosphatidylinositol signalling 
system, ErbB signalling pathway, Salmonella 
infection, Inositol phosphate metabolism 
miR-2113 0.01 3.8 70 17 30 83 PIK3C2A, COL4A3BP, CRH, ELL2, 
NCBP1, CNTLN, MAP4K3, CASK, 
SNTB2, CCDC6  
Notch signalling pathway, Pathways in cancer, 
Renal cell carcinoma, Long-term potentiation, 
Adherens junction 
miR-4529-5p 0.02 3.6 70 17 30 83 CBLL1, SS18L1, CSDE1, PKP3, 
MEX3C, PIP4K2C, LRP1, 
KIRREL2, GRIN2B, DNAJC14 
Leukocyte transendothelial migration, Bacterial 
invasion of epithelial cells, Salmonella infection, 
N-Glycan biosynthesis, Wnt signalling pathway 
miR-4471 0.04 3 70 17 30 83 CDS2, POU2F1, GSTO2, IRS1, 
SLAMF8, DNAJB4, ANKIB1, 
EPB41L5, LIN52, B3GNT2 
Metabolism of xenobiotics by cytochrome P450, 
Biosynthesis of unsaturated fatty acids, 
Regulation of actin cytoskeleton, Neuroactive 
ligand-receptor interaction, Melanogenesis 
 
 
 
 
 
 
97 
 
Table 4.2 Differentially expressed miRNAs between grade II and grade III tumours (≥ 2 fold change) with percentage of differential expression in 
each grade (cont’d).  
 
miRNA p-value Fold 
change  
(II vs III) 
Upregulation  
(% of tumours) 
Downregulation 
(% of tumours) 
Target Pathway 
Grade II Grade III Grade II Grade III 
miR-181a* 0.04 3.5 70 17 30 83 ALDH18A1, ATP13A4, 
ALDH6A1, NIPA2, RIBC1, CFL2, 
RHOBTB1, H1F0, AP1S3, ARL4A  
Ubiquitin mediated proteolysis, Endocytosis, 
Ether lipid metabolism, Nucleotide excision 
repair, Synaptic vesicle cycle 
miR-181a-2* 0.01 3 70 17 30 83 ANTXR2, PRSS12, MGAT4A, 
ARNTL2, PARP16, SRPK2, 
NR1D2, ANKRD44, FEZ1, PAG1 
Same as above for miR-181a* 
miR-3616-5p 0.03 2.7 70 17 30 83 SERBP1, DDX3X, CHL1, KDM5B, 
JMJD1C, PRSS35, WDR72, 
KCNMA1, SOSTDC1, TSPAN7 
Valine, leucine and isoleucine biosynthesis, 
Pantothenate and CoA biosynthesis, Terpenoid 
backbone biosynthesis, mRNA surveillance 
pathway, Calcium signalling pathway 
miR-4733-3p 0.03 2.7 70 17 30 83 CHMP1, DGAT1, LARP1, RIMS3, 
FKBP15, DDX18, CCL8, MIS12, 
PPP6R2, ABHD4 
ABC transporters, Pathogenic Escherichia coli 
infection, Gap junction, ECM-receptor 
interaction, Cyanoamino acid metabolism 
miR-4741 0.01 2 70 17 30 83 NCS1, SDR16C5, MMAB, 
IL17RA, PRPF38A, TDRKH, 
CHRFAM7A, ACOX3,DPYSL5, 
FOXP2 
Axon guidance, Lysine degradation, Aminoacyl-
tRNA biosynthesis, Endocytosis, Hedgehog 
signalling pathway 
miR-4268 0.02 2 70 17 30 83 BBS5, SNX1, MSMO1, IL6ST, 
GOSR1, HOXB6, RIMS4, ADCY1, 
RAD54B, SRCIN1 
Cell cycle, Prostate cancer, Pancreatic cancer, 
Pathways in cancer, Chronic myeloid leukemia 
miR-323b-5p 0.03 2 70 17 30 83 TAF5, STK38, PIK3R3, BTAF1, 
JAK1, LMAN1, SERF2, GLRA2, 
TBC1D23, ALPK3 
Cell cycle, Pathways in cancer, Prostate cancer, 
Pancreatic cancer, Chronic myeloid leukemia 
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Table 4.2 Differentially expressed miRNAs between grade II and grade III tumours (≥ 2 fold change) with percentage of differential expression in 
each grade (cont’d). 
 
miRNA p-value Fold 
change  
(II vs III) 
Upregulation  
(% of tumours) 
Downregulation 
(% of tumours) 
Target Pathway 
Grade II Grade III Grade II Grade III 
miR-3650 0.02 2 70 17 30 83 RTN41P1, CDK14, ABO, 
SH3BP2, DCLRE1C, ELN, 
STEAP2, EIF2C3, BNC2, HDX 
Pathways in cancer, Prostate cancer, Pancreatic 
cancer, Adherens junction, MAPK signalling 
pathway 
miR-4252 0.03 2 70 17 30 83 FNDC3A, CDK6, AK2, HFM1, 
CDK17, AKIRIN2, RELN, DAAM1, 
TGFBR1, DSTYK 
Pathways in cancer, Adipocytokine signalling 
pathway, Thyroid cancer, Small cell lung cancer, 
Non-small cell lung cancer 
miR-4500 0.01 2 70 17 30 83 IGF2BP1, HMGA2, DDI2, 
COIL,GATM, USP38, IGDCC3, 
MRS2, MAP4K3, CCNJ 
ECM-receptor interaction, PI3K-Akt signalling 
pathway, Glycosaminoglycan biosynthesis – 
chondroitin sulphate, Amoebiasis, p53 signalling 
pathway 
miR-4302 0.02 2 70 17 30 83 ITGB1BP1, GAB3, FGD6, SMG7, 
AGAP1, ROCK1, CDS2, DYRK1A, 
TM2D2, FABP2  
Pathways in cancer, Acute myeloid leukemia, 
Chronic myeloid leukemia, B cell receptor 
signalling pathway, ErbB signalling pathway 
miR-141 0.01 2 70 17 30 83 TMEM170B, TNRC6B, ATP8A1, 
DEK, CHD9, IBA57, KIDINS220, 
STRN, DR1, ABL2 
Pathways in cancer, Cell cycle, p53 signalling 
pathway, Chronic myeloid leukemia, Prostate 
cancer 
miR-3689a-5p 0.01 2 70 17 30 83 GPR123, ITM2B, RBM41, 
TNRC6B, EXOC5, TRPS1, CDH9, 
HCN1, MED13, GDAP1 
Drug metabolism – cytochrome P450, Endocrine 
and other factor-regulated calcium reabsorption, 
Synaptic vesicle cycle, Retinol metabolism, 
Vassopresin-regulated water reabsorption 
miR-320d 0.03 2 70 17 30 83 CREB5, TGOLN2, LPPR1, 
ARPP19, ABHD13, PBX3, 
TRIAP1, TMEM108, TMEM47, 
ARFIP1 
Prostate cancer, Endometrial cancer, mTOR 
signalling pathway, Circadian rhythm, Biotin 
metabolism 
Gene targets and pathways that were common between the miRNAs are highlighted in different coloured text. *miR, originates from the same 
precursor as the mature miRNA and the predominant product is given the main name and miR* is from the opposite arm of the precursor. 
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4.8 miRNA EXPRESSION PROFILING OF GRADE II TUMOURS 
The expression profiles of 20 grade II tumours comprising 15 A, 2 OA and 3 O were 
compared. There were 13 cases with IDH1 R132H mutation and 7 with wild type IDH1. 
Unsupervised hierarchical clustering was performed using 1719 miRNAs and the 
resulting dendrogram is shown in Figure 4.3. As in Figure 4.1, BTNW13 and IN99/81 
clustered independently to the remaining cases. Tumours did not separate independently 
according to histology or IDH mutation status. 
 
Supervised hierarchical clustering identified a single significant miRNA (let-7c) that 
was differentially expressed based on IDH mutation status. Let-7c was upregulated in 
61% IDH mutant cases compared to 28% in tumours with IDH wild type. It was 
downregulated in 38% IDH mutant compared to 71% in IDH wild type tumours. The 
top 10 targets for let-7c are HMGA2, GATM, PRTG, MAP4K3, COIL, USP38, CCNJ, 
ADRB2, IGDCC3 and GDF6. According to KEGG pathway analysis, it is involved in 
ECM-receptor interaction, glycosaminoglycan biosynthesis – chondroitin sulphate, 
PI3K-Akt signalling pathway, amoebiasis and protein digestion and absorption.  
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 Figure 4.3 Unsupervised hierarchical clustering for 20 grade II tumours 
 
Expression of 1719 miRNAs in 20 grade II tumours identified using Partek Genomic Suite by ANOVA and with a significance of p < 0.05. 
Red colour represents high levels of miRNA expression and green colour represents low levels of miRNA expression in the tumour. Mut – 
IDH1/IDH2 mutant, WT – IDH1/IDH2 wild type, A – astrocytoma, OA – oligoastrocytoma, O – oligodendroglioma. 
. 
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4.9 miRNA EXPRESSION PROFILING OF GRADE II TUMOURS BASED ON 
HISTOLOGY  
miRNA expression was determined in three histological groupings; A vs OA (n = 17), 
OA vs O (n = 5) and A vs O (n = 18). Hierarchical clustering was performed for each 
group and significant differentially expressed miRNAs were identified (Figure 4.4). In 
A vs OA, only 2 OA and 15 A tumours were present. BTNW13 (OA) was different in 
miRNA expression from rest of the tumours as determined by supervised hierarchical 
clustering. The remaining tumours were divided into two large clusters and UWLV7 
(OA) had different expression profile from the rest of the tumours in one of the clusters. 
In OA vs O, hierarchical clustering resulted in tumours forming 2 independent clusters 
according to histology. In A vs O, only 3 O and 15 A tumours were present. IN99/81 
(O) and IN2800 (A) clustered together and had different profiles from the remaining 
tumours with the rest of the cases dividing into 2 large clusters. UWLV3 and IN2723 
(both O) clustered together with similar expression profiles. Common differentially 
expressed miRNAs between the three histological groups are detailed in Figure 4.5.  
 
The four common differentially expressed miRNAs between A vs OA and OA vs O 
were miR-21, miR-23a, miR-30c and miR-99a, while common miRNAs differentially 
expressed between A vs OA and A vs O were miR-885-3p, miR-936, miR-4736 and 
miR-4728-5p (Table 4.3).   
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Figure 4.4 Supervised hierarchical clustering for 20 grade II tumours based on 
histology  
 
 
 
Expression of differentially expressed miRNAs with ≥ 2 fold change in expression change identified 
using Partek Genomic Suite by ANOVA and with a significance of p < 0.05. Red colour represents 
high levels of miRNA expression and green colour represents low levels of miRNA expression in the 
tumour. A – astrocytoma, OA – oligoastrocytoma, O – oligodendroglioma. 
A vs OA 
OA vs O 
A vs O 
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Figure 4.5 Venn diagram showing common and unique miRNAs among the three 
groups. 
 
 
 
 
 
Using Partek Genomics Suite, A vs OA and OA vs O was compared and four common 
miRNAs were identified with ≥ 2 fold change in expression and significance of p < 0.05 
by ANOVA; when comparing A vs OA and A vs O, four common miRNAs were also 
identified with ≥ 2 fold change in expression and significance of p < 0.05 by ANOVA 
but these were different from that identified between A vs OA and OA vs O; 
Comparison of OA vs O and A vs O identified no common miRNAs with ≥ 2 fold 
change in expression and significance of p < 0.05 by ANOVA. A, astrocytoma; OA, 
oligoastrocytoma; O, oligodendroglioma. 
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Table 4.3 Common miRNAs in the three groups, A vs OA, OA vs O and A vs O with percentage of differential expression in different histology types 
of grade II tumours.  
 
miRNA Upregulation  
(% of tumours)a 
Downregulation  
(% of tumours) 
Target Pathway 
A OA O A OA O 
Common between A vs OA and OA vs O 
miR-21 47 100 33 53 0 67 YOD1, KRIT1, WTH3DI, GPR64, PLEKHA1, 
SKP2, FBXO11, MALT1, PELI1, PBRM1 
Cytokine-cytokine receptor interaction, TGF-beta signalling 
pathway, MAPK signalling pathway, Melanoma 
miR-23a 40 100 67 60 0 33 GIPC3, PTPRT, PCDHB16, PPA2, DSC3, 
XXYLT1, PIK3C2A, USH2A, ASTN1, CORT 
Transcriptional misregulation in cancer, Osteoclast 
differentiation, Pathogenic Escherichia coli infection, 
Glycolysis/Gluconeogenesis, RNA degradation 
miR-30c 40 100 67 60 0 33 TNRC6A, CELSR3, MIER3, EED, LHX8, 
PPARGC1B, PHTF2, SCN2A, ANKRA2, RTKN2  
Neuroactive ligand-receptor interaction, Phosphatidylinositol 
signalling system, Dilated cardiomyopathy, Axon guidance, Focal 
adhesion  
miR-99a 40 100 67 60 0 33 KBTBD8, TARDBP, TMPRSS13, SMARCA5, 
AP1AR, ZADH2, THAP2, MTOR, NOX4, VNN1  
Pathways in cancer, Colorectal cancer, ErbB signalling pathway, 
Chronic myeloid leukemia, Prostate cancer 
Common between A vs OA and A vs O 
miR-885-3p 33 100 100 67 0 0 NAA11, LIN9, WWC3, CARM1, TCL1A, 
PKNOX1, CLIP4, PPP3CB, NDST1, PDE7B 
Glycosaminoglycan biosynthesis – heparan sulphate/heparin, 
Glioma, Pathogenic Escherichia coli infection, Adherens junction, 
Melanoma 
miR-936 33 100 100 67 0 0 ANKRD17, FLRT3, GABRA1, SLC35D1, 
ATP1B1, LRRC4C, GPR137C, FGF2, PHACTR2, 
DTNA 
Glycosaminoglycan biosynthesis – chondroitin sulphate, 
GABAergic synapse, ErbB signalling pathway, Gastric acid 
secretion, Morphine addiction 
miR-4736 33 100 100 67 0 0 ORAI2, SSR1, TBC1D13, MAVS, ABCD3, SYT2, 
KCNMA1, H2AFV, MAP1B, ERC1 
ErbB signalling pathway, GnRH signalling pathway, Vitamin B6 
metabolism, Calcium signalling pathway, SNARE interactions in 
vesicular transport 
miR-4728-5p 33 100 33 67 0 67 FOXP4, NOS1, GNAT1, ORAI2, SMARCD1, 
FAIM2, AR, DUSP8, LRP1, RALB 
Vasopressin-regulated water reabsorption, Axon guidance, Cell 
adhesion molecules (CAMs), Prostate cancer, Pathogenic 
Escherichia coli infection 
a 
A, astrocytoma; OA, oligoastrocytoma; O, oligodendroglioma. Common pathways between miRNAs are highlighted in different coloured text. 
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4.10 miRNA EXPRESSION PROFILING OF GRADE III TUMOURS  
Expression analysis of 12 grade III tumours was performed comprising 2 AA, 4 AOA 
and 6 AO. Five tumours were IDH mutant and 7 were IDH wild type. Unsupervised 
hierarchical clustering was performed using 1719 miRNAs and BTNW614 (AOA) and 
BTNW126 (AA) had different profiles from the remaining tumours as shown in Figure 
4.6. All AO tumours form a large cluster with a single case of AOA (BTNW527).  
 
Supervised hierarchical clustering based on IDH mutation status identified 8 miRNAs 
(≥ 2-fold change) with differential expression. The dendrogram in Figure 4.7 shows that 
the tumours were divided into 2 clusters. The smaller group of 5 cases were all IDH 
wild type tumours with a mixture of histologies (1AA, 3AOA and 1AO). The larger 
cluster comprised a majority of IDH mutant (5/7, 71%) samples and 6/7 (86%) AO. 
Seven of the miRNAs were upregulated in 71% IDH wild type tumours and 
downregulated in 80% IDH mutated tumours, while miR-21 was upregulated in 86% 
wild type tumours and downregulated in 100% IDH mutated tumours as detailed in 
Table 4.4.  
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 Figure 4.6 Unsupervised hierarchical clustering for 12 grade III tumours 
 
 
Expression of 1719 miRNAs in 12 grade III tumours identified using Partek Genomic Suite. Red colour represents high levels of miRNA 
expression and green colour represents low levels of miRNA expression in the tumour. Mut – IDH1/IDH2 mutant, WT – IDH1/IDH2 wild 
type, AA – anaplastic astrocytoma, AOA – anaplastic oligoastrocytoma, AO – anaplastic oligodendroglioma. 
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 Figure 4.7 Supervised hierarchical clustering for 12 grade III tumours based on IDH mutation status  
 
Expression of 8 differentially expressed miRNAs with ≥ 2 fold change in expression identified using Partek Genomic Suite by ANOVA 
and with a significance of p < 0.05. Red colour represents high levels of miRNA expression and green colour represents low levels of 
miRNA expression in the tumour. Mut – IDH1/IDH2 mutant, WT – IDH1/IDH2 wild type, AA – anaplastic astrocytoma, AOA – 
anaplastic oligoastrocytoma, AO – anaplastic oligodendroglioma. 
 
miR-21 
 
miR-711 
 
miR-4734 
 
miR-486-3p 
 
miR-1268b 
 
miR-4763-3p 
 
miR-4667-5p 
 
miR-3621 
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Table 4.4 Differentially expressed miRNAs (≥ 2 fold change) in grade III tumours based on IDH mutation. 
 
miRNA P value Fold change
a
 
(Mut vs WT) 
Upregulation  
(% of tumours) 
Downregulation  
(% of tumours) 
Target Pathway 
Mut WT Mut WT 
miR-1268b 
 
0.04 -2 20 71 80 28 
ADAMTS4, KCNA3, TMEM229A, 
PGR, HIF3A, EGR4, COG2, TOLLIP, 
RBM19 
Ubiquinone and other terepenoid-quinone 
biosynthesis, Phenylalanine metabolism, Calcium 
signalling pathway, ABC transporters, Type II 
diabetes mellitus  
miR-711 
0.04 -2 20 71 80 28 
MAFG, RGS5, FGD2, KRTAP20-3, 
ACTR10, CNKSR2, MAD2L1BP, 
MUC15, CD44, IL18BP 
Pathways in cancer, Colorectal cancer, Wnt 
signalling pathway, Chronic myeloid leukemia, 
Toll-like receptor signalling pathway 
miR-4667-5p 
0.04 -2 20 71 80 28 
AAK1, KCNC1, VSTM4, ADCY6, 
STAM2, DAGLA, ATF6B, KSR2, 
RASSF4, ITGA10 
PI3K-Akt signalling pathway, Steroid hormone 
biosynthesis, Regulation of actin cytoskeleton, 
Fatty acid elongation, Pancreatic cancer 
miR-4763-3p 
0.04 -2 20 71 80 28 
ORAI2, THEM5, PGPEP1, CD276, 
MAFG, CHPF, LHPP, TMEM120B, 
CD3EAP, ASB6 
Glycosaminoglycan biosynthesis – chondroitin 
sulphate, Adherens junction, Synaptic vesicle 
cycle, Calcium signalling pathway, 
Glycosaminoglycan biosynthesis – heparan 
sulphate/heparin 
miR-4734 
0.02 -2.8 20 71 80 28 
USP36, ANKRD52, ANKRD13A, 
SSTR2, INSIG1, COL6A6, CUL1, 
LYL1 
NIcotinate and nicotinamide metabolism, 
Morphine addiction, Oocyte meiosis, N-glycan 
biosynthesis, Circadian rythm 
miR-486-3p 
0.03 -2.9 20 71 80 28 
RAB11FIP4, PLCB1, PRX, FLOT2, 
NSD1, DAB2IP, SF3A1, 
TMEM132E, ORAI2, H6PD 
Synaptic vesicle cycle, Lysine degradation, RNA 
polymerase, ErbB signalling pathway, Shigellosis 
miR-3621 
0.04 -2.9 20 71 80 28 
CARD9, CDC16, USP19, H3F3B, 
ECE1 
Pathways in cancer, TGF-beta signalling pathway, 
Melanogenesis, Renal cell carcinoma, Long-term 
potentiation 
miR-21 
0.01 -3.6 0 
 
86 
 
100 14 
YOD1, KRIT1, WTH3DI, GPR64, 
PLEKHA1, SKP2, FBXO11, MALT1, 
PELI1, PBRM1 
Cytokine-cytokine receptor interaction, TGF-beta 
signalling pathway, MAPK signalling pathway, 
Melanoma 
a 
Mut, IDH mutant; WT, IDH wild type. Pathways common between miRNAs are highlighted in different coloured text. 
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4.11 miRNA EXPRESSION PROFILING OF GRADE III TUMOURS BASED 
ON HISTOLOGY  
Similar to the analysis for grade II tumours, comparisons of miRNA expression were 
performed in three histological groupings; AA compared with AOA (n = 6), AOA 
compared with AO (n = 10) and AA compared with AO (n = 8). Significant 
differentially expressed miRNAs were identified in the three groups and hierarchical 
clustering is shown in Figure 4.8. No differentially expressed miRNAs were found 
when comparing AA with AOA. When comparing AOA with AO, there were 2 clusters 
with one comprising 3 AOA and the other cluster comprising of all AO tumours and 1 
AOA (BTNW527). AA and AO were separated independently according to histology. 
Three miRNAs (miR-3135b, miR-4706 and miR-4748) were differentially expressed 
between the AOA and AO and also between AA and AO as detailed in Figure 4.9. All 3 
miRNAs were upregulated in all AA, 75% of AOA and 17% of AO while they were 
downregulated in 25% of AOA and 83% of AO (Table 4.5).  
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Figure 4.8 Supervised hierarchical clustering for 10 grade III tumours based on 
histology  
 
 
 
 
Expression of differentially expressed miRNAs with ≥ 2 fold change in expression 
identified using Partek Genomic Suite by ANOVA and with a significance of p < 0.05. 
Red colour represents high levels of miRNA expression and green colour represents 
low levels of miRNA expression in the tumour. AA – anaplastic astrocytoma, AOA – 
anaplastic oligoastrocytoma, AO – anaplastic oligodendroglioma. 
AOA vs AO 
AA vs AO 
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Figure 4.9 Venn diagram showing common and unique miRNAs in the two groups (AA vs AO and AOA vs AO) 
 
Using Partek Genomics Suite, AA vs AO and AOA vs AO was compared and three common miRNAs were identified with ≥ 2 fold change  
in expression and significance of p < 0.05 by ANOVA. AA, anaplastic astrocytoma; AO, anaplastic oligodendroglioma; AOA,  
anaplastic oligoastrocytoma. 
 
Table 4.5 Common miRNAs between AA vs AO and AOA vs AO with percentage of differential expression in the three histologies of grade III 
tumours. 
miRNA Upregulation  
(% of tumours)a 
Downregulation 
(% of tumours) 
Target Pathway 
AA AOA AO AA AOA AO 
miR-3135b 100 75 17 0 25 83 KLHL31, NOS1, TRPM7, RORC, AKNA, 
EPHA10, RBBP5, COG2, VIPR2, PACS1 
Mucin type O-Glycan biosynthesis, Valine, leucine and isoleucine 
biosynthesis, Other glycan degradation, Osteoclast 
differentiation, Vasopressin-regulated water reabsorption 
miR-4706 100 75 17 0 25 83 FOXE1, GPRC5B, ANKRD52, TUBB4A, SAP18, 
PTAR1, FOXRED2, ANKRD13A, ELAC2, 
LRRC15 
Tryptophan metabolism, Cocaine addiction, Amphetamine 
addiction, Tyrosine metabolism, Phenylalanine metabolism 
miR-4748 100 75 17 0 25 83 TSFM, PPP2R5A, KALRN, CTSL2, GABRG2, 
TMEM106B, SNF8, ABCD4, GM2A, FERMT1 
Colorectal cancer, Endometrial cancer, Epstein-Barr virus 
infection, B cell receptor signalling pathway 
a 
AA, anaplastic astrocytoma; AOA, anaplastic oligoastrocytoma; AO, anaplastic oligodendroglioma.
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4.12 COMPARISON OF miRNA EXPRESSION PROFILES OF IDH MUTANT 
AND IDH WILD TYPE TUMOURS 
Supervised hierarchical clustering analysis was performed for primary tumours of both 
grade II (n = 17) and grade III tumours (n = 15) based on IDH mutation status but no 
significantly differentially expressed miRNAs were identified. This study suggests that 
tumour grade and histology were the most influential factors on the expression profiles 
of tumours. 
 
 
4.13 RELATIONSHIP BETWEEN miRNA EXPRESSION AND OUTCOME 
In order to determine if there was a relationship between differentially expressed 
miRNAs and patient survival, the miRNA profile was compared in patients who 
survived less than or more than 2 years and also in patients who survived less than or 
more than 3 years from initial diagnosis.  There was no significant association between 
miRNA expression and OS. 
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4.14 DIFFERENTIAL EXPRESSION OF miRNAS IN LGG USING THE 
CANCER GENOME ATLAS (TCGA) DATA  
In order to validate the expression pattern of miRNAs identified and to determine the 
significance of miRNA expression profiling in the present study cohorts, large 
publically available cohorts of LGG (N=530) with available miRNA-seq data from 
TCGA were used.  
 
4.14.1 Data analysis 
miRNA-seq data for the 530 LGG was downloaded from the TCGA data portal and 
analysed using Subio platform V.1.18 (Subio Inc., Japan). The data 
reads_per_million_miRNA_mapped was used as the Ch1 raw signal for analysis. 
Alongside the miRNA expression data, metadata for the patients containing information 
on histological types (A, OA and O), histological grades (G2 and G3), IDH1 mutation 
status (IDH1 mutation - Yes and No) and survival (below or above 3 years) was also 
included. miRNA data series for the LGG TCGA cohorts with all the information was 
created. Undetected miRNA within the data series were assigned a value of ‘0’. The raw 
data was firstly normalized by setting low signal cut off to ‘0.1’, followed by log2 
transformation and finally data centering using median values, to obtain processed 
signal for further analysis. Processed signal stands for log2 ratio against the averages of 
expression patterns per miRNA. The processed signal was analysed for differential 
expression based on specific patients’ data e.g. based on IDH1 mutation status. The 
differential expression analysis was based on ≥ 2 fold change and p < 0.05 (Mann-
Whitney U test). Supervised hierarchical clustering using Pearson correlation coefficient 
was performed to determine the relationship of significant differentially expressed 
miRNAs. 
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4.14.2 Differential expression of miRNA in tumours based on histology  
The TCGA cohort consisted of 165 A, 177 OA and 111 O tumours. A total of 453 
patients were used for the analysis as the remaining patients lacked information 
regarding the histology of the tumours. 
 
As illustrated in Figure 4.10, the differentially expressed miRNAs between A and OA 
tumours consisted of miR-96, miR-10b and miR-196b and those between A and O 
patients consisted of miR-124-1, miR-124-2, miR-7-3, miR-888, miR-196a-1, miR-592, 
miR-2114, miR-21, miR-203, miR-204, miR-891a, miR-891b, miR-10b, miR-3923, 
miR-1-2, miR-124-3, miR-1224, miR-137, miR-892b, miR-3622a, miR-96, miR-1262, 
miR-892b, miR-3065, miR-196b and miR-455. Differentially expressed miRNA 
between OA and O consisted of let-7d, let-7e and miR-3923.  
 
On comparison of the OA and O data from the TCGA cohort and the present study, two 
common miRNAs (let-7d and let-7e) were identified in the two cohorts as shown in 
Figure 4.11.  
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Figure 4.10 Differentially expressed miRNAs in grade II tumours based on 
histology  
 
(A) 
 
 
 
 
 
 
 
 
(B) 
 
 
 
 
 
 
 
 
 
A: Supervised hierarchical clustering showing 3 differentially expressed miRNAs 
between astrocytoma and oligoastrocytoma tumours. B: Supervised hierarchical 
clustering showing 26 differentially expressed miRNAs between astrocytoma and 
oligodendroglioma tumours. The dendrogram colour saturation is proportional to the 
magnitude of the difference from the mean, ranging from red (over-expressed) to blue 
(under-expressed).  
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Figure 4.11 Comparison of TCGA data with the present study 
                          
On comparison of the two data sets, TCGA, The Cancer Genome Atlas; BTRC, Brain 
Tumour Research Centre, two common miRNAs with ≥ 2 fold change in expression 
were identified by ANOVA with a significance of p < 0.05. 
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4.14.3 Differential expression of miRNA in tumours based on grade  
The TCGA cohort consisted of 217 grade II and 236 grade III tumours. A total of 453 
patients were used for the analysis as the remaining patients lacked information 
regarding the grades of the tumours. 
 
As shown in Figure 4.12, the differentially expressed miRNAs between grade II and 
grade III patients consisted of miR-196a, miR-10b and miR-196b.  
 
4.14.4 Differential expression of miRNA in tumours based on IDH1 status  
The TCGA cohort consisted of 77 IDH1 mutant and 29 IDH1 wild type tumours. A 
total of 106 patients were used for the analysis as the remaining patients lacked 
information regarding the IDH1 mutation status of the tumours. 
 
As shown in Figure 4.13, 46 differentially expressed miRNAs between IDH1 mutant 
and IDH1 wild type tumours were identified. These included mir-574, mir-615, mir-
599, mir-887, mir-135a-2, mir-34a, mir-196a-2, mir-196a-1, mir-2115, mir-148a, mir-
2114, mir-767, mir-34c, mir-21, mir-224, mir-221, mir-204, mir-222, mir-146b, mir-
200a, mir-429, mir-200b, mir-3923, mir-187, mir-10a, mir-2277, mir-182, mir-16-2, 
mir-1295, mir-942, mir-31, mir-155, mir-15b, mir-1266, mir-675, mir-892a, mir-651, 
mir-1468, mir-1248, mir-452, mir-196b, mir-135b, mir-455, mir-493, mir-671 and mir-
23a.  
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Figure 4.12 Differentially expressed miRNAs between grade II and grade III 
tumours 
 
 
 
 
 
 
 
 
 
 
 
                        Grade II                              Grade III 
Supervised hierarchical clustering showing 3 differentially expressed miRNAs between 
grade II and grade III tumours. The dendrogram colour saturation is proportional to the 
magnitude of the difference from the mean, ranging from red (over-expressed) to blue 
(under-expressed).  
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Figure 4.13 miRNA differential expression in IDH1 mutant and IDH1 wild type 
tumours 
 
                                                              
IDH1 Mutant                        IDH1 Wild Type 
 
Supervised hierarchical clustering showing 46 differentially expressed miRNAs 
between IDH1 mutant and IDH1 wild type tumours. The dendrogram colour saturation 
is proportional to the magnitude of the difference from the mean, ranging from red 
(over-expressed) to blue (under-expressed).  
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4.14.5 Differential expression of miRNA in tumours based on IDH1 status and 
grade 
In addition, analysis based on IDH1 mutation status and tumour grades was also 
performed. As illustrated in Figure 4.14, no miRNA was significantly differentially 
expressed between IDH1 mutants of grade II and III. Similarly, no miRNA was 
differentially expressed between IDH1 wild types of grade II and III. However, 25 
differentially expressed miRNAs were identified between IDH1 mutants and IDH1 wild 
types in grade II and grade III tumours.  
 
The differentially expressed miRNAs were mir-574, mir-599, mir-887, mir-34a, mir-
196a-2, mir-196a-1, mir-224, mir-221, mir-222, mir-204, mir-200a, mir-200b, mir-10a, 
mir-187, mir-2277, mir-16-2, mir-942, mir-155, mir-31, mir-675, mir-651, mir-1248, 
mir-196b, mir-455 and mir-493.  
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Figure 4.14 miRNA differential expression based on IDH1 mutation status and 
grade 
  
      
                   
IDH1 Mutant      IDH1 Mutant      IDH1 WT           IDH1 WT 
  Grade III               Grade II            Grade II            Grade III 
 
Supervised hierarchical clustering showing 25 differentially expressed miRNA between 
IDH1 mutants and IDH1 wild types of grade II and grade III tumours. The dendrogram 
colour saturation is proportional to the magnitude of the difference from the mean, 
ranging from red (over-expressed) to blue (under-expressed).  
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4.14.6 Differential expression of miRNA in patients based on outcome 
Survival information for patients within the TCGA cohort was available in only 74 
patients which were classified according to survival rate of >3 and <3 years within this 
group. The differentially expressed miRNAs between the two groups of patients 
included mir-135a-2, mir-34a, mir-196a-2, mir-196a-1, mir-148a, mir-34b, mir-34c, 
mir-21, mir-221, mir-204, mir-1179, mir-200a, mir-429, mir-200b, mir-1275, mir-187, 
mir-10a, mir-1298, mir-1296, mir-216a, mir-211, mir-504, mir-31, mir-155, mir-217, 
mir-1247, mir-651, mir-196b and mir-135b and are presented in Figure 4.15. 
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Figure 4.15 miRNA differential expression of patients based on outcome 
 
 
 
 
 
 
 
 
 
 
 
 
Supervised hierarchical clustering showing 29 differentially expressed miRNAs 
between patients with survival rate of >3 years and <3 years. The dendrogram colour 
saturation is proportional to the magnitude of the difference from the mean, ranging 
from red (over-expressed) to blue (under-expressed).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
124 
 
4.15 DISCUSSION 
This chapter focused on understanding the significance of miRNAs in the development 
and progression of LGG. Unsupervised hierarchical clustering of all the primary 
tumours showed a major influence of tumour grade and histology (within each grade) 
on the expression profiles whereas IDH mutation did not have an effect on the profiles. 
 
Unsupervised clustering of all 32 primary tumours resulted in independent clustering of 
two samples, BTNW13 (OA) and IN99/81 (O), both of which were IDH1 mutant. These 
two samples were no different to the remaining samples and they were included as part 
of the analysis and excluding them would mean altering the actual data. 
 
4.15.1 Comparison of miRNA expression profiles of grade II and grade III 
tumours 
Supervised hierarchical clustering identified independent clustering of two samples, 
IN99/81 (O) and IN2800 (A) in this analysis. Seven of the miRNAs identified in this 
analysis, mir-3658, mir-449c, miR-4741, miR-4252, miR-4500, miR-141 and miR-120d 
have been studied in other types of cancer.  
 
In the present study, miR-3658 was upregulated in 70% of grade II tumours and 
downregulated in 83% of grade III tumours. In a study of multiple myeloma (MM) 
patients, dysregulation of miR-3658 was confirmed in MM patients compared to 
healthy donors by quantitative reverse transcription PCR (RT-qPCR) (Hao et al., 2014). 
In the present study, miR-449c had more than 4-fold differential expression. Previously, 
it has been reported to be downregulated in non-small cell lung cancer (NSCLC) tissues 
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and NSCLC cell lines, while overexpression of the miR-449c inhibited cell proliferation 
and promoted apoptosis in NSCLC cells compared with normal tissues (Miao et al., 
2013). Moreover, MYC was directly targeted by miR-449c supressing MYC protein 
expression and downregulation of MYC expression was also observed in nude mice 
promoting carcinogenesis in vivo. miR-4741 had a 2.5 fold differential expression in the 
present study. In a study of hepatocellular carcinoma (HCC), the authors investigated 
the role of plasma circulating miRNAs in predicting the prognosis of HCC patients 
receiving the transarterial chemoembolisation (TACE) treatment (Liu et al., 2014). 
miR-4741 was validated and reported as a candidate biomarker for predicting the 
prognosis of TACE. miR-4252 had a differential expression of > 2 fold in the current 
study. Recently, it has been reported in association with gastric cancer, where it was 
found to be upregulated in patients with positive lymphatic metastasis of the primary 
gastric tumour (Yang et al., 2014). miR-4500 had > 2 fold differential expression in the 
present study. miR-4500 has been studied in NSCLC and downregulation of the miRNA 
was reported in NSCLC cell lines and tissues (Zhang et al., 2014). The miRNA 
expression was correlated with survival and high expression of miR-4500 was 
correlated with better survival rate, indicating a prognostic value of miR-4500 
expression in NSCLC patients. miR-141 showed >2 fold differential expression. 
miRBase identified miR-141 as part of the miR-8 family consisting of miR-200a, miR-
200b, miR-200c and miR-429. Higher expression of miR-141 was associated with 
shorter survival in patients with NSCLC adenocarcinoma (Tejero et al., 2014). miR-
320d had a 2-fold differential expression in this study. A recent study examined the role 
of miRNAs in the pathogenesis of diffuse large B-cell lymphoma (DLBCL) and 
reported that low expression of miR-320d is associated with poor prognosis in DLBCL 
patients treated with cyclophosphamide, doxorubicin, vincristine, and prednisone 
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(CHOP) regimen (Wu et al., 2014). The novel miRNAs identified in the present study 
are miR-466, miR-3142, miR-2113, miR-4529-5p, miR-4471, miR-181a*, miR-181a-
2*, miR-3616-5p, miR-4733-3p, miR-4268, miR-323b-5p, miR-3650, miR-4302 and 
miR-3689a-5p, which have not been studied previously in any type of cancer including 
glioma. 
 
PI3K/mTOR pathway identified as a pathway associated with miRNAs according to 
KEGG pathway analysis, has been studied previously in grade II tumours (McBride et 
al., 2010). The relationship between OS and methylation status and expression of 
PTEN, a negative regulator of PI3K pathway and phosphorylation of proteins in the 
PI3K/mTOR pathway such as S6 and PRAS40 was investigated. PTEN methylated 
patients were associated with poor OS (p = 0.128) and expression of phosphor-PRAS40 
was associated with decreased survival (p = 0.077). Expression of phosphor-S6 and OS 
showed an inverse relationship (p = 0.029). The regulation of PI3K-mTOR pathway and 
OS suggests that mTOR inhibitors could be used in the treatment of grade II tumours.   
 
A study by Barbano et al., (2014) compared miRNA expression profiles of 8 grade II 
and 24 grade III+IV glioma and identified 22 differentially expressed miRNAs in the 
two groups. On validation, 13 of the 22 miRNAs had significant differential expression 
between grade II and grade III+IV tumours. Of the 13 miRNAs, miR-451 was the only 
miRNA that was significant in the results from the grade II and grade III comparison 
reported in the present study. It was differentially expressed in < 70% of the samples; 
upregulated in 40% grade II and 67% grade III tumours and downregulated in 60% 
grade II and 33% grade III tumours. This is in agreement with the data from Barbano et 
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al., (2014) where downregulation of miR-451 in grade II tumours and upregulation in 
grade III tumours was found. 
 
4.15.2 miRNA expression in grade II tumours 
BTNW13 and IN99/81 clustered independently to the remaining tumours as shown in 
Figure 4.1. In the present study, let-7c was the only miRNA identified when comparing 
expression profiles of IDH mutant and IDH wild type grade II tumours and it was 
downregulated in 71% tumours with IDH wild type. Let-7c is a member of the let-7 
family and reportedly acts as a regulator of cell proliferation pathways (Johnson et al., 
2007). It has been recently studied in breast cancer and prostate cancer. Björner et al., 
(2014) identified miRNA signatures that could represent alterations leading to breast 
cancer progression. Let-7c was downregulated in the epithelial compartment and 
increased proliferation in columnar cell hyperplasia (CCH), earliest stage linked to 
cancer progression. Ren et al., (2014) examined miRNA expression levels in prostate 
cancer (PCa) epithelium and stroma. Downregulation of let-7c was significantly 
associated with metastasis (p = 0.01) and androgen-dependent PCa (p = 0.003) and in 
PCa stromal cells, downregulation of let-7c was significantly associated with 
extraprostatic extension (p = 0.02).  
 
4.15.3 miRNA expression in grade II tumours based on histology 
As shown in Figure 4.5, identification of four common miRNAs between A vs OA and 
OA vs O clearly indicates that they represent differentially expressed miRNAs present 
in OA tumours. All four miRNAs upregulated in OA include miR-21, miR-23a, miR-
30c and miR-99a, which have been previously studied in cancers including glioma. 
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According to Barbano et al. (2014), miR-21 showed a significant differential expression 
in grade II tumours compared to tumours of higher grades III and IV. miR-21 showed 
highest expression in astrocytic tumours characterised by worst prognosis. In a previous 
study of 152 glioma, expression of miR-21 was observed to be higher in grade III-IV 
(high-grade) tumours compared to grade I-II (low-grade) tumours (p < 0.001) (Wu et 
al., 2013). Patients with low miR-21 expression had significantly longer survival 
compared to those with high miR-21 expression (p < 0.001) and multivariate analysis 
showed that high miR-21 expression was a significant and independent indicator for 
poor prognosis in glioma patients (p < 0.001). In colorectal cancer blood and tissue 
samples, miR-23a expression was upregulated and significant reduction of cell viability 
and promotion of apoptosis was observed following transfection with miR-23a inhibitor 
(Yong et al., 2014). miR-30c was recently studied in breast cancer using TCGA dataset 
(Dobson et al., 2014). miR-30c was upregulated or had high copy number in about 4% 
of breast cancer patients. These patients had significantly worse OS compared to those 
with normal miR-30c, suggesting an important role of miR-30c in breast cancer 
progression. The role of miR-99a expression was studied in GBM cells and xenograft 
models in a previous study (Chakrabarti et al., 2013). The authors showed that photofrin 
based photodynamic therapy (PDT) and overexpression of miR-99a could inhibit 
fibroblast growth factor receptor 3 (FGFR3) and PI3K-Akt signalling pathways to 
promote p53-mediated apoptosis in p53 wild type GBM cells in vitro and in vivo.      
Koshkin et al., (2014) investigated 20 significant miRNAs with differential expression 
in different grades identified from a previous study (de Biase et al., 2012) to determine 
correlation between the miRNA expression and tumour grades. Expression of two 
miRNAs, miR-21 and miR-23a was upregulated in higher grade tumours. Both the 
miRNAs were identified as differentially expressed in grade II tumours in this study. 
129 
 
miR-21 was most frequently upregulated and downregulated in OA (100%) and O 
(67%) respectively, whereas miR-23a showed most frequent upregulation in OA 
(100%) and most frequent downregulation in A (60%). The expression of miR-21 and 
miR-23a does not correlate with tumour grade and miRNA expression was significant 
in grade II tumours only.   
The findings from the current study suggest that oligoastrocytoma tumours are more 
similar to oligodendroglioma as there were only four significant differentially expressed 
miRNAs identified between the two histological groups. 
 
4.15.4 miRNA expression in grade III tumours 
The miRNA expression of grade III tumours revealed independent clustering of two 
samples, BTNW614 (AOA) and BTNW126 (AA), both of which had different 
expression profiles from the remaining samples in the cohort. Of the eight miRNAs 
identified as differentially expressed in grade III tumours, only three (miR-21, miR-711 
and miR-486-3p) have been previously reported in cancer studies.  
 
miRNA-711 was studied in cutaneous T-cell lymphomas (CTCL) and the authors 
showed that it was one of the most induced miRNAs that distinguished CTCL from 
benign skin diseases with > 90% accuracy in a cohort of 148 patients (Ralfkiaer et al., 
2011). It also distinguished malignant and benign lesions in peripheral T-cell lymphoma 
(PTL) and skin inflammation and in xenograft models of psoriasis and CTCL in an 
independent cohort of 50 patients. miR-486-3p was reported in a study of 
neurofibromatosis type 1 (NF1) examining the role of miRNAs in tumourigenesis of 
NF1 (Masliah-Planchon et al., 2013). miR-486-3p was the most significantly 
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upregulated miRNA in plexiform neurofibromas, which targets the tumour suppressor 
gene PTEN. miR-486-3p was studied in hepatocellular carcinoma to identify 
postoperative prognostic predictors (Huang et al., 2012). The prognostic value of miR-
486-3p was examined and high expression of miR-486-3p was significantly associated 
with longer PFS (p < 0.020) and longer OS (p < 0.041). Multivariate analysis showed 
that miR-486-3p expression level was an independent predictor of PFS (p = 0.004). In 
the current study, 5 of the miRNAs, miR-4734, miR-1268b, miR-4763-3p, miR-4667-
5p and miR-3621 were identified in glioma for the first time.  
 
4.15.5 miRNA expression in grade III tumours based on histology  
None of the three differentially expressed miRNAs (miR-3135b, miR-4706 and miR-
4748) that were common between AA vs AO and AOA vs AO have been investigated 
in any cancer studies previously. Hierarchical clustering for histology comparison 
analysis indicates that anaplastic oligoastrocytoma tumours have more similar profiles 
to anaplastic astrocytoma tumours, as there were no differentially expressed miRNAs 
between the two histology types. 
 
4.15.6 Comparison with the TCGA data  
TCGA miRNA-seq data for LGG cohorts became only recently available after the 
commencement of the present study. Therefore, it was important to determine the status 
of the different clinical scenarios such as identification of differentially expressed 
miRNAs between different histological groups, tumour grades, IDH mutation status, 
progression and survival in a larger cohort of patients such as that of TCGA.   
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Differentially expressed miRNAs for OA vs A in the TCGA cohort had two common 
miRNAs (let-7d and let-7e) for the respective comparison in the present study cohort. 
Mitra et al., (2011) studied the regulation of miRNAs in breast cancer progression. The 
authors showed epigenetic repression of let-7e expression by the histone demethylase 
Jumonji/ARID1 B (JARID1B). JARID1B promotes cell proliferation by G1 to S 
transition. No other miRNAs were common between the data from the TCGA analysis 
and that from the present study. This is mainly due to a large difference in the size of 
the cohorts with 453 cases in the TCGA cohort and 32 cases in the present study.  
Comparison of grade II and grade III tumours in the present study identified 42 
differentially expressed miRNAs, while the TCGA analysis with more number of 
samples in the cohort had only 3 differentially expressed miRNAs between grade II and 
grade III tumours. These 3 miRNAs were different from the 42 differentially expressed 
miRNAs identified.  
miRNA expression analysis for tumours with IDH1 mutation and tumours with IDH1 
wild type showed no significant differentially expressed miRNAs in the current study. 
In the TCGA data analysis, 46 miRNAs were differentially expressed in IDH1 mutant 
vs IDH1 wild type tumour samples. 
Differential expression of miRNA in patients based on outcome identified 29 
differentially expressed miRNAs in the TCGA data between patients with survival rate 
of >3 years and <3 years, but no significant differentially expressed miRNAs were 
identified in the present study. 
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In conclusion, the present study shows that tumour grade has a greater impact on the 
miRNA expression profiles compared to the other parameters such as IDH status and 
histology. Forty-two significant differentially expressed miRNAs were identified 
between grade II and grade III tumours that had different expression levels in grade II 
and grade III tumours. Histological group analysis showed that OA was more similar in 
profile to O and AOA was more similar to AA suggesting a miRNA signature in the 
histological groups. The results from this study were compared to analysis of TCGA 
data and only two common miRNAs were identified in the two datasets, let-7d and let-
7e from OA vs A analysis. 
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CHAPTER 5 
GENETIC ANALYSIS OF PRIMARY/RECURRENT PAIRS 
 
5.1 INTRODUCTION 
LGG almost invariably recur and progress to a higher histological grade (grade III and 
IV) with worse prognosis (Westphal et al., 2011). It is not possible to predict when and 
if this progression will take place on an individual basis (Sanai et al., 2011) and little is 
known about the genetic differences between the primary and recurrent tumour and if 
that might give information relating to choice of treatment (Riehmer et al., 2014).  
The aim of this chapter was to identify molecular markers between primary and 
recurrent tumours that could drive the malignant progression of LGG tumours. To 
achieve this, the mutation status of IDH1/IDH2 and the MGMT promoter methylation 
status and MGMT expression was determined in a small cohort of patients, in which 
samples were available at the time of diagnosis and subsequently at the time of 
recurrence. In addition, the genomic and miRNA expression profiles of those 
primary/recurrent pairs were established using array CGH and miRNA array analysis 
respectively.  
 
5.2 IDH MUTATION ANALYSIS 
The cohort consisted of paired samples from 10 patients comprising 5 grade II (4A and 
1O) and 5 grade III tumours (1AA, 3AOA and 1AO) at first diagnosis (Table 5.1). Of 
the 5 grade II cases, 2 tumours recurred at the same grade and 2 underwent malignant 
transformation and recurred as grade III tumours. In Patient 2, a grade II A progressed 
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to a grade III tumour with further malignant transformation to GBM and an additional 
recurrence. In the 5 grade III tumours, 4 recurred as same histological grade and in one 
of these patients, there was a subsequent recurrence at the same grade (Patient 8).  One 
grade III case progressed to GBM. 
Mutation analysis for IDH1 was carried out by direct sequencing for all primary 
tumours and their recurrences. In addition, IDH2 was sequenced for all samples with 
sufficient DNA as summarised in Table 5.1. The IDH1 R132H mutation was present in 
4 of 10 primary tumours with the IDH2 R172K mutation present in an additional case.  
All these IDH mutations were maintained in subsequent recurrences, including those 
which had undergone malignant transformation. IDH wild-type genotypes were 
similarly preserved during tumour recurrence and progression. 
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Table 5.1 Primary and recurrent pairs used for IDH analysis 
Patient 
Number 
Tumour Agea Sexb Grade Histologyc IDH1 
statusd 
IDH2 
statuse 
Time to 
recurrencef 
Overall 
survivalg 
1 BTNW20 
26 M II A R132H WT 
83 94 (A) 
 BTNW1378 
  II A R132H NA 
  
2 BTNW365 
42 F II A R132H WT 
28.5 37.5 (D) 
 BTNW861   
III AA R132H NA 
  
 BTNW946   
IV GBM R132H NA 
  
 BTNW974   
IV GBM R132H NA 
  
3 BTNW367 
56 M II A WT WT 
0.5 62 (A) 
 BTNW380 
  II A WT WT 
  
4 BTNW870 
17 M II A WT WT 
1 33 (A) 
 BTNW885 
  III AA WT WT 
  
5 BTNW326 
56 F II O R132H NA 
33.5 
37.5 (D) 
 BTNW883 
  III O R132H NA 
  
6 BTNW126 
66 M III AA WT WT 
5 
6 (D) 
 BTNW196 
  III AA WT WT 
  
7 BTNW174 
42 F III AOA WT WT 
36 45.5 (D) 
 BTNW749 
  III AOA WT NA 
  
8 BTNW325 
46 M III AOA WT NA 
230.5 
263 (D) 
 BTNW515 
  III AOA WT WT 
 
 
 BTNW778 
  III AOA WT NA 
  
9 BTNW614 
49 M III AOA R132H NA 
14.5 21.5 (D) 
 BTNW848 
  IV GBM R132H NA 
  
10 BTNW15 
56 M III AO WT R172K 
13.5 14.5 (D) 
 BTNW107 
  III AO WT R172K 
  
 
a
 Age at diagnosis in years; 
b
 M, male; F, female; 
c
 A, astrocytoma; O, 
oligodendroglioma; AA, anaplastic astrocytoma; AOA, anaplastic oligoastrocytoma; 
AO – anaplastic oligodendroglioma; d R132H, IDH1 mutant; WT, wild type; e R172K, 
IDH2 mutant; WT, wild type; 
f 
Time to recurrence in months; 
g 
OS in months; A, alive; 
D, dead; NA, not available. 
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5.3 ANALYSIS OF MGMT PROMOTER METHYLATION BY MS PCR AND 
IHC 
Due to constraints of DNA availability, it was only possible to determine MGMT 
methylation status by MS PCR in primary and recurrent tumours for 4 patients as 
detailed in Table 5.2. In Patient 6, the MGMT promoter was unmethlyated in the 
primary tumour and the recurrence and in Patient 10, methylation of MGMT was 
present in both primary and recurrent tumours. Conversely, in Patient 3, MGMT 
methylation was lost in the recurrent tumour and in Patient 9, MGMT was partially 
methylated in the recurrent tumour even though the promoter was unmethylated in the 
primary biopsy. 
The level of MGMT expression was determined by IHC in primary and recurrent 
tumours for 6 patients and the Allred scoring system was used as described in Chapter  
2 (Table 5.2). Examples of IHC results are shown in Figure 5.1. Patient 2 and Patient 3 
maintained high levels of MGMT expression in primary tumours and the subsequent 
recurrences, using both the proportion and combined Allred scoring systems. The 
second recurrence (BTNW946) in Patient 2 had zero expression; however, given that 
high expression of MGMT was observed in previous (BTNW861) and subsequent 
(BTNW974) recurrences, this may be due to experimental failure. In these 2 patients, all 
tumours for which data was available had either no methylation or partial methylation 
of the MGMT gene promoter. In Patient 6, the level of MGMT expression was lower in 
the recurrent tumour sample using both the proportion and combined Allred scoring 
system although the same unmethylated MGMT gene promoter status was established 
by MS PCR in both primary and recurrent tumours. A reduction in MGMT expression 
at recurrence was also observed in Patient 7. However, the Allred scores of zero in 
recurrent tumour BTNW749 may also indicate technical failure. In Patient 8, high levels 
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of MGMT expression were noted in the primary tumour and first recurrence by both 
proportion and combined Allred scores. However, MGMT expression was reduced 
considerably in the second recurrence. Unfortunately, no MGMT promoter methylation 
data was available for this patient. In Patient 9, high levels of expression in the primary 
sample measured by Allred proportion and combined scores of 5 and 8, respectively, 
were reduced in the recurrent tumour to Allred proportion and combined scores of 3 and 
5, respectively, and this was accompanied by a change in MGMT promoter status from 
unmethylated to partially methylated. 
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Table 5.2 MGMT methylation status of tumours by IHC and MS PCR 
Patient 
Number  
Tumour 
 
Grade Histology
a 
IHC MS PCR
b 
Proportion Intensity Combined 
score 
2 BTNW365 
II A 
3 2 5 NA 
 BTNW861 
III A 
3 2 5 NA 
 BTNW946 
IV GBM 
0 0 0 PM 
 BTNW974 
IV GBM 
4 2 6 PM 
3 BTNW367 
II A 
5 3 8 PM 
 BTNW380 
II A 
5 2 7 U 
6 BTNW126 
III AA 
4 2 6 U 
 BTNW196 
III AA 
2 1 3 U 
7 BTNW174 
III 
AOA 3 1 4 M 
 BTNW749 
III 
AOA 0 0 0 NA 
8 BTNW325 
III 
AOA 3 2 5 NA 
 BTNW515 
III 
AOA 4 2 6 NA 
 BTNW778 
III 
AOA 1 1 2 NA 
9 BTNW614 
III AOA 
5 3 8 U 
 BTNW848 
IV GBM 
3 2 5 PM 
10 BTNW15 
III AO 
NA NA NA M 
 BTNW107 
III AO 
NA NA NA M 
 
a
 A, astrocytoma; AA, anaplastic astrocytoma; AOA, anaplastic astrocytoma; AO, 
anaplastic oligodendroglioma; GBM, glioblastoma multiforme; 
b
 M, methylated; PM, 
partially methylated; U, unmethylated; NA, not available.  
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Figure 5.1 IHC staining for MGMT expression in Patient 3 
                             BTNW367                    BTNW380 
 
     
          
Slides were stained positively with streptavidin/HRP-biotin staining and counterstained 
with haematoxylin. Pictures taken at 40x magnification A: BTNW367, Tumour at 
diagnosis; B: BTNW380, Tumour at recurrence.  
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5.4 COMPARISON OF COPY NUMBER CHANGES IN PATIENTS WITH 
PAIRED SAMPLES AT DIAGNOSIS AND RECURRENCE  
Copy number analysis for primary/recurrent pairs from 3 patients (Table 5.3) was 
performed using Agilent’s 244K array as described previously in Chapter 2, section 
2.15. Genomic segmentation (Partek) was used to identify regions of gain and loss on 
the chromosomes for each sample. Copy number aberrations (CNAs) were identified in 
all samples. 
 
Table 5.3 Primary/recurrent pairs used for aCGH analysis 
Patient 
number 
Tumour samples Histology 
at 
diagnosis
a 
Histology at 
recurrence
a 
IDH1 
status
b
 
IDH2 
status
c
 
Time to 
recurrence
d
 
1 BTNW20/BTNW1378 A A R132H WT 83 
9 BTNW614/BTNW848 AOA GBM R132H WT 14.5 
10 BTNW15/BTNW107 AO AO WT R172K 13.5 
 
a
 A, astrocytoma; AOA, anaplastic oligoastrocytoma; AO, anaplastic 
oligodendroglioma; GBM, glioblastoma multiforme;
 b
 R132H, IDH1 mutant; WT, wild 
type; 
c
 R172K, IDH2 mutant; WT, wild type;  
d
 Time to recurrence in months. 
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5.4.1 Patient 1 (Samples BTNW20 and BTNW1378) 
At diagnosis in sample BTNW20, there were 124 CNAs identified with 115 regions of 
gain and 9 regions of loss. In the recurrent tumour, the number of CNAs had increased 
to 206 with 196 gains and 10 losses (Figure 5.2).  The majority (65%; 80/124) of CNAs 
were maintained in the recurrent tumour. CNAs are detailed in supplementary data. 
The genomic profiles of the two tumour samples were divergent. CNAs that were no 
longer present in the recurrent tumour included gains on chromosomes 11p-q, 19p and 
losses on 15q and Xp. Similarly, CNAs that were detected in the recurrent tumour 
included gains on chromosomes 2q, 7q, 10p and 15q and losses at 1p, 4q, 14q and 18q. 
Chromosome 20 had no CNAs in BTNW20 but had a gain at 20q in the recurrent 
tumour. Chromosome 22 had no aberrations in both the tumour samples. 
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Figure 5.2 Genome summary with CNAs for Patient 1 
 
BTNW20 
 
  
 
 
 
 
 
 
 
 
 
BTNW1378 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Gain Loss 
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5.4.2 Patient 9 (Samples BTNW614 and BTNW848) 
At diagnosis in sample BTNW614, there were 118 CNAs present with 95 regions of 
gain and 23 regions of loss. At recurrence in sample BTNW848, the number of CNAs 
had increased to 152, of which 136 were gains and 16 were losses (Figure 5.3).  The 
number of CNAs maintained in the recurrent tumour was smaller than in Patient 1 
(49%; 58/118). CNAs are detailed in supplementary data.   
Some of the copy number changes in tumour at diagnosis were not present in the 
recurrent tumour which included gains on chromosomes 1p, 1q, 10p and 11q and losses 
on 2q, 3q, 4p, 6q, 12p, 12q, 18p, 22q and Xp. Gain of whole chromosome 7 was 
observed in BTNW614 whilst gains at 7p and 7q were detected in the recurrent tumour. 
New CNA changes that were present at recurrence included gains on chromosomes 16 
and 20q and losses on 10, 11p and 18q. Gain of whole chromosome 8 was maintained in 
both the samples.  
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Figure 5.3 Genome summary with CNAs for Patient 9 
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5.4.3 Patient 10 (Samples BTNW15 and BTNW107) 
At diagnosis in sample BTNW15, there were 119 CNAs identified, of which 90 were 
regions of gain and 29 were regions of loss. At recurrence, the number of CNAs 
increased to 139 CNAs with 127 gains and 12 losses (Figure 5.4). In Patient 12, only 
28% (34/119) of CNAs were maintained in the recurrent tumour. CNAs are detailed in 
supplementary data. 
 
CNAs present in BTNW15 that were not maintained in the recurrent tumour were gains 
on chromosomes 2q, 7p and 11q and losses on 1p, 2p, 2q, 4p, 4q, 5p, 7q, 10q, 13q, 15q, 
18q and 20q. CNAs present only at recurrence were gains on chromosomes 14q, whole 
chromosome 17, 20q and 21q and losses on 2q, 6p-q, 9p, 15p, 19 and Xp. On the 
contrary, loss on chromosome 22q was present in BTNW15 while chromosome 22 was 
normal in the recurrent tumour.  
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Figure 5.4 Genome summary with CNAs for Patient 10 
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5.5 COMPARISON OF miRNA EXPRESSION IN 5 PATIENTS WITH PAIRED 
SAMPLES AT DIAGNOSIS AND RECURRENCE 
Paired samples from 5 patients were available for miRNA analysis as described in Table 
5.7. miRNA array analysis was carried out as described previously in Chapter 2, section 
2.16. Data analysis was carried out using Partek Genomics Suite (version 6.6; Partek 
Inc., USA). Raw data was normalised with log2 median before ANOVA test was used to 
identify differentially expressed miRNAs with ≥ 2-fold change in expression. The 
number of differentially expressed miRNAs from pairwise comparisons with ≥ 2-fold 
change in expression are listed in Table 5.7. Two of the tumours that maintained the 
same grade at recurrence (BTNW20 and BTNW126) had the highest number of 
differentially expressed miRNAs, whilst tumour BTNW614 (AOA) that progressed to 
GBM had the least number of differentially expressed miRNAs.  
 
Unsupervised hierarchical clustering of the 5 paired samples was performed using 1719 
miRNAs and is represented by a dendrogram with the miRNA expression profiles of all 
pairs in Figure 5.5. Only the primary/recurrent pair from Patient 10 clustered together 
with similar expression profiles. PCA showed that primary and recurrent tumours from 
Patient 10 had the most similar profiles while tumour samples from Patient 6 had the 
most different profiles (Figure 5.6). 
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Table 5.7 Summary of primary/recurrent pairs showing differentially expressed 
miRNAs with different histology types and malignant progression and differentially 
expressed miRNAs (≥ 2-fold change) between primary and recurrent tumours. 
 
Patient 
number 
Tumour samples Histology 
at 
diagnosis
a 
Histology at 
diagnosis
a 
IDH1 
status
b
 
IDH2 
status
c
 
Differentially 
expressed 
miRNAs 
(P vs R) 
(≥ 2-fold 
change)
d
 
1 BTNW20/BTNW1378 A A R132H WT 243 
2 BTNW365/BTNW974 A GBM R132H WT 78 
6 BTNW126/BTNW196 AA AA WT WT 209 
9 BTNW614/BTNW848 AOA GBM R132H NA 4 
10 BTNW15/BTNW107 AO AO WT R172K 42 
 
a
 A, astrocytoma; AA, anaplastic astrocytoma; AOA, anaplastic oligoastrocytoma; AO, 
anaplastic oligodendroglioma; GBM, glioblastoma multiforme; 
b
 R132H, IDH1 mutant; 
WT, wild type; 
c
 R172K, IDH2 mutant; WT, wild type; 
d
 P, primary tumour; R, 
recurrent tumour; NA, not available. 
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Figure 5.5 Unsupervised hierarchical clustering for primary/recurrent pairs 
 
Expression of 1719 miRNAs in 5 paired samples. Red colour represents high levels of miRNA expression and green colour represents 
low levels of miRNA expression in the tumour. Abbreviations: R – recurrent tumour, A – astrocytoma, AA – anaplastic astrocytoma, 
AOA – anaplastic oligoastrocytoma, AO – anaplastic oligodendroglioma, GBM – glioblastoma multiforme.  
 
  Patient 10                  Patient 10                      Patient 6                    Patient 1                    Patient 9                     Patient 2                      Patient 9                    Patient 6                    Patient 2                     Patient 1 
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Figure 5.6 PCA of primary/recurrent pairs 
 
The results are depicted 3-dimensionally with PC1 (73%), PC2 (18.2%) and PC3 
(2.47%) as the X, Y and Z axes, respectively. Primary and recurrent pairs for the same 
tumour are shown by the same colour. R – recurrent tumour 
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5.5.1 Patient 1 (Samples BTNW20 and BTNW1378) 
There were 243 miRNAs that were differentially expressed with ≥ 2-fold change in 
expression, of which 189 were upregulated and 54 were downregulated in the primary 
tumour as compared to the tumour at recurrence. The 10 most differentially expressed 
miRNAs are listed in Table 5.8 with their targets and pathways.  
 
5.5.2 Patient 2 (Samples BTNW365 and BTNW974) 
In tumour samples from Patient 2, there were 78 differentially expressed miRNAs with 
≥ 2-fold change in expression; 21 were upregulated and 57 were downregulated in the 
primary tumour as compared with its recurrence. The 10 most differentially expressed 
miRNAs were analysed for target prediction and pathway analysis as detailed in Table 
5.9.  
 
5.5.3 Patient 6 (Samples BTNW126 and BTNW196) 
In this patient, 209 differentially expressed miRNAs with ≥ 2-fold change in expression 
were identified between tumour samples with 91 upregulated miRNAs and 118 
downregulated miRNAs in the primary tumour compared with its recurrent tumour. The 
10 most differentially expressed miRNAs are listed in Table 5.10 with the targets and 
pathways.  
 
5.5.4 Patient 9 (Samples BTNW614 and BTNW848) 
For these tumour samples, four differentially expressed miRNAs (≥ 2-fold change) were 
identified, all of which were upregulated in the primary tumour compared with its 
recurrence. These are presented with the targets and pathways in Table 5.11.  
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5.5.5 Patient 10 (BTNW15 and BTNW107) 
A total of 42 differentially expressed miRNAs (≥ 2-fold change) were identified; 33 
were upregulated and 9 were downregulated in the primary tumour compared with its 
recurrence. The 10 most differentially expressed miRNAs are listed in Table 5.12 with 
the targets and pathways.  
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Table 5.8 The 10 most differentially expressed miRNAs identified in Patient 1 with the 
predicted targets and pathways. 
 
miRNA Fold 
change  
(P vs R)
a 
Target Pathway 
miR-4454 
448.889 
WDR72, ENAH, FAM125B, 
ENPP6, DLG5, GK, EIF4E3 
ErbB signalling pathway 
miR-4787-5p 
99.2121 
NFIX, TMEM2, SURF4, FGF18, 
PLK4, RBM41, DNAJB5, 
SPTSSA, FAM64A, HIPK2 
Propanoate metabolism, Glioma, 
Melanoma, Prostate cancer, PI3K-Akt 
signalling pathway 
miR-4284 
88.6408 
GNG13, VPS53, MAVS, ORAI2, 
SPN, TMEM120B, CYP20A1, 
CDK17, OPA3, RAB3B 
Morphine addiction, Retrograde 
endocannabinoid signalling, 
Serotonergic synapse, Circadian 
entrainment, Ether lipid metabolism 
miR-3665 
85.8987 
BOK, FUT6, NDFIP1, PTPRT, 
SUV39H1, SFMBT1, FAM155A, 
LEPROT, NCEH1, EVC 
Glycosphingolipid biosynthesis - lacto 
and neolacto series, Lysine 
degradation, Vasopressin-regulated 
water reabsorption, ABC transporters, 
Bile secretion 
miR-4723-5p 
78.4327 
MECP2, PLXNA4, PPP1R9B, 
SNX29, PACS1, NAT16, 
SLC28A1, CREB1, MUC3A, 
FOXE1 
Glycosaminoglycan biosynthesis - 
chondroitin sulphate, Tight junction, 
Circadian rhythm, Synaptic vesicle 
cycle, Cell adhesion molecules (CAMs) 
miR-4471 
-22.9926 
CDS2, POU2F1, GSTO2, IRS1, 
SLAMF8, DNAJB4, ANKIB1, 
EPB41L5, LIN52, B3GNT2 
Metabolism of xenobiotics by 
cytochrome P450, Biosynthesis of 
unsaturated fatty acids, Regulation of 
actin cytoskeleton, Neuroactive ligand-
receptor interaction, Melanogenesis 
miR-3142 
-65.4807 
WDFY3, EVC, SEH1L, CASK, 
SPOPL, PCYT1B, ITGB1BP1, 
OGFR, THAP4, GABRA1 
 
Renal cell carcinoma, Nicotinate and 
nicotinamide metabolism, mTOR 
signalling pathway 
miR-466 
-70.607 
PLCXD1, KLHL23, GPR137C, 
DCLK1, DCUN1D4, TNRC6B, 
VAMP4, RIMKLB, LEMD3, 
INO80D 
PI3K-Akt signalling pathway, TGF-beta 
signalling pathway, T cell receptor 
signalling pathway, Chronic myeloid 
leukemia, Non-small cell lung cancer 
miR-449c 
-83.865 
NUP50, STMN2, CDK19, ODZ1,  
CREB1, PAPOLA, MAPK1IP1L, 
ACTL6A, TMEM48, STK38L 
Hepatitis B, Phosphatidylinositol 
signalling system, ErbB signalling 
pathway, Salmonella infection, Inositol 
phosphate metabolism 
miR-4521 
-549.28 
FOXM1, PABPC5, GABARAPL2,  
BTLA, SLC4A8, FBXW2, 
SRGAP1, MAPK1, HIPK2, IPMK 
Fc epsilon RI signalling pathway, 
Neurotrophin signalling pathway, 
Acute myeloid leukemia, VEGF 
signalling pathway, MAPK signalling 
pathway 
 
a 
P, primary tumour; R, recurrent tumour. Common targets and pathways between 
miRNAs are highlighted in different coloured text. 
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Table 5.9 The 10 most differentially expressed miRNAs identified in Patient 2 with the 
predicted targets and pathways.   
 
miRNA Fold 
change  
(P vs R)
a 
Target Pathway 
miR-9 
5.70413 
POU2F1, ONECUT2, PRTG, LYVE1, 
SH3TC2, MDGA2, TNC, SLC35B3, 
PRDM6, STARD13 
Cell adhesion molecules (CAMs), Axon 
guidance, Cytokine-cytokine receptor 
interaction, Pathways in cancer, Tight 
junction 
miR-187* 
4.33032 
CD276, SRSF8, MAN1B1, AQP4, 
DYRK2, EML2, RPP25 
Neuroactive ligand-receptor interaction, 
Type I diabetes mellitus, Cell adhesion 
molecules (CAMs) 
miR-9* 
4.10055 
YOD1, ONECUT2, CD109, BNIP3L, 
KITLG, ITGB1, SPOPL, ACTL6A, 
GABRA1, BICD2 
Biotin metabolism, mRNA surveillance 
pathway, TGF-beta signalling pathway,  
Glycosaminoglycan biosynthesis - 
chondroitin sulphate, Circadian rhythm 
miR-125b 
4.09974 
ISL2, NMI, KCTD20 Calcium signalling pathway, Hypertrophic 
cardiomyopathy (HCM), Dilated 
cardiomyopathy, Arrhythmogenic right 
ventricular cardiomyopathy (ARVC), Cell 
adhesion molecules (CAMs) 
miR-4324 
2.8696 
FAM169B, LIN28A, PAPD5, 
ABCC5, CEP164, SYT2, IBA57, 
RPS6KL1, PPP1R12B, PCTP 
Glycosphingolipid biosynthesis - lacto 
and neolacto series, Regulation of 
autophagy, Notch signalling pathway, 
Pyrimidine metabolism, Lysine 
degradation 
miR-4756-5p 
-4.1132 
RPH3A, PRRT2, KSR2, SKI, 
WDTC1, SMARCD1, AIF1L, 
CDC42EP4, NFAM1, TMEM104 
ABC transporters, Notch signalling 
pathway, Cell adhesion molecules 
(CAMs), Leukocyte transendothelial 
migration, Pathways in cancer 
miR-451 
-4.15441 
PSMB8, TBC1D9B, MEX3C, 
CXCL16, MBP, CMTM6, CDKN2B, 
WDFY2, KCNK15, TSC1 
mTOR signalling pathway,  
Proteasome, Protein export,  
Glyoxylate and dicarboxylate 
metabolism, Propanoate metabolism 
 
miR-4516 
-5.14872 
SHOX, ENTPD7, AHCYL2, NTRK2, 
SLC7A6, UHRF1BP1, FAM105B, 
OTX1, TMCC2, MSN 
Glycosaminoglycan biosynthesis - 
chondroitin sulphate, Long-term 
potentiation, Wnt signalling pathway, 
Prostate cancer, Glycosaminoglycan 
biosynthesis - heparan sulfate / heparin 
miR-4732-5p 
-5.41818 
DBT, TMEM237, NHLH1,  
BCLAF1, WASL, RBPJ, PARM1,  
SFMBT1, ALKBH5, OXGR1 
Fatty acid metabolism, Basal 
transcription factors, PPAR signalling 
pathway, Notch signalling pathway, 
Proteasome 
miR-1246 
-5.79696 
GSG1L, MSR1, BRWD1, RTKN2, 
SMG7, SLC16A7, MUT, GLRB, 
BEND4, TMEM123 
Neurotrophin signalling pathway,  
N-Glycan biosynthesis, Inositol 
phosphate metabolism, Protein 
processing in endoplasmic reticulum, 
ErbB signalling pathway 
 
a 
P, primary tumour; R, recurrent tumour. Common targets and pathways between miRNAs are 
highlighted in different coloured text. 
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Table 5.10 The 10 most differentially expressed miRNAs identified in Patient 6 with 
the predicted targets and pathways.   
 
miRNA Fold 
change  
(P vs R)
a 
Target Pathway 
miR-4521 
551.415 
FOXM1, PABPC5, 
GABARAPL2, BTLA, SLC4A8, 
FBXW2, SRGAP1, MAPK1, 
HIPK2, IPMK 
Fc epsilon RI signalling pathway, 
Neurotrophin signalling pathway, 
Acute myeloid leukemia, VEGF 
signalling pathway, MAPK signalling 
pathway 
miR-466 
28.3463 
PLCXD1, KLHL23, GPR137C, 
DCLK1, DCUN1D4, TNRC6B, 
VAMP4, RIMKLB, LEMD3, 
INO80D 
PI3K-Akt signalling pathway, TGF-
beta signalling pathway, T cell 
receptor signalling pathway, Chronic 
myeloid leukemia, Non-small cell 
lung cancer 
miR-3142 
23.1375 
WDFY3, EVC, SEH1L, CASK, 
SPOPL, PCYT1B, ITGB1BP1, 
OGFR, THAP4, GABRA1 
Renal cell carcinoma, Nicotinate and 
nicotinamide metabolism, mTOR 
signalling pathway 
miR-4526 
19.1503 
MIER1, FNBP1L, RIN2, 
FAM104B, CSF2RB, ATF3, 
RORA, RAP1A, MGAT4A, 
ATXN7 
Neurotrophin signalling pathway, 
Caffeine metabolism, Propanoate 
metabolism, Glioma, ErbB signalling 
pathway 
miR-4661-5p 
16.92 
FRS2, LCORL, DNALI1, 
HDGFRP3, DEPDC1B, JAG1, 
NFIB, WEE1, CCNB1, 
PRKAA1 
Synaptic vesicle cycle, Cell cycle, 
SNARE interactions in vesicular 
transport, Spliceosome, mRNA 
surveillance pathway 
miR-1260b 
-39.2843 
EIF2C1, CTAGE1, ABL2, 
NUB1, CDC25A, UGGT1, 
GPKOW, TARDBP, UNC13C, 
GPR316226 
Glycosaminoglycan biosynthesis - 
heparan sulfate / heparin, 
Complement and coagulation 
cascades, Citrate cycle, Rheumatoid 
arthritis 
miR-1280 
-56.2369 
JAG2, SEC14L2, UBTF, 
RALGAPB, PDE8A, NPY2R, 
PXMP4, NRXN2 
Pathways in cancer 
miR-4286 
-56.5281 
CLN8, PTBP2, KREMEN1, 
PLXNA2, FBXW2, PPP4R1,  
PTPRF, CCDC129, FOXO4, 
SREK1 
Glycosphingolipid biosynthesis - 
ganglio series, Mucin type O-Glycan 
biosynthesis, Amoebiasis, N-Glycan 
biosynthesis, Vasopressin-regulated 
water reabsorption 
miR-3960 
-63.1386 
EN1, CERS1, FAM127A, 
WWP2, RFX1 
Calcium signalling pathway, 
Neuroactive ligand-receptor 
interaction 
miR-4454 
-413.514 
ENAH, WDR72, FAM125B, 
DLG5, ENPP6, EIF4E3, GK 
ErbB signalling pathway 
 
a 
P, primary tumour; R, recurrent tumour. Common targets and pathways between 
miRNAs are highlighted in different coloured text. 
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Table 5.11 Differentially expressed miRNAs identified in Patient 9 with the predicted 
targets and pathways. 
 
miRNA Fold 
change  
(P vs R)
a 
Target Pathway 
miR-4529-5p 
3.37359 
CBLL1, SS18L1, CSDE1, PKP3,  
MEX3C, PIP4K2C, LRP1, 
KIRREL2, GRIN2B, DNAJC14 
Leukocyte transendothelial 
migration, Bacterial invasion of 
epithelial cells, Salmonella infection, 
N-Glycan biosynthesis, Wnt signalling 
pathway 
miR-663b 
2.92884 
SLC4A8, STAT5B, ATCAY, 
NCAM2, IL17D, GNAQ, NICN1,  
BSPRY, SCAI, STK40 
Other glycan degradation, 
Sphingolipid metabolism, 
Endocytosis, ECM-receptor 
interaction, Systemic lupus 
erythematosus 
miR-4803 
2.45766 
 
LPPR5, MKX, XIAP, ARMC8, 
ZEB1, CEP170, TAF2, SACS, 
LPHN3, NRCAM 
TGF-beta signalling pathway, MAPK 
signalling pathway, Nicotinate and 
nicotinamide metabolism, Wnt 
signalling pathway, PI3K-Akt 
signalling pathway 
miR-4757-3p 
2.22097 
SAR1B, IKBIP, RAB7L1, 
PCDHA12, PCDHA6, PCDHA2,  
PCDHA11, PCDHA7, PCDHA5,  
PCDHA10 
Cell adhesion molecules (CAMs),  
Apoptosis, Ubiquitin mediated 
proteolysis 
 
a 
P, primary tumour; R, recurrent tumour. Common pathways between miRNAs are 
highlighted in different coloured text. 
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Table 5.12 The 10 most differentially expressed miRNAs identified in Patient 10 with 
the predicted targets and pathways.   
 
miRNA Fold 
change  
(P vs R)
a 
Target Pathway 
miR-451 
6.08149 
PSMB8, TBC1D9B, MEX3C, 
CXCL16, MBP, CMTM6, 
CDKN2B, WDFY2, KCNK15, TSC1 
mTOR signalling pathway, 
Proteasome, Protein export, 
Glyoxylate and dicarboxylate 
metabolism, Propanoate metabolism 
miR-1246 
4.70218 
GSG1L, MSR1, BRWD1, RTKN2, 
SMG7, SLC16A7, MUT, GLRB, 
BEND4, TMEM123 
Neurotrophin signalling pathway,  
N-Glycan biosynthesis, Inositol 
phosphate metabolism, Protein 
processing in endoplasmic reticulum, 
ErbB signalling pathway 
miR-4732-5p 
4.25007 
DBT, TMEM237, NHLH1, 
BCLAF1, WASL, RBPJ, PARM1, 
SFMBT1, ALKBH5, OXGR1 
Fatty acid metabolism, Basal 
transcription factors, PPAR signalling 
pathway, Notch signalling pathway, 
Proteasome 
miR-4530 
3.9028 
VPS53, FUT3, SMARCD2, JRK, 
DDX6, NDOR1, FOXK1, MRPS25,  
DAGLA, MAVS 
N-Glycan biosynthesis, 
Glycosphingolipid biosynthesis - lacto 
and neolacto series, Fatty acid 
biosynthesis, Amino sugar and 
nucleotide sugar metabolism, 
Glycosaminoglycan degradation 
miR-124 
3.33354 
TXNRD1, SNX2, RSU1, FLRT3,  
DSCR6, COPS2, TMEM56, 
STRBP, UHRF1, ATPBD4 
Hypertrophic cardiomyopathy 
(HCM), Neurotrophin signalling 
pathway, Dilated cardiomyopathy, 
Arrhythmogenic right ventricular 
cardiomyopathy (ARVC), Axon 
guidance 
miR-338-3p 
-2.46375 
VPS53, DGKB, PREX2, SLC2A10,  
B4GALT7, NRP1, HMOX2, VAPB,  
TATDN3, CACNG8 
Glycolysis / Gluconeogenesis,  
Hypertrophic cardiomyopathy 
(HCM), ErbB signalling pathway,  
Dilated cardiomyopathy, 
Cardiac muscle contraction 
let-7c 
-2.71537 
LIN28B, IGF2BP1, HMGA2, 
FIGURENL2, LRIG3, DDI2, 
GATM, MAP4K3, PRTG, USP38 
Axon guidance, MAPK signalling 
pathway, Hypertrophic 
cardiomyopathy (HCM), T cell 
receptor signalling pathway, Dilated 
cardiomyopathy 
miR-21 
-2.96269 
YOD1, KRIT1, WTH3DI, GPR64, 
PLEKHA1, SKP2, FBXO11, 
MALT1, PELI1, PBRM1 
Cytokine-cytokine receptor 
interaction, TGF-beta signalling 
pathway, MAPK signalling pathway, 
Melanoma 
miR-29b 
-3.04418 
USP28, NEUROD1, ZDHHC5, 
LIN9, TNPO3, CLEC2B, WDR26, 
SNX30, SLC30A7, PROS1 
ECM-receptor interaction, Small cell 
lung cancer, Focal adhesion, Axon 
guidance, Pathways in cancer 
miR-29a 
-3.12436 
TET3, COL3A1, SESTD1, NFIA, 
PI15, HBP1, ATAD2B, PXDN, 
TET2, IGF1 
ECM-receptor interaction,  
Protein digestion and absorption, 
Amoebiasis, Focal adhesion,  
PI3K-Akt signalling pathway 
 
a 
P, primary tumour; R, recurrent tumour. Common targets and pathways between 
miRNAs are highlighted in different coloured text. 
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Both Patients 1 and 6, who maintained the same grading at recurrence, had the largest 
fold changes in miRNA expression of > 500-fold change in the primary tumour 
compared to its recurrence. Paired samples from Patients 1 and 6 had four common 
differentially expressed miRNAs; miR-3142, miR-4454, mir-4521 and miR-466. All but 
miR-4454 were downregulated in the primary tumour in Patient 1, while all but miR-
4454 were upregulated in the primary tumour in Patient 6. The difference in expression 
of miR-4454, with downregulation in 1 tumour and upregulation in the other may be 
due to primary tumours being of different tumour grades.  
 
Differences in miRNA expression between tumour sample pairs from Patients 1, 6 and 
10, with the same histological grading at recurrence were compared to identify common 
miRNAs, but none were found. The reason for this could be that two of the primary 
tumours were astrocytic and one was oligodendroglial in origin.  
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5.6 DISCUSSION 
In the current study, IDH1 and IDH2 mutation status and MGMT methylation status was 
determined in paired samples at diagnosis and recurrence. Genomic profiles and 
miRNA expression analysis was also investigated in three and five patients respectively 
with paired samples at diagnosis and recurrence.   
 
5.6.1 IDH mutation and MGMT methylation 
IDH1 and IDH2 mutation status of all tumours at diagnosis was maintained in their 
recurrent tumours. Of the four patients for MGMT methylation, the methylation status 
was maintained in tumour samples from two patients but showed variation in two cases. 
A recent study of 23 LGG primary tumours and their recurrences also reported that 
IDH1 status was matched between the primary and the paired recurrent tumour 
(Johnson et al., 2014). Another study with 53 primary and recurrent paired tumours 
including 29 LGG, 16 anaplastic tumours and 8 GBM reported that IDH1 and IDH2 
status in the recurrent tumours was consistent with their respective primary tumours 
(Yao et al., 2013). In a study of 21 primary and progressive paired O tumours, the 
authors showed that the IDH1 status remained unchanged in all the tumours after 
progression, while the frequency of MGMT promoter methylation increased from 38.1% 
in primary tumours to 52.4% in the recurrent tumours (Kuo et al., 2013).  
 
5.6.2 Copy number analysis 
CNAs were identified in a cohort of three patients with paired tumour samples at 
diagnosis and recurrence. For all the patients, the paired samples were genomically 
different and the recurrent tumours had more CNAs than the corresponding primary 
tumours. Interestingly, for Patient 1, paired tumour samples which are grade II at 
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diagnosis and recurrence had a larger difference in the number of aberrations with 124 
in the primary tumour and 206 aberrations in the recurrent tumour. For Patients 9 and 
10, the difference in the number of aberrations between the tumour samples at diagnosis 
and at recurrence was relatively small with additional 34 and 20 aberrations respectively 
in the recurrent tumours. These findings suggest that paired tumour samples have clonal 
cell populations, some of which remain stable and unaffected by time or any treatment 
such as radiotherapy and chemotherapy. Recurrent tumours consist of tumour cells that 
proliferate with additional genomic changes to those present in the tumour at diagnosis. 
These new changes may have been developed during progression or present in a 
subclonal population of the primary tumour and selected for during therapy. The 
additional regions of genomic aberrations may contain genes linked to resistance against 
treatment, thereby, promoting tumour recurrence.  
In a study by Kuo et al. (2013), genetic profiles of 21 pairs of primary and progressive 
O tumours were investigated using aCGH. In the primary tumour, losses were identified 
on 1p36, 19q13 and 9p22 in 57.1% (12/21), 81% (17/21) and 52.3% (11/21) 
respectively of all the cases. In the recurrent tumour, additional losses on 1p, 9p, 10q, 
17p, 19q and 22q were identified in 14.3% (3/21), 4.8% (1/21), 14.3% (3/21), 9.5% 
(2/21), 4.8% (1/21) and 14.3% (3/21) respectively of all the cases. In the present study, 
losses on 1p36 and 19q13 were observed in 33% (1/3) and 67% (2/3) respectively in the 
primary tumours, while in the recurrent tumours, additional losses on 1p, 9p, 10q and 
19q were present in 67% (2/3), 33% (1/3), 33% (1/3) and 67% (2/3) respectively of all 
the cases. 
In a recent study of 27 paired primary and recurrent GBM tumours, the genomic 
profiles of the paired samples were compared by aCGH (Riehmer et al., 2014). About 
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33% (9/27) of recurrent pairs had all chromosomal aberrations of the primary tumour 
plus some additional changes. In 41% (11/27) of the pairs, the genomic profiles of the 
paired primary and recurrent tumours were disparate with recurrent tumours having 
additional aberrations but had lost aberrations present in the primary tumour. The 
authors showed that 75% of recurrent GBM tumours develop additional genomic 
changes compared to their primary tumours and that this may be promoted by loss on 
9p21.3 in primary tumours.  
  
5.6.3 miRNA expression analysis 
miRNA expression analysis was completed with paired tumour samples at diagnosis 
and recurrence from five patients. Patient 1 and Patient 6, with primary tumours of 
astrocytic origin had the most number of differentially expressed miRNAs between the 
paired samples with 243 and 209 miRNAs respectively.  
miR-4521, a common differentially expressed miRNA identified in Patients 1 and 6 has 
been reported previously in a breast cancer study. Camps et al., (2014) investigated the 
regulation of miRNA expression by hypoxia in breast cancer cell line, MCF-7. Under 
hypoxic conditions, HIF family of transcription factors induce a transcriptional response 
affecting several biological processes such as glycolysis, angiogenesis and apoptosis. 
The expression of miR-4521 was downregulated after 16h, 32h and 48h of hypoxia in 
MCF-7 cells. The downregulation of miR-4521 observed by next generation sequencing 
was validated by qPCR and was in accordance.  
No common differentially expressed miRNAs were found between the comparative 
analyses of the 5 patients. A possible explanation for this could be that the sample 
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cohort is small and comprised a mix of histologies and grades. As mentioned previously 
in Chapter 1, A, OA and O exhibit different genetic changes and therefore, the miRNA 
expression profiles may also be varied in the three histological groups in both grade II 
and grade III tumours. The results from this study demonstrate that miRNA expression 
profiles showed variation in histological groups in both the grades.  
Ilhan-Mutlu et al., (2013) compared the miRNA expression levels between primary and 
recurrent GBM tumours. Seven miRNAs selected that had relevance with GBM from 
previous studies were miR-10b, miR-21, miR-181b, miR-181c, miR-195, miR-221 and 
miR-222. The miRNA expression levels were determined by qPCR and for all the 
miRNAs, no significant difference was observed between the paired primary and 
recurrent tumours. In contrast, the present study showed variation in miRNA expression 
levels in the paired tumour samples from the same patients. This could be a sequential 
effect altering the miRNA expression levels during progression or acquiring new 
aberrations that may induce changes in the expression profiles at recurrence.  
 
In summary, the present study is one of only a few that have compared primary and 
recurrent tumours from the same patient and the findings of this study are important due 
to the lack of studies analysing primary/recurrent paired samples. Comparison of 
tumours at diagnosis and recurrence revealed that additional changes arise in the 
genomic and miRNA expression profiles of the recurrent tumours that may contribute to 
the malignant progression of the tumours.  
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CHAPTER 6 
CHARACTERISATION OF LGG SHORT-TERM CELL 
CULTURES 
 
6.1 INTRODUCTION 
There are numerous established cell lines representing GBM available for research, but 
no cell lines representing LGG are listed in the American Type Culture Collection 
(ATCC) and ECACC databases. Short-term culture remains the only in vitro model at 
present.  
The aim of the chapter was to assess the reliability of using LGG cell cultures grown as 
monolayers as representative in vitro models for LGG. Previous investigations had 
demonstrated that IDH mutations are not maintained in cell culture (Piaskowski et al., 
2011). A number of paired frozen biopsy samples and their derivative short-term cell 
cultures were available for analysis in the present study. All samples were analysed for 
IDH1 and IDH2 mutation status and MGMT promoter methylation status was 
determined in 12 sample sets. Genomic copy number analysis and miRNA expression 
profiling were completed for subsets of eight and five paired samples respectively, 
depending on tissue availability. The expression of a panel of cellular markers was 
determined by IHC and comparative proliferation rates and tumourigenic potential was 
assessed in a small number of cases.  
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6.2 TUMOUR SAMPLES 
The sample cohort of 17 lower grade diffuse glioma comprised 15 grade II tumours (9 
A, 1 OA, 5 O) and 2 grade III tumours (2 AO). Patients with grade II tumours had an 
age range of 35-56 years with a median of 45.5 years and those with grade III tumours 
had an age range of 47-66 years with a median of 56.5 years.  
 
6.3 IDH MUTATION AND MGMT PROMOTER METHYLATION ANALYSIS 
The mutation status of IDH1 and IDH2 was determined in 17 biopsy tissues and their 
paired cell cultures by direct sequencing and the results are summarised in Table 6.1. 
IDH1 mutation was detected in seven biopsy tissues comprising 2/9 A (22%), 1/1 OA 
(100%), 3/5 O (60%) and 1/2 AO (50%) and in all cases, the mutations were 
heterozygous R132H (CGT to CAT). However, none of these mutations were 
maintained in the derivative cell cultures. No IDH2 mutations were detected.    
MGMT methylation status was determined by MS-PCR for 12 paired samples (Table 
6.1). Methylation was observed in one biopsy tissue (IN2184) and partial methylation 
was observed in four biopsy tissues (IN99/81, IN2990, IN3020 and UWLV3), all but 
one of which also carried the IDH1 R132H mutation. However, no MGMT promoter 
methylation was detected in any of the cell cultures. All four of the tumours with partial 
methylation were O and the methylated tumour was an AO.  
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Table 6.1 Tumour samples for IDH mutation and MGMT promoter methylation 
analysis 
Tumour Age
a 
Sex
b
 Source
c
 Grade Histology
d 
IDH1 
Mutation 
status
e
 
IDH2 
Mutation 
status
 
MGMT 
methylation 
status
f
 
IN4 56 F B II A WT WT U 
   CC   WT WT U 
IN118/81 47 M B II A R132H WT ND 
   CC   WT WT ND 
IN143 N/A F B II A R132H WT U 
   CC   WT WT U 
IN1705 47 F B II A WT WT U 
   CC   WT WT U 
IN1853 47 M B II A WT WT U 
   CC   WT WT U 
IN2190 45 M B II A WT WT U 
   CC   WT WT U 
IN2800 32 M B II A WT WT U 
   CC   WT WT U 
IN2985 41 F B II A WT WT ND 
   CC   WT WT ND 
IN3139 74 F B II A WT WT ND 
   CC   WT WT ND 
UWLV7 38 M B II OA R132H WT ND 
   CC   WT WT ND 
IN99/81 N/A F B II O R132H WT PM 
   CC   WT WT U 
IN2723 55 F B II O WT WT ND 
   CC   WT WT ND 
IN2990 31 F B II O R132H WT PM 
   CC   WT WT U 
IN3020 35 F B II O WT WT PM 
   CC   WT WT U 
UWLV3 43 M B II O R132H WT PM 
   CC   WT WT U 
IN2184 47 F B III AO R132H WT M 
   CC   WT WT U 
IN3045 66 M B III AO WT WT U 
   CC   WT WT U 
 
a
 Age at diagnosis in years; 
b
 M, male; F, female; 
c
 B, biopsy tissue; CC, cell culture; 
d
 
A, astrocytoma; OA, oligoastrocytoma; O, oligodendroglioma; AO, anaplastic 
oligodendroglioma; 
e
 R132H, IDH1 mutant; WT, wild type; 
f
 M, methylated; PM, 
partially methylated; U, unmethylated; ND, not done.  
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6.4 COMPARISON OF COPY NUMBER CHANGES IN PAIRED BIOPSY AND 
CELL CULTURE SAMPLES  
In order to determine whether any other genetic abnormalities are maintained in cell 
culture, aCGH was performed on a 244K array using high quality DNA from eight 
paired samples of biopsy tissues and short-term cell cultures, IN118/81 (A), IN1853 
(A), IN2190 (A), IN2800 (A), UWLV7 (OA), IN2723 (O), UWLV3 (O) and IN2184 
(AO) as detailed in Table 6.2. The IDH1-R132H mutation was detected in four biopsy 
tissues, IN188/81, UWLV3, UWLV7 and IN2184, while no mutation of IDH2 was 
present in any of the samples assessed by direct sequencing analysis. Following 
genomic segmentation to obtain the CNAs, gains/losses on the chromosomes were 
identified. CNAs were detected in all eight pairs and common aberrations were 
identified for each pair. 
 
Table 6.2 Tumour samples with paired biopsy tissue and derivative short-term cell 
cultures used for aCGH analysis 
 
Tumour sample 
(paired biopsy 
and culture) 
Agea Sexb Grade Histologyc IDH1 
Mutation 
statusd 
IDH2 
Mutation 
status 
IN118/81 47 M II A R132H WT 
IN1853 47 M II A WT WT 
IN2190 45 M II A WT WT 
IN2800 32 M II A WT WT 
UWLV7 38 M II OA R132H WT 
IN2723 55 F II O WT WT 
UWLV3 43 M II O R132H WT 
IN2184 47 F III AO R132H WT 
 
a
 Age at diagnosis in years; 
b
 M, male; F, female; 
c
 A, astrocytoma; OA, 
oligoastrocytoma; O, oligodendroglioma; AO, anaplastic oligodendroglioma; 
d
 R132H, 
IDH1 mutant; WT, wild type. 
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6.4.1 Tumour sample IN118/81 
In IN118/81 tumour biopsy, there were 78 CNAs, of which 45 were gains and 33 were 
losses. In IN18/81 cell culture, there were 45 CNAs with 24 regions of gain and 21 of 
loss. Only 9% (7/78) of CNAs present in the biopsy tissue were maintained in the cell 
culture. The genomic summaries for the biopsy and cell culture are shown in Figure 6.1 
and the common CNAs are summarised in Table 6.3.  
 
6.4.2 Tumour samples IN1853 
In IN1853 biopsy tissue, there were 113 CNAs, of which 78 were regions of gain and 
35 were regions of loss. In the IN1853 culture, 103 CNAs were identified with 96 gains 
and 7 losses. Fifty three percent (61/113) of CNAs were maintained in the cell culture. 
The genomic summaries for the biopsy and cell culture are shown in Figure 6.2 and the 
common aberrations are detailed in Table 6.4. 
 
6.4.3 Tumour sample IN2190 
In IN2190 biopsy tissue, there were 52 CNAs, of which 40 were regions of gain and 12 
were regions of loss. In 2190CC, 84 CNAs were identified with 20 regions of gain and 
64 regions of loss. Eleven percent (6/52) of CNAs of the biopsy tissue were maintained 
in the cell culture. The genomic summaries for the biopsy and cell culture are presented 
in Figure 6.3 and the common CNAs are listed in Table 6.5. 
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6.4.4 Tumour sample IN2800 
In IN2800 biopsy tissue, 57 CNAs were identified, of which 44 were regions with gain 
and 13 were regions with loss. In the cell culture, there were 48 CNAs with 33 regions 
of gain and 15 regions of loss. Eighteen percent (10/57) of the CNAs present in 
IN2800B were maintained in the cell culture. The genomic summaries for the biopsy 
and cell culture are shown in Figure 6.4 and the common CNAs are summarised in 
Table 6.6. 
 
6.4.5 Tumour sample UWLV7 
In UWLV7 biopsy tissue, there were 71 CNAs with 58 regions of gain and 13 regions 
of loss. In the cell culture, there were 26 CNAs, of which 20 were regions with gain and 
6 were regions with loss. Only 1% (1/71) of CNA present in the biopsy tissue was 
maintained in the cell culture. The genomic summaries for the biopsy and cell culture 
are shown in Figure 6.5. The common CNA was loss on chromosome 14 at 14q11.1 - 
14q11.2 with an average copy number of -0.519397 and the overlapping gene was 
OR4K1. 
 
6.4.6 Tumour sample IN2723 
In IN2723 biopsy tissue, 45 CNAs were identified, of which 32 were regions of gain 
and 13 were regions of loss. In the cell culture, there were 93 CNAs with 61 regions of 
gain and 32 regions of loss. Only 15% (7/45) of CNAs found in IN2723B were 
maintained in the cell culture. The genomic summaries for the biopsy and cell culture 
are illustrated in Figure 6.6 and the common CNAs are detailed in Table 6.7. 
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6.4.7 Tumour sample UWLV3 
There were 61 CNAs identified in UWLV3 biopsy tissue, of which 53 were regions of 
gain and 8 were regions of loss. In the cell culture, there were 33 CNAs with 18 regions 
of gain and 15 regions of loss. Only 2% (1/61) of CNAs identified in UWLV3B were 
maintained in the cell culture. The genomic summaries for the biopsy and cell culture 
are presented in Figure 6.7. The common CNA was gain on chromosome 15 at 15q26.1 
with an average copy number of 0.357862 and no gene was present in the region. 
 
6.4.8 Tumour sample IN2184 
In IN2184 biopsy tissue, there were 246 CNAs with 112 regions of gain and 134 
regions of loss. In the cell culture, there were 209 CNAs, of which 148 were regions of 
gain and 61 were regions of loss. Less than 1 percent (2/246) of the CNA present in the 
biopsy tissue was maintained in the cell culture. 1p/19q loss was detected in IN2184B. 
The genomic summaries for the biopsy and cell culture are shown in Figure 6.8 and the 
common CNAs are detailed in Table 6.8. 
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Figure 6.1 Genome summary of CNAs for tumour IN118/81 biopsy and cell culture 
IN118/81B       
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IN118/81CC 
 
 
 
 
 
 
 
 
 
Table 6.3 CNAs maintained in IN118/81 cell culture 
 
Chromosome Cytoband CNA
 
Overlapping genes 
4 4q28.1 Gain ANKRD50 
5 5q33.3 Gain SOX30 
7 
7q34 Gain 
LOC100124692, MOXD2P, PRSS58, LOC730441, 
MTRNR2L6, PRSS1, TRY6 
12 12q24.31 Gain CAMKK2, ANAPC5 
14 14q11.1 - 
14q11.2 Loss 
POTEM, OR11H2, OR4Q3, OR4M1, OR4N2, OR4K2, 
OR4K5, OR4K1 
17 17q25.3 Gain LOC100507351 
18 18q11.2 Gain TTC39C 
 
 
 
 
 
 
 
  
 
  Gain Loss 
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Figure 6.2 Genome summary of CNAs for tumour IN1853 biopsy and cell culture 
IN1853B 
 
 
 
 
 
 
IN1853CC 
           
           
           
           
           
            
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Gain Loss 
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Table 6.4 CNAs maintained in IN1853 cell culture 
 
Chromosome Cytoband CNA Overlapping genes 
chr1 1p32.1 Gain FGGY 
chr1 1p22.1 Gain TGFBR3 
chr2 2q37.3 Deletion C2orf85 
chr2 2p16.1 Deletion CCDC88A 
chr2 2q31.1 Deletion ITGA6 
chr2 2p25.3 Deletion LOC100505964 
chr2 2q24.2 Gain SLC4A10, DPP4, GCG, FAP, IFIH1, GCA, 
KCNH7 
chr2 2p23.3 Deletion KLHL29 
chr3 3p26.3 Gain CNTN6 
chr3 3q29 Gain PIGX 
chr3 3q13.2 Deletion WDR52 
chr3 3p12.1 Deletion ROBO2, ROBO1, GBE1, LOC440970 
chr4 4q21.22 Gain TMEM150C, C4orf11 
chr4 4q24 Deletion TBCK 
chr5 5q11.2 Gain CDC20B 
chr5 5q12.1 Gain FLJ37543 
chr5 5q31.1 Gain FSTL4 
chr5 5q35.1 Deletion KCNMB1 
chr5 5q31.3 Gain PCDHA7 
chr6 6p22.2 Gain NRSN1 
chr6 6p12.1 Gain TINAG 
chr6 6p12.2 - 6p12.1 Gain TMEM14A 
chr7 7q21.13 Deletion CDK14 
chr7 7q22.1 Deletion GJC3 
chr7 7q22.1 Gain MOGAT3 
chr7 7q21.3 Deletion SLC25A13 
chr7 7q11.22 Deletion STAG3L4 
chr8 8q24.12 Deletion MAL2 
chr8 8p12 Gain RAB11FIP1 
chr8 8q21.2 Gain RALYL 
chr8 8q21.13 Deletion ZNF704 
chr9 9q22.33 Gain HEMGN 
chr9 9q33.2 Gain STRBP 
chr10 10q23.33 Deletion HELLS 
chr10 10q21.1 Gain PCDH15 
chr10 10q23.33 Gain TMEM20 
chr11 11q22.1 Gain CNTN5 
chr11 11p15.5 Deletion LOC338651 
chr11 11p15.4 Deletion OR52E4 
chr12 12p13.31 Gain CLEC2B 
chr13 13q34 Gain COL4A1 
chr14 14q32.33 Gain ASPG 
chr14 14q24.2 Deletion PCNX 
chr14 14q32.12 Gain SMEK1 
chr15 15q11.2 Deletion NF1P1 
chr15 15q26.1 Deletion ST8SIA2 
chr16 16p13.3 Gain CREBBP 
chr16 16p13.13 Deletion EMP2 
chr16 16p13.3 Deletion NAT15 
chr16 16q12.1 Deletion SIAH1 
chr17 17p13.3 Gain ABR 
chr17 17q12 Deletion ERBB2 
chr17 17p11.2 Gain PRPSAP2 
chr18 18q22.2 Gain SOCS6 
chr19 19q13.2 Gain PSMC4 
chr20 20q11.1 - 20q11.21 Deletion FRG1B 
chr20 20p11.23 Gain LOC100130264 
chr20 20q11.22 Deletion NCOA6 
chr21 21q22.12 Deletion SETD4 
chr22 22q13.1 Gain GRAP2 
chrX Xp11.21 Deletion RRAGB 
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Figure 6.3 Genome summary of CNAs for tumour IN2190 biopsy and cell culture 
IN2190B          
            
 
           
           
           
           
           
      
 
 
 
IN2190CC 
 
 
 
 
 
 
 
 
           
      
Table 6.5 CNAs maintained in IN2190 cell culture 
 
Chromosome Cytoband CNA
 
Overlapping genes 
2 2q37.3 Loss C2orf85 
3 
3p12.3 Loss 
FAM86DP, FLJ20518, FRG2C, 
MIR1324 
8 8p23.1 Loss FLJ10661  
14 14q11.1 - 14q11.2 Loss OR11H2  
21 21p11.2 - 21p11.1 Loss BAGE  
X Xp22.33 - Xp11.23 Gain ARAF  
 
 
 
 
 
 
 
  Gain Loss 
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Figure 6.4 Genome summary of CNAs for tumour IN2800 biopsy and cell culture 
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Table 6.6 CNAs maintained in IN2800 cell culture 
 
Chromosome Cytoband CNA
 
Overlapping genes 
1 1p32.1 Gain JUN 
2 2p16.2 Gain SPTBN1 
2 2p13.3 Gain ANKRD53 
3 3p21.1 Gain CACNA2D3 
11 11q13.1 Loss PACS1, KLC2, RAB1B, CNIH2, YIF1A 
15 15q26.1 Gain MIR9-3, LOC254559 
16 16p13.3 Gain HS3ST6, SEPX1, RPL3L 
17 17p13.2 Gain WSCD1 
19 19q13.2 Gain PSMC4, ZNF546, ZNF780B 
19 19q13.32 Gain APOE, APOC1, APOC1P1, APOC4, 
APOC2, CLPTM1 
 
 
 
 
  Gain Loss 
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Figure 6.5 Genome summary of CNAs for tumour UWLV7 biopsy and cell culture 
 
 
UWLV7B 
 
 
 
 
 
 
 
UWLV7CC 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Gain Loss 
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Figure 6.6 Genome summary of CNAs for tumour IN2723 biopsy and cell culture 
 
IN2723B 
 
 
 
 
 
 
 
 
IN2723CC 
 
 
 
 
 
 
 
 
 
Table 6.7 CNAs maintained in IN2723 cell culture 
 
Chromosome Cytoband CNA
 
Overlapping genes 
1 1q12 - 1q21.1 Loss NBPF10  
3 3p12.3 Loss FAM86DP, FLJ20518, FRG2C, MIR1324, 
MIR4273, ZNF717, MIR4273 
4 4q35.2 Loss TUBB4Q 
10 10q23.2 Loss FAM22D 
14 14q32.33 Loss TMEM121  
20 20p13 - 20p12.1 Gain C20orf7 
21 21p11.2 - 21p11.1 Loss BAGE  
 
 
 
  Gain Loss 
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Figure 6.7 Genome summary of CNAs for tumour UWLV3 biopsy and cell culture 
 
UWLV3B 
  
 
 
 
 
 
 
UWLV3CC 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  Gain Loss 
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Figure 6.8 Genome summary of CNAs for tumour IN2184 biopsy and cell culture 
 
IN2184B 
 
  
 
 
 
 
 
 
IN2184CC 
 
 
 
 
 
 
 
 
Table 6.8 CNAs maintained in IN2184 cell culture 
 
Chromosome Cytoband CNA
 
Overlapping genes 
1 
1q21.3 - 1q22 Gain ZBTB7B, DCST2, DCST1, ADAM15 
12 12q24.33 Loss CDK4, CEP290, CLLU1 
 
 
 
 
 
 
 
 
  Gain Loss 
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The results from the comparison of biopsy and derived cell cultures in individual 
tumours are summarised in Table 6.9. In grade II tumours, the number of CNAs present 
in the biopsy tissue ranged from 45-113 and, with the exception of gain 7q in IN118/81 
and IN2190 and loss 3p in UWLV7, gains and losses were restricted to small interstitial 
regions. In contrast, 246 CNAs were present in the AO tumour IN2184, including whole 
arm aneuploidies. In addition to deletion (1p,19q), loss of 9p and gain of 9q and 11q 
were identified. There were also many large interstitial regions of both loss (6q, 13, 14 
and 15) and gain (6p, 12q and 17q). Within the grade II group of biopsies, there was no 
difference in the frequency or spectrum of CNAs between tumours with mutant R132H, 
IDH1 and wild type IDH1 or between histological subtypes. 
It is apparent that the majority of CNAs present in tumour biopsy are not maintained in 
the derivative short-term cell cultures, particularly large regions of loss and gain such as 
gain of 7q in biopsy samples IN118/18 and IN2190. Conversely, additional gains and 
losses were observed in the cell cultures compared to their paired biopsies. The cell 
culture derived from UWLV3 had trisomy 7 and 8, neither of which was present in the 
tumour tissue. Similarly, cell culture IN2723 had additional gain of the short arm of 20 
and a large gain on 7q. All of the CNAs that were maintained in the derivative cell 
cultures involved small regions, which were often centromeric, telomeric or in other 
heterochromatic regions where the accuracy of aCGH is sub-optimal. 
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Table 6.9 Comparison of CNAs in tumour samples with biopsy and derived culture 
 
Tumour sample 
(paired biopsy 
and culture) 
Grade Histologya IDH1 
Mutation 
statusb 
IDH2 
Mutation 
status 
Number 
of CNAs 
in biopsyc 
CNAs 
maintained 
in cultured 
IN118/81 II A R132H WT 78 8% 
IN1853 II A WT WT 113 53% 
IN2190 II A WT WT 52 10% 
IN2800 II A WT WT 57 18% 
UWLV7 II OA R132H WT 71 1% 
IN2723 II O WT WT 45 9% 
UWLV3 II O R132H WT 61 2% 
IN2184 III AO R132H WT 246 <1% 
 
a
 A, astrocytoma; OA, oligoastrocytoma; O, oligodendroglioma; AO, anaplastic 
oligodendroglioma;
b
 R132H, IDH1 mutant; WT, wild type; 
c
 CNAs, copy number 
aberrations; 
d
 Percentage of CNAs maintained in culture. 
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6.5 COMPARISON OF miRNA EXPRESSION IN PAIRED BIOPSY AND CELL 
CULTURE SAMPLES  
Expression profiling of miRNA was carried out on 5 paired samples of biopsy tissue 
and derived short-term cell cultures from grade II tumours. The cohort comprised 
IN2190 (A), IN2800 (A), UWLV7 (OA), IN2723 (O) and UWLV3 (O). IDH1-R132H 
mutation was detected in 2 biopsy tissues, UWLV3 and UWLV7, while no mutation of 
IDH2 was present in any of the samples assessed by direct sequencing analysis (Table 
6.10).   
 
6.5.1 miRNA array and data analysis 
miRNA expression analysis was performed using 3D Gene Human miRNA oligo chips 
(Toray, Japan) as described previously in Chapters 2 and 4. Data analysis was carried 
out using Partek Genomics Suite (version 6.6; Partek Inc., USA). Raw data was 
normalised with log2 median and one-way ANOVA test was used to determine 
differentially expressed miRNAs with ≥ 2-fold change. Unsupervised clustering 
analysis was performed with all biopsy and cell culture samples (n = 10).  Identification 
of differentially expressed miRNAs was carried out between each tumour biopsy and its 
derived cell culture (n= 5) and commonly differentiated miRNAs for each paired 
analysis were noted. PCA was used to demonstrate differences in miRNA expression 
profiles amongst the pairs. miRNAs with significantly differential expression (p value < 
0.05) were reported in the study. 
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Table 6.10 Paired samples of biopsy tissues and cell cultures used for miRNA analysis 
Sample Age at 
diagnosis
a 
Sex
b 
Grade Histology
c 
IDH1 
mutation
d 
IDH2 
mutation
 
IN2190 
45 M II A 
WT WT 
IN2800 
32 M II A 
WT WT 
UWLV7 
38 M II OA 
R132H WT 
IN2723 
55 F II O 
WT WT 
UWLV3 
43 M II O 
R132H WT 
 
a
 Age at diagnosis in years; 
b
 M, male; F, female; 
c
 A, astrocytoma; OA, 
oligoastrocytoma; O, oligodendroglioma; 
d
 R132H, IDH1 mutant; WT, wild type. 
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Unsupervised hierarchical clustering was performed using 1719 miRNAs and is 
represented by a dendrogram with samples having similar expression profiles clustered 
together (Figure 6.9). IN2190B and IN2800B clustered independently of any other 
samples while the remaining samples formed another cluster that further splits into two. 
Four of the cell cultures (IN2723CC, UWLV3CC, IN2800CC and UWLV7CC) had 
very similar expression profiles and clustered closely, indicating that culture conditions 
impart a strong influence on miRNA expression profiles.  
The number of differentially expressed miRNAs with ≥ 2-fold change in expression 
between each tumour biopsy and its derived short-term cell culture are listed in Table 
6.11. The greatest number of differentially expressed miRNAs was observed between 
the biopsy and cell culture in the astrocytoma sample IN2800 (249 miRNAs). In 
contrast, there were relatively few differences in miRNA expression between biopsy 
and cell culture in the oligodendroglioma sample UWLV3 (34 differentially expressed 
miRNAs). This is illustrated using PCA which confirms that the UWLV3 paired sample 
had the most similar expression profile compared to the IN2190 and IN2800 pairs that 
had the most different expression profiles (Figure 6.10).  
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Table 6.11 Differentially expressed miRNAs for each tumour sample (CC vs B) with 
≥ 2-fold change in expression 
 
Pairs Histology at 
diagnosisa 
Grade Differentially expressed 
miRNAs  
(CC vs B) 
(≥ 2-fold change)b 
IN2190  A II 86 
IN2800  A II 249 
UWLV7  OA II 82 
IN2723  O II 64 
UWLV3  O II 34 
 
a 
A, astrocytoma; OA, oligoastrocytoma; O, oligodendroglioma; 
b 
CC, cell culture; B, 
biopsy tissue.  
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Figure 6.9 Unsupervised hierarchical clustering for biopsy samples and their derived cell cultures 
 
Expression of 1719 miRNAs shown in 5 paired samples using Partek Genomics Suite. Red colour represents high levels of miRNA expression 
and green colour represents low levels of miRNA expression in the tumour. B – biopsy tissue, CC – cell culture. 
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Figure 6.10 PCA of biopsy samples and their derived cell cultures 
 
The results are depicted 3-dimensionally with PC1 (59.8%), PC2 (24%) and PC3 
(9.11%) as the X, Y and Z axes, respectively. Biopsy and short-term cell culture for the 
same tumour are shown by the same colour. B, biopsy tissue; CC, cell culture. 
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6.5.2 Tumour sample IN2190 
There were 86 differentially expressed miRNAs (> 2-fold change) between the biopsy 
and cell culture of which 38 were upregulated and 48 were downregulated in the cell 
culture compared to its biopsy tissue. The 10 most differentially expressed miRNAs are 
listed in Table 6.12 with the miRNA targets and deregulated pathways.  
 
6.5.3 Tumour sample IN2800 
In tumour sample IN2800, there were 249 differentially expressed miRNAs with > 2-
fold change in expression; 4 miRNAs were upregulated and 245 were downregulated in 
the cell culture compared to its biopsy tissue. The 10 most differentially expressed 
miRNAs are listed in Table 6.13 with the targets and pathways.  
 
6.5.4 Tumour sample UWLV7 
There were 82 differentially expressed miRNAs (> 2-fold change) identified between 
tumour biopsy UWLV7 and its derivative culture with 3 upregulated miRNAs and 79 
downregulated miRNAs in the cell culture compared to its biopsy tissue. The 10 most 
differentially expressed miRNAs are listed in Table 6.14 with the targets and pathways.  
 
6.5.5 Tumour sample IN2723 
A total of 64 miRNAs with differential expression (> 2-fold change) were identified, of 
which 1 was upregulated and 63 were downregulated in the cell culture compared to its 
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biopsy tissue. The 10 most differentially expressed miRNAs were listed in Table 6.15 
with the targets and pathways.  
 
6.5.6 Tumour sample UWLV3 
In tumour sample UWLV3, 34 differentially expressed miRNAs with > 2-fold change in 
expression were identified, of which 10 were upregulated and 24 were downregulated in 
the cell culture compared to its biopsy tissue. The 10 most differentially expressed 
miRNAs were listed in Table 6.16 with the targets and pathways.  
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Table 6.12 The 10 most differentially expressed miRNAs in IN2190 pair with the 
predicted targets and pathways.   
 
miRNA Fold change 
(CC vs B)
a 
Target Pathway 
miR-4787-3p 
17.8897 
GABRA4, SNX22, SLC25A13, 
IMPAD1, USP29, PCBP2 
Inositol phosphate metabolism, 
Synaptic vesicle cycle, 
Phosphatidylinositol signalling 
system, Sulfur metabolism, 
SNARE interactions in vesicular 
transport 
miR-4762-5p 
15.3156 
ARMC8, EIF2C1, HOOK3, FAT1, 
NUCKS1, TRAM1, FGF7, NLK, 
TRA2B, PTBP3 
Spliceosome, mRNA surveillance 
pathway, Insulin signalling 
pathway, Neurotrophin signalling 
pathway, Lysine degradation 
miR-21 
10.2508 
YOD1, KRIT1, WTH3DI, GPR64, 
PLEKHA1, SKP2, FBXO11, 
MALT1, PELI1, PBRM1 
Cytokine-cytokine receptor 
interaction, TGF-beta signalling 
pathway, MAPK signalling 
pathway, Melanoma 
miR-636 
9.84185 
AP3M1, ONECUT2, ARID4B, 
PKN2, PHC3, HAPLN1, RUNX2, 
VSIG10, ABCA13, RPS6KA3 
Adipocytokine signalling 
pathway, RNA degradation, PI3K-
Akt signalling pathway, Vascular 
smooth muscle contraction, 
Insulin signalling pathway 
miR-4733-3p 
9.55126 
CHMP1A, DGAT1, SLC46A2, 
LARP1, RIMS3, DDX18, FKBP15, 
CCL8, MIS12, PPP6R2 
ABC transporters, Pathogenic 
Escherichia coli infection, Gap 
junction, ECM-receptor 
interaction, Cyanoamino acid 
metabolism 
miR-4787-5p 
-11.2118 
NFIX, TMEM2, SURF4, FGF18, 
PLK4, RBM41, DNAJB5, SPTSSA, 
FAM64A, HIPK2 
Propanoate metabolism, Glioma, 
Melanoma, Prostate cancer, PI3K-
Akt signalling pathway 
miR-122 
-11.7277 
KCNN3, ATF6, HNRNPU, CCNG1, 
SPOCK2, NICN1, RFXAP, RBM43, 
ANKRD13C, RBMS2 
Hematopoietic cell lineage, T cell 
receptor signalling pathway, 
Neuroactive ligand-receptor 
interaction 
miR-720 
-24.7896 
GALR1, TUSC1, DNMT3A, 
SPTLC3, TMEM200B, NHSL1, 
NANOG, FBXO24, CYP4F11, 
FEZ1 
 
Nicotine addiction, Other types of 
O-glycan biosynthesis, Synaptic 
vesicle cycle, Taste transduction, 
Endocrine and other factor-
regulated calcium reabsorption 
miR-9 
-29.6037 
POU2F1, ONECUT2, PRTG, 
LYVE1, SH3TC2, MDGA2, TNC, 
SLC35B3, PRDM6, STARD13 
Cell adhesion molecules (CAMs), 
Axon guidance, Cytokine-cytokine 
receptor interaction, Pathways in 
cancer, Tight junction 
miR-4723-5p 
-41.1579 
MECP2, PLXNA4, PPP1R9B, 
SNX29, PACS1, NAT16, 
SLC28A1, CREB1, MUC3A, 
FOXE1 
Glycosaminoglycan biosynthesis - 
chondroitin sulphate, Tight 
junction, Circadian rhythm, 
Synaptic vesicle cycle, Cell 
adhesion molecules (CAMs) 
 
a
 CC, cell culture; B, biopsy tissue. Gene targets and pathways that were common 
between the miRNAs are highlighted in different coloured text. 
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Table 6.13 The 10 most differentially expressed miRNAs identified in IN2800 pair with 
the predicted targets and pathways.   
 
miRNA Fold change 
(CC vs B)
a 
Target Pathway 
miR-21 
5.87631 
YOD1, KRIT1, WTH3DI, GPR64, 
PLEKHA1, SKP2, FBXO11, 
MALT1, PELI1, PBRM1 
Cytokine-cytokine receptor 
interaction, TGF-beta signalling 
pathway, MAPK signalling pathway, 
Melanoma 
miR-27a 
2.50142 
CUX1, INO80D, FECH, 
PCDHB4,  
KCTD20, SAMD12, CD1C, 
PSMA1, PIGK, EIF1AX 
Vasopressin-regulated water 
reabsorption, Cell adhesion 
molecules (CAMs), Leukocyte 
transendothelial migration, 
Intestinal immune network for IgA 
production, Base excision repair 
miR-142-3p 
2.42483 
WASL, TSEN34, TAB2, BOD1, 
DCUN1D4, ASH1L, FAM208B, 
CLTA, CASK, GAB1 
Axon guidance, Dopaminergic 
synapse, Pancreatic secretion, 
Pancreatic cancer, NF-kappa B 
signalling pathway 
miR-24 
2.14467 
SRSF11, FMR1, HNRNPU, IGIP, 
SRPK2, ACTR2, CALD1, 
TM9SF3, TNFAIP8, LAMTOR3 
Glycerophospholipid metabolism, 
MAPK signalling pathway, Osteoclast 
differentiation, Pathways in cancer, 
Colorectal cancer 
miR-3658 
 
-26.3272 
AEBP2, DCUN1D5, LPP, 
MCTS1, GNB4, LRP6, TMED5, 
UBE2K, SMAD5, UHMK1 
TGF-beta signalling pathway, 
GABAergic synapse, Wnt signalling 
pathway, Prostate cancer, Chronic 
myeloid leukemia  
miR-4526 
-26.4359 
MIER1, FNBP1L, RIN2, 
FAM104B, CSF2RB, ATF3, 
RORA, RAP1A, MGAT4A, 
ATXN7 
Neurotrophin signalling pathway, 
Caffeine metabolism, Propanoate 
metabolism, Glioma, ErbB signalling 
pathway 
miR-4661-5p 
-26.9255 
FRS2, LCORL, DNALI1, 
HDGFRP3, DEPDC1B, JAG1, 
NFIB, WEE1, CCNB1, PRKAA1 
Synaptic vesicle cycle, Cell cycle, 
SNARE interactions in vesicular 
transport, Spliceosome, mRNA 
surveillance pathway 
miR-4481 
-27.777 
GNG13, GMEB1, VAPA, EZH1, 
ARF3, AP1G1, FZD3, 
APOBEC3H, DHRS3, PHYHIP 
Circadian entrainment, Cholinergic 
synapse, Arginine and proline 
metabolism, Taste transduction 
miR-323b-5p 
-47.1917 
TAF5, STK38, PIK3R3, BTAF1, 
JAK1, LMAN1, SERF2, GLRA2, 
TBC1D23, SLC39A9 
Metabolism of xenobiotics by 
cytochrome P450, D-Glutamine and 
D-glutamate metabolism, 
Phenylalanine, tyrosine and 
tryptophan biosynthesis, Proximal 
tubule bicarbonate reclamation, 
Proteasome 
miR-122 
-51.9519 
KCNN3, ATF6, HNRNPU, 
CCNG1, SPOCK2, NICN1, 
RFXAP, RBM43, ANKRD13C, 
RBMS2 
Hematopoietic cell lineage, T cell 
receptor signalling pathway, 
Neuroactive ligand-receptor 
interaction 
 
a 
CC, cell culture; B, biopsy tissue. Gene targets and pathways that were common 
between the miRNAs are highlighted in different coloured text. 
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Table 6.14 The 10 most differentially expressed miRNAs identified in UWLV7 pair 
with the predicted targets and pathways.   
 
miRNA Fold change 
(CC vs B)
a 
Target Pathway 
miR-3978 
 
5.80892 
SV2B, ONECUT2, FCHO2, 
OSBP2, SNAP25, RDX, GATM, 
KLF8, FAR1, HGSNAT 
Hematopoietic cell lineage,  
Glycerophospholipid metabolism, 
Endocrine and other factor-regulated 
calcium reabsorption, PI3K-Akt signalling 
pathway, Acute myeloid leukemia 
miR-432* 
 3.97517 
GSG1L, FAM169B, TLK2, 
TM9SF3, LYST, PRKCA, ATL2, 
YPEL2, CDH6, SLC8A1 
Pathogenic Escherichia coli infection, Gap 
junction, ABC transporters, Regulation of 
actin cytoskeleton, Arrhythmogenic right 
ventricular cardiomyopathy (ARVC) 
miR-4418 
2.43276 
ORAI2, PRR11, N4BP1, VPS53, 
TNRC6B, FAM168B, OPA3, 
CLSPN, RAB11A, GNL3L 
Other glycan degradation, mTOR signalling 
pathway, Biosynthesis of unsaturated fatty 
acids, Oocyte meiosis, D-Glutamine and D-
glutamate metabolism 
miR-30c 
-5.59553 
TNRC6A, CELSR3, MIER3, EED, 
LHX8, PPARGC1B, PHTF2, 
SCN2A, ANKRA2, RTKN2 
Neuroactive ligand-receptor interaction, 
Phosphatidylinositol signalling system, 
Dilated cardiomyopathy, Axon guidance, 
Focal adhesion 
miR-4302 
 
 
-5.83664 
FGD6, KCNK10, RAB31, 
QTRTD1, NFAT5, DDX46, 
NR1D2, AP2B1, KCNK3, PREPL 
Pathways in cancer, Acute myeloid 
leukemia, Chronic myeloid leukemia, B cell 
receptor signalling pathway, ErbB signalling 
pathway 
miR-9 
-8.18236 
POU2F1, ONECUT2, PRTG, 
LYVE1, SH3TC2, MDGA2, TNC, 
SLC35B3, PRDM6, STARD13 
Cell adhesion molecules (CAMs), Axon 
guidance, Cytokine-cytokine receptor 
interaction, Pathways in cancer, Tight 
junction 
miR-124 
-8.31175 
TXNRD1, SNX2, RSU1, FLRT3, 
DSCR6, COPS2, TMEM56, 
STRBP, UHRF1, ATPBD4 
Hypertrophic cardiomyopathy (HCM), 
Neurotrophin signalling pathway, Dilated 
cardiomyopathy, Arrhythmogenic right 
ventricular cardiomyopathy (ARVC), Axon 
guidance 
miR-323b-5p 
-14.5479 
TAF5, STK38, PIK3R3, BTAF1, 
JAK1, LMAN1, SERF2, GLRA2, 
TBC1D23, SLC39A9 
Metabolism of xenobiotics by cytochrome 
P450, D-Glutamine and D-glutamate 
metabolism, Phenylalanine, tyrosine and 
tryptophan biosynthesis, Proximal tubule 
bicarbonate reclamation, Proteasome 
miR-449c 
-21.9275 
NUP50, STMN2, CDK19, ODZ1, 
CREB1, PAPOLA, MAPK1IP1L, 
ACTL6A, TMEM48, STK38L 
Hepatitis B, Phosphatidylinositol signalling 
system, ErbB signalling pathway, 
Salmonella infection, Inositol phosphate 
metabolism 
miR-191 
-22.5432 
TMOD2, DDHD1, SLC25A24, 
TAF5,  
MAPK9, AMMECR1L, NRCAM, 
ORC3, SPO11, EHHADH 
Calcium signalling pathway, Glioma, Long-
term potentiation, Long-term depression, 
Melanoma 
 
a 
CC, cell culture; B, biopsy tissue. Common gene targets and pathways between the 
miRNAs are highlighted in different coloured text. 
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Table 6.15 The 10 most differentially expressed miRNAs identified in IN2723 pair with 
the predicted targets and pathways.   
 
miRNA Fold change 
(CC vs B)
a 
Target Pathway 
miR-21 
 4.55833 
YOD1, KRIT1, WTH3DI, GPR64, 
PLEKHA1, SKP2, FBXO11, 
MALT1, PELI1, PBRM1 
Cytokine-cytokine receptor 
interaction, TGF-beta signalling 
pathway, MAPK signalling pathway, 
Melanoma 
miR-3650  
-4.72264 
KCNIP1, CREB3, ECM1, GRIP2, 
GEMC1, RPP14, ABCB5, TSC1, 
KPNB1, CSMD2 
Renal cell carcinoma, Nicotinate and 
nicotinamide metabolism, mTOR 
signalling pathway 
miR-4526  
-5.30246 
MIER1, FNBP1L, RIN2, 
FAM104B, CSF2RB, ATF3, 
RORA, RAP1A, MGAT4A, 
ATXN7 
Neurotrophin signalling pathway, 
Caffeine metabolism, Propanoate 
metabolism, Glioma, ErbB signalling 
pathway 
miR-4787-3p 
 
-5.33518 
GABRA4, SNX22, SLC25A13, 
IMPAD1, USP29, PCBP2 
Inositol phosphate metabolism, 
Synaptic vesicle cycle, 
Phosphatidylinositol signalling 
system, Sulfur metabolism, SNARE 
interactions in vesicular transport 
miR-181a*  
-5.49688 
ALDH18A1, ATP13A4, 
ALDH6A1, NIPA2, RIBC1, 
SLC20A2, CFL2, RHOBTB1, 
HIF0, AP1S3 
Pathways in cancer, Acute myeloid 
leukemia, Chronic myeloid leukemia, 
Colorectal cancer, Prostate cancer 
miR-3658 
 
-5.83977 
AEBP2, DCUN1D5, LPP, MCTS1, 
GNB4, LRP6, TMED5, UBE2K, 
SMAD5, UHMK1 
TGF-beta signalling pathway, 
GABAergic synapse, Wnt signalling 
pathway, Prostate cancer, Chronic 
myeloid leukemia  
miR-9 
-6.7221 
POU2F1, ONECUT2, PRTG, 
LYVE1, SH3TC2, MDGA2, TNC, 
SLC35B3, PRDM6, STARD13 
Cell adhesion molecules (CAMs), 
Axon guidance, Cytokine-cytokine 
receptor interaction, Pathways in 
cancer, Tight junction 
miR-4481 
-6.75082 
GNG13, GMEB1, VAPA, EZH1, 
ARF3, AP1G1, FZD3, 
APOBEC3H, DHRS3, PHYHIP 
Circadian entrainment, Cholinergic 
synapse, Arginine and proline 
metabolism, Taste transduction 
miR-191 
-10.2189 
TMOD2, DDHD1, SLC25A24, 
TAF5, MAPK9, AMMECR1L, 
NRCAM, ORC3, SPO11, 
PWWP2A 
Calcium signalling pathway, Glioma, 
Long-term potentiation, Long-term 
depression, Melanoma 
miR-122 
-14.2231 
MBTD1, FAM178A, COL11A2,  
CNO, HAPLN1, FGFR4, UBE2I 
Hematopoietic cell lineage, T cell 
receptor signalling pathway, 
Neuroactive ligand-receptor 
interaction 
 
a 
CC, cell culture; B, biopsy tissue. Common pathways between the miRNAs are 
highlighted in different coloured text. 
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Table 6.16 The 10 most differentially expressed miRNAs identified in UWLV3 pair 
with the predicted targets and pathways.   
 
miRNA Fold change 
(CC vs B)
a 
Target Pathway 
miR-21 
 9.17437 
YOD1, KRIT1, WTH3DI, GPR64, 
PLEKHA1, SKP2, FBXO11, 
MALT1, PELI1, PBRM1 
Cytokine-cytokine receptor 
interaction, TGF-beta signalling 
pathway, MAPK signalling pathway, 
Melanoma 
miR-4418 
 
4.41772 
ORAI2, PRR11, N4BP1, VPS53,  
TNRC6B, FAM168B, OPA3, 
CLSPN, RAB11A, GNL3L 
Other glycan degradation, mTOR 
signalling pathway, Biosynthesis of 
unsaturated fatty acids, Oocyte 
meiosis, D-Glutamine and D-glutamate 
metabolism 
miR-27a 
 
3.06853 
CUX1, INO80D, FECH, PCDHB4,  
KCTD20, SAMD12, CD1C, 
PSMA1, PIGK, EIF1AX 
Vasopressin-regulated water 
reabsorption, Cell adhesion molecules 
(CAMs), Leukocyte transendothelial 
migration, Intestinal immune network 
for IgA production, Base excision 
repair 
miR-142-3p 
2.8793 
WASL, TSEN34, TAB2, BOD1, 
DCUN1D4, ASH1L, FAM208B, 
CLTA, CASK, GAB1 
Axon guidance, Dopaminergic synapse, 
Pancreatic secretion, Pancreatic 
cancer, NF-kappa B signalling pathway 
miR-432* 
2.62519 
GSG1L, FAM169B, TLK2, 
TM9SF3, LYST, PRKCA, ATL2, 
YPEL2, CDH6, SLC8A1 
Pathogenic Escherichia coli infection, 
Gap junction, ABC transporters, 
Regulation of actin cytoskeleton, 
Arrhythmogenic right ventricular 
cardiomyopathy (ARVC) 
miR-26a 
-3.67749 
MAN1A2, HS6ST3, ENPP4, 
SLC30A5, CALCOCO2, TACR1, 
CDK6, SLC6A14, GJB2, 
SMARCE1 
GnRH signalling pathway, 
Neurotrophin signalling pathway 
miR-449c 
-4.42601 
NUP50, STMN2, CDK19, ODZ1,  
CREB1, PAPOLA, MAPK1IP1L, 
ACTL6A, TMEM48, STK38L 
Hepatitis B, Phosphatidylinositol 
signalling system, ErbB signalling 
pathway, Salmonella infection, Inositol 
phosphate metabolism 
miR-122 
-4.67672 
KCNN3, ATF6, HNRNPU, 
CCNG1, SPOCK2, NICN1, 
RFXAP, RBM43, ANKRD13C, 
RBMS2 
Hematopoietic cell lineage, T cell 
receptor signalling pathway, 
Neuroactive ligand-receptor 
interaction 
miR-9 
-6.58838 
POU2F1, ONECUT2, PRTG, 
LYVE1, SH3TC2, MDGA2, TNC, 
SLC35B3, PRDM6, STARD13 
Cell adhesion molecules (CAMs), Axon 
guidance, Cytokine-cytokine receptor 
interaction, Pathways in cancer, Tight 
junction 
miR-191 
-10.4976 
TMOD2, DDHD1, SLC25A24, 
TAF5, MAPK9, AMMECR1L, 
NRCAM, ORC3, SPO11, 
EHHADH 
Calcium signalling pathway, Glioma, 
Long-term potentiation, Long-term 
depression, Melanoma 
 
a 
CC, cell culture; B, biopsy tissue. Common pathways between the miRNAs are 
highlighted in different coloured text. 
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Interestingly, a large proportion of differentially expressed miRNAs in 4/5 pairs 
(IN2800, UWLV7, IN2723 and UWLV3) were downregulated in the cell culture as 
compared to the biopsy tissue. This may be due to the cell culture conditions not 
replicating the tumour environment in vivo. IN2190 (A) was the only pair that had a 
relatively small difference in the number of upregulated and downregulated miRNAs in 
the cell culture compared to its biopsy tissue. The largest changes in fold expression 
were identified in the A pairs followed by OA and O pairs respectively.  
Results from the hierarchical clustering, PCA analysis and individual comparisons 
between tumour biopsies and their derived cultures suggest that O and OA cell cultures 
are more representative of the biopsy tissues than the A cell cultures with regard to 
miRNA expression profiles.  
The most common miRNAs amongst the pairwise comparisons were miR-9, miR-21 
and miR-122 present in 80% of the pairs followed by miR-191 present in 60% of the 
pairs. miR-9 was downregulated in the cell culture of four pairs (IN2190, UWLV7, 
IN2723 and UWLV3). miR-21 was upregulated in the cell culture of four pairs 
(IN2190, IN2800, IN2723 and UWLV3). miR-122 was downregulated in the cell 
culture of four pairs (IN2190, IN2800, IN2723 and UWLV3). miR-191 was 
downregulated in the cell culture of three pairs (UWLV7, IN2723 and UWLV3). 
Histology comparison revealed miR-21 and miR-122 as the most common miRNAs in 
A pairs (IN2190, IN2800) and miR-9, miR-21, miR-122 and miR-191 in O pairs 
(IN2723, UWLV3). Amongst all the pairs, the most common pathways were melanoma 
and cytokine-cytokine receptor interactions present in 60% of the pairs, axon guidance, 
TGF-β signalling pathway, pathways in cancer and CAMs present in 40% of the pairs. 
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The five paired samples had 11 common miRNAs with differential expression, 
identified by a Venn diagram (Figure 6.11). Of the 11 miRNAs, 7 miRNAs (mir-4456, 
miR-4534, miR-29b, miR-2113, miR-3650, miR-9 and miR-191) were downregulated 
in all the cell cultures, 3 miRNAs (miR-4733-3p, miR-4740-5p and miR-4748) were 
downregulated in 80% and 1 miRNA (miR-21) was downregulated in 20% of cell 
cultures compared to the biopsy tissues. The common miRNAs are detailed in Table 
6.17 with percentage of differential expression in the pairs.  
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Figure 6.11 Venn diagram showing unique and common miRNAs in all pairs 
 
 
 
Using Partek Genomics Suite, paired samples were compared and differentially 
expressed miRNAs were identified with ≥ 2-fold change in expression and significance 
of p < 0.05 by ANOVA. IN2190 pair had 86 differentially expressed miRNAs, UWLV7 
had 82 miRNAs, UWLV3 had 34 miRNAs, IN2800 had 249 miRNAs and IN2723 had 
64 miRNAs that were differentially expressed. Eleven common differentially expressed 
miRNAs were identified among the five paired samples.  
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Table 6.17 Common miRNAs in the biopsy/cell culture pairs with percentage of 
differential expression. 
 
miRNA Upregulation (%)a Downregulation (%) Target Pathway 
CC B CC B 
miR-4456 0 100 100 0 ERC1, RND2, FAM101B, 
NACC1, CNR1, RANBP10, 
DNAJC6, PACS1, GCC2, 
MBL2 
Axon guidance, N-Glycan 
biosynthesis, Histidine metabolism, 
Glycosylphosphatidylinositol (GPI)-
anchor biosynthesis, Cyanoamino 
acid metabolism 
miR-4534 0 100 100 0 OLA1, GNG13, SPN, 
LRRTM2, NAB1, KLK10, 
CHRNB2, PDP2, PLCXD1, 
RBBP5 
Glutamatergic synapse, Taste 
transduction, Pathogenic 
Escherichia coli infection, Oocyte 
meiosis, Circadian entrainment 
miR-4740-
5p 
20 80 80 20 PDK3, THSD4, STAM2, 
ENOPH1, AGAP1, RBMS3, 
RAG1, MSR1,SPTLC2, 
ARAP2 
Glycosphingolipid biosynthesis – 
lacto and neolacto series, 
Morphine addiction, Circadian 
entrainment, GABAergic synapse, 
SNARE interactions in vesicular 
transport 
miR-29b 0 100 100 0 USP28, NEUROD1, 
ZDHHC5, LIN9, TNPO3, 
CLEC2B, WDR26, SNX30, 
SLC30A7, PROS1 
ECM-receptor interaction, Small 
cell lung cancer, Focal adhesion, 
Axon guidance, Pathways in cancer 
miR-2113 0 100 100 0 PIK3C2A, COL4A3BP, CRH, 
ELL2, NCBP1, CNTLN, 
MAP4K3, CASK, SNTB2, 
CCDC6  
Notch signalling pathway, Pathways 
in cancer, Renal cell carcinoma, 
Long-term potentiation, Adherens 
junction 
miR-4748 20 80 80 20 TSFM, PPP2R5A, KALRN, 
CTSL2, GABRG2, 
TMEM106B, SNF8, ABCD4, 
GM2A, FERMT1 
Colorectal cancer, Endometrial 
cancer, Epstein-Barr virus infection, 
B cell receptor signalling pathway 
miR-3650 0 100 100 0 RTN41P1, CDK14, ABO, 
SH3BP2, DCLRE1C, ELN, 
STEAP2, EIF2C3, BNC2, 
HDX 
Pathways in cancer, Prostate 
cancer, Pancreatic cancer, 
Adherens junction, MAPK signalling 
pathway 
miR-4733-
3p 
20 80 80 20 CHMP1, DGAT1, LARP1, 
RIMS3, FKBP15, DDX18, 
CCL8, MIS12, PPP6R2, 
ABHD4 
ABC transporters, Pathogenic 
Escherichia coli infection, Gap 
junction, ECM-receptor interaction, 
Cyanoamino acid metabolism 
miR-21 80 20 20 80 YOD1, KRIT1, WTH3DI, 
GPR64, PLEKHA1, SKP2, 
FBXO11, MALT1, PELI1, 
PBRM1 
Cytokine-cytokine receptor 
interaction, TGF-beta signalling 
pathway, MAPK signalling pathway, 
Melanoma 
miR-9 0 100 100 0 POU2F1, ONECUT2, PRTG, 
LYVE1, SH3TC2, MDGA2, 
TNC, SLC35B3, PRDM6, 
STARD13 
Cell adhesion molecules (CAMs), 
Axon guidance, Cytokine-cytokine 
receptor interaction, Pathways in 
cancer, Tight junction 
miR-191 0 100 100 0 TMOD2, DDHD1, 
SLC25A24, TAF5, MAPK9, 
NRCAM, ORC3, EHHADH, 
SATB, CERS6 
Phosphatidylinositol signalling 
system, GnRH signalling pathway, 
Adherens junction, Cytokine-
cytokine receptor interaction, Cell 
adhesion molecules (CAMs) 
 
a 
CC, cell culture; B, biopsy tissue. Common pathways between the miRNAs are 
highlighted in different coloured text. 
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6.6 PROTEIN EXPRESSION OF GENETIC MARKERS IN BIOPSY TISSUES 
AND CELL CULTURES 
IHC was performed on four biopsy/cell culture pairs (IN2190 (A), IN2800 (A), 
UWLV7 (OA) and UWLV3 (O)) and four additional cell cultures for which no further 
biopsy tissue was available for analysis (IN118/81 (A), IN1853 (A), IN2723 (O), 
IN2184 (AO)) using antibodies against GFAP, IDH1 R132H mutant protein, Nestin, Ki-
67, p53, CD34 and EMA and the results are summarised in Table 6.18. There was no 
staining for GFAP, IDH1 R132H mutant protein, p53, CD34 and EMA in any sample. 
Positive cytoplasmic staining was detected for Nestin in all 8 cultures and 2 biopsy 
samples (UWLV7 and UWLV3). For Ki-67, the astrocytoma cell culture IN118/81CC 
showed the highest protein expression at 67%, considerably greater than any other 
sample. This was surprising as this culture had the longest doubling time. The levels of 
Ki67 staining between the paired biopsy/cell culture samples were very similar for 
IN2190 (21% and 22% respectively) and UWLV7 (14% and 13%, respectively). In the 
UWLV3 biopsy, 12% of cells stained positive for Ki67 although no signal was detected 
in the UWLV3 cell culture. Ki67 expression was detected in less than 1% of cells of the 
IN2800 biopsy and again, no signal was detected in the IN2800 cell culture or the 
unpaired IN1853 cell culture. The remaining 2 unpaired cell cultures, IN2723 and 
IN2184 had very low levels of Ki-67 expression (< 1%). Examples for Nestin and Ki-67 
in both cell culture and biopsy tissue are shown in Figure 6.12.  
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Table 6.18 Expression of nestin and  Ki67 in LGG determined by IHC 
Sample
a
 Grade
 
Histology
b
 Nestin
c
 Ki67 (%)
d
 
IN2190B II A 0 21 
IN2190CC   c2 22 
     
IN2800B II A 0 <1 
IN2800CC   c2 0 
     
UWLV7B II OA c2 14 
UWLV7CC   c3 13 
     
UWLV3B II O c1 12 
UWLV3CC   c3 0 
     
IN118/81CC II A c3 67 
     
IN1853CC II A c3 0 
     
IN2723CC II O c3 <1 
     
IN2184CC III AO c3 <1 
 
a 
Paired samples of biopsy tissue (B) and cell culture (CC); 
b 
A, astrocytoma; OA, 
oligoastrocytoma; O, oligodendroglioma; AO, anaplastic oligodendroglioma; 
c 
0: no 
staining, 1: weak staining, 2: moderate staining, 3: strong staining; c: cytoplasmic; 
d
 
Percentage of cells with staining. 
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Figure 6.12 Immunohistochemistry staining for cell cultures 
 
      
 
       
 
Representative example, photographs were taken at 20x magnification. A: Positive 
staining for UWLV3CC Nestin (c3), B: IN118/81CC Ki-67 (67%), C: UWLV7B Nestin 
(c2) and D: UWLV3B Ki-67 (12%). Arrow highlights a positively stained cell.  
 
 
 
 
 
 
 
 
 
 
 
A B 
C D 
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6.7 CHARACTERISATION OF GROWTH CHARACTERISTICS OF LGG 
SHORT-TERM CULTURES 
Growth curves were generated for six LGG cell cultures, IN118/81 (A), IN1853 (A), 
IN2190 (A), IN2800 (A), UWLV7 (OA) and UWLV3 (O) in order to calculate doubling 
times. 
Cells were seeded at a plating density of 5000 cells/well for all cell cultures between 
passages 7-11 as previously described in Chapter 2. The three replicate experiments for 
each cell culture are shown in the same graph. The passage number at the time of 
plating increased by 1 for each replicate experiment (Figure 6.13). Cells were grown 
and counted over a maximum period of 11 days. 
 
Doubling times in hours were calculated for each experiment and the mean ± standard 
deviation is presented in Table 6.19. The doubling times of the 6 cultures ranged from 
27-42 hours with a mean of 33 hours. The slowest and fastest growing cell cultures 
were IN118/81 and IN2190 respectively. There was no significant difference in the 
doubling times of the four astrocytoma cultures compared to the two cultures with 
oligodendroglial differentiation (p = 0.778).  
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Figure 6.13 Growth curves for 6 LGG cell cultures used in this study 
    
 
    
 
    
Three replicate experiments for each cell culture have been shown on the same graph. Passages 
7-11 used for the six cell cultures.  
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Table 6.19 Cell cultures used for growth curves 
Cell culture Histology
a 
Mean Doubling time (hrs)  
± Standard deviation 
IN118/81 A 41.6 ± 0.69 
IN1853 A 32.6 ± 0.25 
IN2190 A 27.1 ± 0 
IN2800 A 31.5 ± 0.17 
UWLV7 OA 34.2 ± 0.11 
UWLV3 O 29.3 ± 0 
 
a
 A, astrocytoma; OA, oligoastrocytoma; O, oligodendroglioma. 
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6.8 ABILITY OF LGG CELLS TO GROW ON A FEEDER LAYER 
LGG cells were seeded on to a feeder layer of mitomycin-treated 3T3 cells and 
monitored for growth of colonies. The colony assay was performed for 6 cell cultures, 
IN118/81 (A), IN1853 (A), IN2190 (A), IN2800 (A), UWLV7 (OA) and UWLV3 (O) 
and cultures were seeded at passage numbers 4-12. Photographs of each cell culture 
were taken every 3 days and examples of colonies are shown in Figure 6.14. Colony 
growth was observed for a maximum period of 24 days, during which time all LGG 
cultures formed at least one colony.  The culture for which least number of colonies was 
observed was IN118/81, also the culture which had the longest doubling time. 
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Figure 6.14 Colonies for LGG cells on 3T3 feeder layer 
     
   
Photographs were taken with 20x magnification. A: 3T3 cells treated with mitomycin; 
B: IN118/81 p4; C: IN2800 p9 and D: UWLV3 p12. 
 
 
 
 
 
 
 
 
 
Day 24 
Day 9 Day 14 
A B 
C D 
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6.9 DISCUSSION 
This chapter describes the characterisation of the short term cell cultures derived from 
lower grade glioma tumour biopsy tissues. Comparison of paired samples was 
performed to identify genomic changes and differentially expressed miRNAs within 
each pair. 
 
6.9.1 IDH1 mutation in vitro 
In the first instance, the IDH mutation status was established in tumour biopsies and 
derived cell cultures and IDH1 mutation was not maintained in any cell culture. The 
artificial culture conditions select the cell populations that can thrive in the artificial 
growth environment and hence, the more stable IDH1 wild type cells grow and the sub-
population of cells with IDH1 mutation are lost. This has been reported by Piaskowski 
et al., (2011) and described previously in Chapter 1. Similarly, MGMT methylation (if 
any) was present in only the biopsy tissues and not in any cell cultures. Serum used in 
the growth medium was always batch tested and the same batch of serum was used for a 
year in order to avoid any variability in the cell culture conditions.  
Stoczynska-Fidelus et al., (2014) established eight glioma 3D cell cultures with IDH1-
R132H mutation from GBM tumours and analysed in vitro senescence. In artificial 
growth conditions, IDH1 R132H-positive cells decreased rapidly in number and in 
GBM, these cells were present up to 4 passages. The remaining IDH1 R132H-negative 
cells proliferated efficiently and subsequently, overgrew the IDH1 R132H-positive 
cells. 3D culture conditions maintained the IDH1 R132H mutation for 1-2 months in 
contrast to monolayer cultures. The lack of proliferation of these IDH1 R132H-positive 
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cells was linked with in vitro senescence, characterised by SA-β-Gal activity and 
morphological changes. The observed senescence is induced by the cell culture 
conditions (both classical and serum-free). IDH1 R132H-positive cells showed 
expression of SOX2, a stemness marker.   
 
6.9.2 Copy number analysis 
Few studies have reported genomic aberrations in grade II astrocytoma, which were 
identified using CGH and aCGH analysis. Hirose et al., (2003) also used CGH to 
determine CNAs in 30 grade II astrocytoma tumours. The most frequent aberrations 
determined were gain on chromosome 7q (12 cases), losses on 19q (7 cases) and 1p (6 
cases) and gain on 5p (5 cases). The current study also detected gain on 7q (2 cases) and 
loss on 19q (2 cases).  
Wiltshire et al., (2004) used CGH to identify copy number changes in astrocytoma 
tumours. The authors reported that 10 grade II astrocytoma detected gains and losses on 
chromosomes 3, 7, 11, 13, 19, 22, X and Y. These results were in line with the present 
study that showed both gains and losses on chromosomes 3, 7, 13 and 19.  
Arslantas et al., (2007) identified genomic aberrations using CGH in 18 low-grade 
astrocytoma and the most frequent were gains on chromosomes 7/7q (5 cases), 8q (4 
cases), 20q (3 cases) and loss of 19q (3 cases). Some of these aberrations were also 
observed in the current study including gains on 7q and 8q. The most frequent 
aberration in grade II astrocytoma reported in previous studies was gain on 7q which 
was observed in 50% of the cases in the current study.  
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It is apparent from this study that the majority of numerical genomic changes present in 
LGG biopsies are not maintained in short-term cell cultures. The copy number analysis 
shows difference in the genomic profiles of the paired samples where 75% of the pairs 
have more aberrations in the biopsy tissues compared to their cell cultures. This 
indicates that along with IDH1 mutation and MGMT methylation, other genetic features 
are eliminated due to the cell culture conditions. The total number of aberrations for the 
AO pair (IN2184) was the highest while OA (UWLV7) and one of the O (UWLV3) had 
a relatively smaller number. This may contribute to a more aggressive behaviour of the 
anaplastic tumour although there was only one in the sample cohort. The four 
astrocytoma pairs were compared to identify common CNAs in biopsy tissues and cell 
cultures respectively. Similarly, the two oligodendroglioma pairs were compared. The 
limitation of this comparison was the small number of tumours with same histology.  
 
6.9.3 miRNA expression 
In this chapter, comparison of miRNA expression profiles for five paired samples was 
performed in order to identify changes in each pair. To date, miRNA expression profiles 
in biopsy and cell culture paired samples have not been investigated. Unsupervised 
hierarchical clustering shows 4/5 cell cultures forming a cluster and 2/5 biopsy tissues 
with similar miRNA expression profiles (Figure 6.13). The two remaining biopsy 
tissues had different profiles from the rest of the samples in the analysis. The expression 
profiles did not have any significant differences between the IDH mutant and IDH wild 
type tumours. This may be due to the small sample size with different histology types. 
PCA showed UWLV3 pair to have the most similar profile, whereas IN2190 and 
IN2800 had the most variation in profiles. Following the pairwise comparisons, all 
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paired samples were combined together resulting in 11 differentially expressed miRNAs 
that were common among all 5 pairs. None of the miRNAs have been studied in cell 
cultures and therefore, their role in cell culture and the change in expression levels in 
both biopsy tissue and cell culture derived from the same tumour needs to be 
investigated further.   
 
6.9.4 Growth characteristics  
The experiments used to assess the growth characteristics show that LGG cells are 
slow-growing and tumorigenic as they formed colonies on the 3T3 feeder layer. The cell 
cultures investigated here were grown from the biopsy tissue as described previously in 
Chapter 2. The profile of the cell cultures studied here represents a cell population of the 
LGG tumours but the profile may not involve the majority of tumour mass population. 
This accounts for variation in the biopsy tissues and cell cultures from the same tumour 
which is illustrated in the array CGH and miRNA expression analysis.  
 
In summary, this study shows that IDH1 R132H mutation was not maintained in the 
derived cell cultures established from the IDH1 R132H mutant biopsy tissues. Also, it 
was demonstrated that biopsy tissues and short-term cell cultures from the same tumour 
show variation in genomic and miRNA expression profiles. It was evident from the 
results in the present study that cells in culture undergo various alterations that influence 
the genetic profile. Moreover, these findings suggest that a better model needs to be 
identified in order to study the LGG tumours in vitro. 
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CHAPTER 7 
SUMMARY AND FUTURE STUDIES 
 
In this study, mutation status of IDH1 and IDH2 and promoter methylation status of 
MGMT was determined in a sample cohort. The key findings were that IDH1 mutation 
was an independent favourable prognostic factor for OS and patients with grade II 
tumours having IDH1 mutation had a better outcome. MGMT promoter methylation was 
not significantly associated with OS in either of the two grades.  
For mutation analysis and clinical correlation, IDH2 mutant tumours were classed 
different from IDH1 mutant tumours. Only one sample carried IDH2 mutation in the 
entire cohort used in this study. IDH1 and IDH2 mutation do not cause the same effects 
and little is known about the biological consequences of IDH2 mutation. IDH1 mutation 
was widely studied for correlation with different clinical parameters in this study. For 
miRNA expression analysis, IDH1 R132H and IDH2 mutant tumours were combined 
and represented as IDH mutant tumours. The IDH2 mutant tumour did not seem to 
influence the expression profiles of the mutant tumours. A number of studies mentioned 
in chapters 3 have grouped IDH1 R132H mutant and IDH2 mutant tumours for varied 
analyses including correlation of IDH mutation with MGMT methylation and 
association with OS and PFS. The question remains whether IDH2 mutation is to be 
grouped with IDH1 R132H mutation in an analysis. The consequences of IDH2 
mutation need to be investigated further.  
MGMT methylation status is heterogeneous in malignant glioma, hence, identifying 
methylation status of tumours can be challenging. Methodologies such as IHC have 
limitations that include non-specificity of the antibody, subjective scoring and controls 
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for positive staining against the antibodies. A study by Quillien et al. (2012), compared 
five methods to analyse MGMT comprising of MS-PCR, MethyLight, Pyrosequencing, 
Methylation-Sensitive High-Resolution Melting and IHC. IHC is used despite its 
limitations as the technique is inexpensive and widespread with visualisation of tumour 
cells and significant association of MGMT protein with outcome has been reported for 
glioma patients. For IHC to be established as a reliable technique, a standard protocol is 
required which takes into account the staining process including slide pretreatment, 
antibody type and dilution as well as the method of scoring positively stained cells.  
Cell cultures can have further variation growing in a monolayer, as a 2-dimensional 
culture or as a result of FCS in the growth medium. On the other hand, MS PCR is a 
more reliable technique and primers for MS PCR can be designed in a way such that all 
the CpG sites for methylation are covered. In future studies, degree of MGMT 
methylation, protein expression and enzyme activity should all be considered to identify 
the promoter methylation status of tumours.  
There was lack of treatment information across the three centres, from where the 
samples were collected and the treatment information that was available in some cases 
did not provide information about the time when treatment was carried out. This needs 
to be provided in order to correlate treatment regimen, i.e. chemotherapy using TMZ 
with MGMT promoter methylation.  
miRNA analysis was carried out to identify a panel of miRNAs that can be used in a 
clinical trial to predict tumour progression. This can be achieved by comparing miRNAs 
identified in this study to miRNAs found in previous studies, including any other cancer 
or disease. Candidate miRNAs could be identified following further pathway analysis 
that gives common pathways exclusive to each histological group or grade. Correlation 
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of copy number aberrations and differentially expressed miRNAs should be performed 
and target genes for these miRNAs should be linked to the array CGH results.  
One of the miRNAs, miR-181d has been previously associated with MGMT 
methylation. miR-181d was studied using 82 GBM samples and it was shown that 
MGMT is a downstream target of miR-181d (Zhang et al., 2012). The authors 
transfected a mimic of miR-181d in A1207 GBM cell line that resulted in 
downregulation of the mRNA and protein expression of MGMT. Expression of miR-
181d was found to be inversely correlated with overall survival in a TCGA validation 
set (p = 0.001) analysed by qRT-PCR. miRNAs such as miR-181d that regulate MGMT 
could be used as a biomarker to predict response of patients to TMZ. In a study by Shi 
et al. (2010), miR-21 was shown to protect U87-MG cells from TMZ induced 
apoptosis. Conversely, overexpression of miR-21 in U87-MG cells significantly 
reduced TMZ induced apoptosis (p < 0.05). This was induced by decreased ratio of anti-
apoptotic proteins, Bax/Bcl-2 and change in caspase-3 activity. 
Novel miRNAs were identified when comparing primary tumours of grade II and grade 
III. These may contribute to a miRNA signature pattern in the two tumour grades. In 
grade II tumours, OA were more similar to O with regard to expression profiles, while 
in grade III tumours, AOA were more similar to AA. OA tumours apparently are a mix 
of cells similar to those present in A and O. The results from this study identified the 
pattern of miRNA expression for OA and AOA. Also, it was seen that tumour grade 
greatly influenced the miRNA expression but not IDH mutation status.  
Tumours of histological types, O and OA are difficult to differentiate between, with the 
two types having different prognosis and treatment regimes. A new WHO classification 
system is due to come out next year which will be based on the molecular biology and 
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not the pathology of glioma. Also, OA histological group will no longer exist as it has 
been quite controversial. OA is often thought to be a tumour that the pathologists fail to 
classify under either the A or O histological groups. Biomarkers such as copy number 
aberrations and differentially expressed miRNAs will be useful for molecular 
classification of glioma.  
This is the first study to compare primary and recurrent paired tumour samples by 
aCGH and miRNA expression analysis. Copy number analysis showed that all of the 
recurrent tumours analysed developed additional genomic changes at recurrence. These 
additional changes may play a role in tumour progression. These included gains on 
chromosomes 2q, 7q, 10p, 14q, 15q, 16q, whole chromosome 17, 20q and 21q and 
losses at 1p, 2q, 4q, 6p-q, 9p, 10, 11p, 14q, 15p, 18q, 19 and Xp. As part of the future 
work, overlapping genes in these genomic regions need to be validated.  
It is for the very first time that paired samples of biopsy and derived short-term cell 
cultures of lower grade diffuse glioma have been investigated. The paired samples were 
analysed for copy number changes and miRNA expression. 1p/19q loss was detected by 
aCGH in one AO. Tumour samples were not screened for co-deletion of 1p/19q loss due 
to limited tissue availability, which was primarily used for IDH1 and IDH2 mutation 
analysis and aCGH analysis. Archival paraffin tissues yielded low quality DNA, 
suitable only for IDH mutation analysis or MGMT methylation analysis. Large genomic 
aberrations present in the tumour biopsy were not maintained in the derived short-term 
cell culture. The cell cultures contained only small interstitial changes. CNAs 
maintained in the cell cultures ranged from < 1% to 53%. miRNA expression analysis 
showed majority of the cell cultures forming a cluster, representing similar expression 
profiles. Histology may play an important role as the A paired sample had the maximum 
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number of differentially expressed miRNAs, while O paired sample had the least 
number of differentially expressed miRNAs. In IHC, it was surprising that two of the 
IDH1-R132H mutant tumours, UWLV3 and UWLV7 did not show any staining for the 
IDH1 mutant protein. For Ki-67, no protein expression was detected in the three cell 
cultures, although mitotic figures were distinctly visible when examined under the 
microscope. The experiments carried out using short-term cell cultures clearly indicate 
that LGG cell cultures are not a good representative model of the tumour in vivo.  
In a study by Turcan et al. (2012), human astrocytes were transfected with wild type 
and mutant IDH1-R132H using retroviruses. IDH1 mutant cells were analysed for 50 
passages and methylome was collected to identify methylated genes. The present study 
on the other hand, used monolayer culture to grow cells and IDH1-R132H mutation 
present in the tumour biopsy was not maintained in the corresponding cell culture. 
Similarly, a previous study by Piaskowski et al. (2011) reportedly was unable to 
maintain IDH1 mutation in cell cultures as well as in 15 commercially available cell 
lines. Future work would include developing a 3D cell culture model, retaining the 
IDH1-R132H mutation and using retroviruses and adenoviruses to tranfect cells with 
IDH1 mutation to examine the effects of the mutation in vitro. 
 
The present study contributes to a better understanding of LGG tumours with regard to 
the genetic and miRNA profiles as well as developing a good model of LGG tumours 
for future work. It also imparts information on the tumour progression through 
primary/recurrent paired tumour samples.  
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Appendix I 
Supplier information 
Product                                              Supplier 
HEPES Ham’s F10 nutrient mix       Life Technologies Ltd, 3 Fountain Drive, 
Inchinnan Business Park, Paisley, PA4 9RF. UK 
www.lifetechnologies.com 
 
Penicillin      Sigma-Aldrich Company Ltd, The Old Brickyard, 
New Road, Gillingham, Dorset, SP8 4XT. UK 
                                                            www.sigmaaldrich.com 
 
Streptomycin Sigma-Aldrich Company Ltd, The Old Brickyard, 
New Road, Gillingham, Dorset, SP8 4XT. UK 
                                                            www.sigmaaldrich.com 
 
Kanamycin Sigma-Aldrich Company Ltd, The Old Brickyard, 
New Road, Gillingham, Dorset, SP8 4XT. UK 
                                                            www.sigmaaldrich.com 
 
Foetal calf serum Life Technologies Ltd, 3 Fountain Drive, 
Inchinnan Business Park, Paisley, PA4 9RF. UK 
www.lifetechnologies.com 
 
Collagenase Sigma-Aldrich Company Ltd, The Old Brickyard, 
New Road, Gillingham, Dorset, SP8 4XT. UK 
                                                            www.sigmaaldrich.com 
 
Hank’s buffered salt solution Sigma-Aldrich Company Ltd, The Old Brickyard, 
New Road, Gillingham, Dorset, SP8 4XT. UK 
                                                            www.sigmaaldrich.com 
 
Trypsin EDTA Life Technologies Ltd, 3 Fountain Drive, 
Inchinnan Business Park, Paisley, PA4 9RF. UK 
www.lifetechnologies.com 
 
Dimethyl sulfoxide  Sigma-Aldrich Company Ltd, The Old Brickyard, 
New Road, Gillingham, Dorset, SP8 4XT. UK 
                                                            www.sigmaaldrich.com 
 
TCA Sigma-Aldrich Company Ltd, The Old Brickyard, 
New Road, Gillingham, Dorset, SP8 4XT. UK 
                                                            www.sigmaaldrich.com 
 
SRB Sigma-Aldrich Company Ltd, The Old Brickyard, 
New Road, Gillingham, Dorset, SP8 4XT. UK 
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                                                            www.sigmaaldrich.com 
 
Acetic acid Sigma-Aldrich Company Ltd, The Old Brickyard, 
New Road, Gillingham, Dorset, SP8 4XT. UK 
                                                            www.sigmaaldrich.com 
 
Mitomycin C Sigma-Aldrich Company Ltd, The Old Brickyard, 
New Road, Gillingham, Dorset, SP8 4XT. UK 
                                                            www.sigmaaldrich.com 
 
GFAP antibody Dako UK Ltd, Cambridge House, St Thomas 
Place, Ely, Cambridgeshire, CB7 4EX, UK 
   www.dako.com 
  
IDH1-R132H antibody GmbH / Warburgstr. 45/20354 Hamburg, 
Germany 
   www.dianova.com 
 
Nestin antibody Millipore (U.K.) Limited, Suite 3 & 5, Building 6, 
Croxley Green Business Park Watford, 
Hertfordshire WD18 8YH, UK 
     www.merckmillipore.com 
 
Ki-67 antibody Dako UK Ltd, Cambridge House, St Thomas 
Place, Ely, Cambridgeshire, CB7 4EX, UK 
   www.dako.com 
 
p53 antibody Dako UK Ltd, Cambridge House, St Thomas 
Place, Ely, Cambridgeshire, CB7 4EX, UK 
   www.dako.com 
 
CD34 antibody Leica Biosystems Newcastle Ltd, Balliol Business 
Park West, Newcastle Upon Tyne, NE12 8EW, 
UK     
   www.leicabiosystems.com 
 
EMA antibody Leica Biosystems Newcastle Ltd, Balliol Business 
Park West, Newcastle Upon Tyne, NE12 8EW, 
UK     
   www.leicabiosystems.com 
 
MGMT antibody   Abcam, 330 Cambridge Science Park, Cambridge 
CB4 0FL, UK 
www.abcam.com 
 
Vectastain Universal Elite ABC Kit Vector Laboratories Ltd, 3, Accent Park, Bakewell  
     Road Orton Southgate, Peterborough, PE2 6XS,  
     UK 
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www.vectorlabs.com 
 
Vectastain Elite ABC Reagent Vector Laboratories Ltd, 3, Accent Park, Bakewell 
Road, Orton Southgate, Peterborough, PE2 6XS, 
UK 
www.vectorlabs.com 
 
DAB solution Dako UK Ltd, Cambridge House, St Thomas 
Place, Ely, Cambridgeshire, CB7 4EX, UK 
     www.dako.com 
 
QIAamp DNA Mini and Blood kit Qiagen Ltd, Skelton House, Lloyd Street North, 
Manchester M15 6SH. UK 
 www.qiagen.com 
 
Phosphate buffered saline Sigma-Aldrich Company Ltd, The Old Brickyard, 
New Road, Gillingham, Dorset, SP8 4XT. UK 
                                                            www.sigmaaldrich.com 
 
Sodium thiocyanate Sigma-Aldrich Company Ltd, The Old Brickyard, 
New Road, Gillingham, Dorset, SP8 4XT. UK 
                                                            www.sigmaaldrich.com 
 
100bp ladder  Thermo Fisher Scientific Inc., 81 Wyman Street,     
  Waltham, MA 02454. UK 
     www.thermofisher.com 
 
mirVana miRNA isolation kit Life Technologies Ltd, 3 Fountain Drive, 
Inchinnan Business Park, Paisley, PA4 9RF. UK 
www.lifetechnologies.com 
 
Acid-Phenol:Chloroform Sigma-Aldrich Company Ltd, The Old Brickyard, 
New Road, Gillingham, Dorset, SP8 4XT. UK 
                                                            www.sigmaaldrich.com 
 
HotStarTaq polymerase Qiagen Ltd, Skelton House, Lloyd Street North, 
Manchester M15 6SH. UK 
 www.qiagen.com 
 
Deoxynucleotide set  Sigma-Aldrich Company Ltd, The Old Brickyard, 
New Road, Gillingham, Dorset, SP8 4XT. UK 
                                                            www.sigmaaldrich.com 
 
Primers Sigma-Aldrich Company Ltd, The Old Brickyard, 
New Road, Gillingham, Dorset, SP8 4XT. UK 
                                                            www.sigmaaldrich.com 
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Magnesium chloride  Qiagen Ltd, Skelton House, Lloyd Street North, 
Manchester M15 6SH. UK 
 www.qiagen.com 
 
Agarose Sigma-Aldrich Company Ltd, The Old Brickyard, 
New Road, Gillingham, Dorset, SP8 4XT. UK 
                                                            www.sigmaaldrich.com 
 
GenElute PCR Clean-Up Kit Sigma-Aldrich Company Ltd, The Old Brickyard, 
New Road, Gillingham, Dorset, SP8 4XT. UK 
                                                            www.sigmaaldrich.com 
 
BigDye® Terminator v3.1 cycle  Life Technologies Ltd, 3 Fountain Drive,  
Sequencing kit  Inchinnan Business Park, Paisley, PA4 9RF, UK 
www.lifetechnologies.com 
 
EZ DNA Methylation-Gold Kit Zymo Research Europe GmbH, Güterhallenstrasse 
3, 79106 Freiburg, Deutschland. 
     www.zymoresearch.eu 
 
50bp ladder    Thermo Fisher Scientific Inc., 81 Wyman Street,     
     Waltham, MA 02454. UK 
     www.thermofisher.com 
 
HighRanger 1kb DNA ladder Geneflow Ltd, Paul Fisher House, 1 The 
Sycamore Tree, Elmhurst Business Park, 
Elmhurst, Lichfield, Staffordshire, WS13 8EX 
 www.geneflow.co.uk 
 
ULS-Cy3 and ULS-Cy5 Agilent Technologies UK Ltd., 610 Wharfedale 
Road, IQ Winnersh, Wokingham, Berkshire, 
RG41 5TP. UK 
 www.agilent.com 
 
Reference DNA (male and female) Promega, Delta House, Southampton Science 
Park, Southampton SO16 7NS. UK 
 www.promega.com 
 
ULS Labelling Kit Agilent Technologies UK Ltd., 610 Wharfedale 
Road, IQ Winnersh, Wokingham, Berkshire, 
RG41 5TP. UK 
     www.agilent.com                                                          
 
100x blocking agent Agilent Technologies UK Ltd., 610 Wharfedale 
Road, IQ Winnersh, Wokingham, Berkshire, 
RG41 5TP. UK 
     www.agilent.com           
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Cot-1 DNA Invitrogen, Life Technologies Ltd, 3 Fountain 
Drive, Inchinnan Business Park, Paisley, PA4 
9RF. UK  
www.lifetechnologies.com 
                                              
HI-RIPM hybridisation buffer Agilent Technologies UK Ltd., 610 Wharfedale 
Road, IQ Winnersh, Wokingham, Berkshire, 
RG41 5TP. UK 
     www.agilent.com          
 
Agilent CGH block Agilent Technologies UK Ltd., 610 Wharfedale 
Road, IQ Winnersh, Wokingham, Berkshire, 
RG41 5TP. UK 
     www.agilent.com                                                                                                          
 
Human Genome CGH Microarray     Agilent Technologies UK Ltd., 610 Wharfedale  
Kit 244K Road, IQ Winnersh, Wokingham, Berkshire, 
RG41 5TP. UK 
     www.agilent.com                                                          
 
miRCURY LNA Array miR  Exiqon A/S, Skelstedet 16, 2950 Vedbaek,  
labelling kit Denmark   
www.exiqon.com 
 
3D Gene Human miRNA oligo Toray Industries Inc., Nihonbashi Mitsui Tower, 
chips      1-1, Nihonbashi-Muromachi 2-chome, Chuo-ku,  
     Tokyo 103-8666, Japan 
 www.toray.com 
 
1kb ladder Life Technologies Ltd, 3 Fountain Drive, 
Inchinnan Business Park, Paisley, PA4 9RF. UK 
www.lifetechnologies.com 
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APPENDIX II 
 
Gel image showing aCGH samples after heat fragmentation 
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APPENDIX III 
 
Treatment information available for patients in this study 
Tumour Age
a 
Sex
b 
Grade Histology
c 
Treatment
d 
Overall survival
e 
BTNW17 69 F II A Radiotherapy 4.5 (D) 
BTNW20 26 M II A Radiotherapy 83.5 (A) 
BTNW124 29 M II A 
Radiotherapy, 
Chemotherapy (TMZ) 
65.5 (D) 
BTNW160 35 M II A Radiotherapy 67.5 (A) 
BTNW203 42 F II A Chemotherapy (TMZ) 64.5 (A) 
BTNW210 53 F II A Radiotherapy 64 (A) 
BTNW212 50 M II A Radiotherapy 45.5 (D) 
BTNW365 42 F II A Radiotherapy 37.5 (D) 
BTNW367 56 M II A Radiotherapy 51.5 (A) 
BTNW870 17 M II A Chemotherapy (TMZ) 22.5 (A) 
Liv002 34 F II A Radiotherapy 25 (A) 
Liv007 40 M II A Radiotherapy 8 (D) 
BTNW726 45 M II OA Chemotherapy (TMZ) 33 (A) 
BTNW929 43 F II OA Chemotherapy (TMZ) 18 (A) 
BTNW326 56 F II O Radiotherapy 37.5 (D) 
Liv026 58 M II O Radiotherapy 13.5 (A) 
BTNW14 43 M III AOA Chemotherapy (PCV) 85 (A) 
 
a 
Age at diagnosis in years; 
b
 M, male; F, female; 
c
 A, astrocytoma; OA, 
oligoastrocytoma; O, oligodendroglioma; AOA, anaplastic oligoastrocytoma; 
d
 TMZ, 
temozolomide; PCV,  procarbazine, lomustine (CCNU), and vincristine; 
e 
OS in months; 
A, alive; D, dead. 
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MGMT methylation status of primary tumours by IHC and MS PCR 
Tumour Grade Histology
a 
Proportion 
 
Proportion 
score 
Intensity 
score 
Combined 
score 
MS PCR
b 
Count 1 Count 2 Count 3 Total (%) 
BTNW20 
II A 
0/100 0/100 2/100 < 1 1 3 4 U 
BTNW61 
II 
A 77/100 64/104 70/100 69 5 3 8 U 
BTNW160 
II 
A 19/100 22/100 21/100 21 3 1 4 PM 
BTNW203 
II 
A 71/121 47/100 51/119 50 4 2 6 U 
BTNW210 
II 
A 1/100 0/100 0/100 < 1 1 2 3 U 
BTNW212 
II 
A 26/108 21/110 16/101 20 3 2 5 M 
BTNW365 
II 
A 37/103 26/103 24/102 28 3 2 5 ND 
BTNW367 
II A 
100/100 100/100 100/100 100 5 3 8 PM 
BTNW380 
II A 
88/100 97/100 94/100 93 5 2 7 U 
BTNW381 
II A 
6/100 5/100 8/100 6 2 2 4 U 
BTNW680 
II A 
72/100 78/101 85/104 77 5 2 7 U 
BTNW736 
II A 
0/100 0/100 1/100 < 1 1 2 3 U 
BTNW761 
II 
A 0 0 0 0 0 0 0 U 
BTNW818 
II A 
87/100 78/100 92/100 86 5 3 8 U 
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BTNW823 
II 
A 22/100 25/100 18/100 22 3 3 6 U 
BTNW830 
II A 
50/101 59/116 54/105 51 4 2 6 U 
BTNW870 
II A 
43/100 40/100 30/100 38 4 2 6 U 
BTNW868 
II 
A 42/100 31/100 34/100 36 4 3 7 U 
BTNW931 
II 
A 40/100 41/106 34/111 36 4 2 6 ND 
BTNW13 
II OA 
67/100 62/104 59/101 62 4 2 6 U 
BTNW503 
II OA 
30/100 26/100 27/106 27 3 1 4 U 
BTNW613 
II OA 
97/100 100/100 94/100 97 5 3 8 PM 
BTNW726 
II OA 
80/100 84/100 89/100 84 5 3 8 U 
BTNW929 
II OA 
15/100 22/100 20/100 19 3 2 5 ND 
BTNW188 
II O 
54/100 60/100 54/108 54 4 2 6 M 
BTNW326 
II O 
49/100 72/100 54/100 58 4 3 7 M 
BTNW531 
II O 
21/114 19/104 23/109 19 3 2 5 M 
BTNW882 
II O 
33/100 41/100 28/100 34 4 2 6 U 
BTNW38 
III AA 
12/101 16/114 17/121 13 3 2 5 PM 
BTNW126 
III AA 
55/100 52/100 51/100 53 4 2 6 U 
BTNW173 
III AA 
5/100 3/100 4/100 4 2 1 3 U 
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BTNW196 
III AA 
13/101 12/110 9/100 11 3 1 4 U 
BTNW211 
III AA 
51/100 42/124 39/109 40 4 2 6 U 
BTNW421 
III AA 
74/103 69/101 81/100 74 5 3 8 U 
BTNW458 
III AA 
36/100 23/100 15/100 25 3 2 5 M 
BTNW925 
III AA 
0 2/100 0 < 1 1 1 2 U 
BTNW9 
III AOA 
1/100 2/119 0/100 < 1 1 2 3 U 
BTNW14 
III AOA 
1/100 0/100 0/100 < 1 1 2 3 M 
BTNW120 
III AOA 
5/100 1/100 4/100 3 2 2 4 PM 
BTNW174 
III AOA 
30/100 30/100 16/103 25 3 1 4 M 
BTNW183 
III AOA 
38/100 35/100 32/100 35 4 2 6 PM 
BTNW325 
III AOA 
32/105 30/107 31/103 29 3 2 5 ND 
BTNW495 
III AOA 
34/102 26/100 24/100 28 3 2 5 U 
BTNW515 
III AOA 
62/100 56/100 52/100 57 4 2 6 ND 
BTNW527 
III AOA 
0 0 0 0 0 0 0 U 
BTNW614 
III AOA 
78/100 85/100 90/101 84 5 3 8 U 
BTNW703 
III AOA 
69/100 55/100 62/100 62 4 3 7 U 
BTNW749 
III AOA 
0 0 0 0 0 0 0 ND 
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a
 A, astrocytoma; OA, oligoastrocytoma; O, oligodendroglioma; AA, anaplastic astrocytoma; AOA, anaplastic oligoastrocytoma; AO, anaplastic 
oligodendroglioma; 
b
 M, methylated; PM, partially methylated; U, unmethylated; ND, not done.  
 
 
 
 
 
 
 
 
 
 
BTNW778 
III AOA 
0 0 1/100 < 1 1 1 2 ND 
BTNW825 
III AOA 
4/100 1/100 1/100 2 2 1 3 U 
BTNW864 
III AOA 
17/100 25/120 25/100 21 3 3 6 U 
BTNW15 
III AO 
27/101 17/103 21/105 21 3 2 5 M 
BTNW460 
III AO 
29/100 25/100 16/100 23 3 3 6 U 
BTNW738 
III AO 
3/108 5/100 7/100 5 2 2 4 U 
BTNW757 
III AO 
41/100 41/100 30/100 37 4 2 6 U 
BTNW804 
III AO 
48/100 31/100 34/100 38 4 2 6 PM 
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MGMT methylation status of primary/recurrent pairs by IHC and MS PCR 
 
Tumour Grade Histology
a 
Proportion 
 
Proportion 
score 
Intensity 
score 
Combined 
score 
MS PCR
b 
Count 1 Count 2 Count 3 Total (%) 
BTNW365 
II 
A 37/103 26/103 24/102 28 3 2 5 ND 
BTNW861 
III 
AA 23/108 17/102 15/121 17 3 2 5 ND 
BTNW946 
IV GBM 
0 0 0 0 0 0 0 PM 
BTNW974 
IV GBM 
74/125 66/102 59/102 60 4 2 6 PM 
BTNW367 
II A 
100/100 100/100 100/100 100 5 3 8 PM 
BTNW380 
II A 
88/100 97/100 94/100 93 5 2 7 U 
BTNW126 
III AA 
55/100 52/100 51/100 53 4 2 6 U 
BTNW196 
III AA 
13/101 12/110 9/100 11 3 1 4 U 
BTNW325 
III 
AOA 32/100 30/100 31/100 31 3 2 5 ND 
BTNW515 
III 
AOA 62/100 56/100 52/100 57 4 2 6 ND 
BTNW778 
III 
AOA 0/100 0/100 1/100 <1 1 1 2 ND 
BTNW614 
III AOA 
78/100 85/100 90/101 84 5 3 8 U 
BTNW848 
IV GBM 
20/104 27/103 16/101 20 3 2 5 PM 
a
 A, astrocytoma; OA, oligoastrocytoma; AA, anaplastic astrocytoma; AOA, anaplastic oligoastrocytoma; GBM, glioblastoma multiforme; 
b
 M, methylated; 
PM, partially methylated; U, unmethylated; ND, not done. 
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